0001437749-22-020306 10-Q 55 20220630 20220812 20220812 SAFEGUARD SCIENTIFICS INC 0000086115 6799 231609753 PA 1231 10-Q 34 001-05620 221159289 150 NORTH RADNOR-CHESTER ROAD SUITE F-200 RADNOR PA 19087 610 293 0600 150 NORTH RADNOR-CHESTER ROAD SUITE F-200 RADNOR PA 19087 SAFEGUARD INDUSTRIES INC 19810525 SAFEGUARD CORP 19690521 10-Q 1 sfe20220630_10q.htm FORM 10-Q sfe20220630_10q.htm
0000086115 SAFEGUARD SCIENTIFICS INC false --12-31 Q2 2022 0.10 0.10 1,000 1,000 0.10 0.10 83,333 83,333 21,573 21,573 21,573 21,573 2,157 5,261 5,068 17,510 17,510 25 25 2,407 2,407 24,739 24,739 25 25 4,549 4,549 1 0 0 0 00000861152022-01-012022-06-30 xbrli:shares 00000861152022-08-08 thunderdome:item iso4217:USD 00000861152022-06-30 00000861152021-12-31 iso4217:USDxbrli:shares 00000861152022-04-012022-06-30 00000861152021-04-012021-06-30 00000861152021-01-012021-06-30 00000861152020-12-31 00000861152021-06-30 0000086115us-gaap:RetainedEarningsMember2021-12-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0000086115us-gaap:CommonStockMember2021-12-31 0000086115us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000086115us-gaap:TreasuryStockMember2021-12-31 00000861152022-01-012022-03-31 0000086115us-gaap:RetainedEarningsMember2022-01-012022-03-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-31 0000086115us-gaap:CommonStockMember2022-01-012022-03-31 0000086115us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-31 0000086115us-gaap:TreasuryStockMember2022-01-012022-03-31 00000861152022-03-31 0000086115us-gaap:RetainedEarningsMember2022-03-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-31 0000086115us-gaap:CommonStockMember2022-03-31 0000086115us-gaap:AdditionalPaidInCapitalMember2022-03-31 0000086115us-gaap:TreasuryStockMember2022-03-31 0000086115us-gaap:RetainedEarningsMember2022-04-012022-06-30 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-30 0000086115us-gaap:CommonStockMember2022-04-012022-06-30 0000086115us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-30 0000086115us-gaap:TreasuryStockMember2022-04-012022-06-30 0000086115us-gaap:RetainedEarningsMember2022-06-30 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-30 0000086115us-gaap:CommonStockMember2022-06-30 0000086115us-gaap:AdditionalPaidInCapitalMember2022-06-30 0000086115us-gaap:TreasuryStockMember2022-06-30 0000086115us-gaap:RetainedEarningsMember2020-12-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 0000086115us-gaap:CommonStockMember2020-12-31 0000086115us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000086115us-gaap:TreasuryStockMember2020-12-31 00000861152021-01-012021-03-31 0000086115us-gaap:RetainedEarningsMember2021-01-012021-03-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-31 0000086115us-gaap:CommonStockMember2021-01-012021-03-31 0000086115us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-31 0000086115us-gaap:TreasuryStockMember2021-01-012021-03-31 00000861152021-03-31 0000086115us-gaap:RetainedEarningsMember2021-03-31 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-31 0000086115us-gaap:CommonStockMember2021-03-31 0000086115us-gaap:AdditionalPaidInCapitalMember2021-03-31 0000086115us-gaap:TreasuryStockMember2021-03-31 0000086115us-gaap:RetainedEarningsMember2021-04-012021-06-30 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-30 0000086115us-gaap:CommonStockMember2021-04-012021-06-30 0000086115us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-30 0000086115us-gaap:TreasuryStockMember2021-04-012021-06-30 0000086115us-gaap:RetainedEarningsMember2021-06-30 0000086115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-30 0000086115us-gaap:CommonStockMember2021-06-30 0000086115us-gaap:AdditionalPaidInCapitalMember2021-06-30 0000086115us-gaap:TreasuryStockMember2021-06-30 0000086115sfe:BrightHealthMember2022-06-30 0000086115srt:PartnershipInterestMember2022-06-30 0000086115srt:PartnershipInterestMember2021-12-31 0000086115us-gaap:PrivateEquityFundsMember2022-06-30 0000086115us-gaap:PrivateEquityFundsMember2021-12-31 xbrli:pure 0000086115sfe:AktanaIncMember2022-06-30 0000086115sfe:ClutchHoldingsMember2022-06-30 0000086115sfe:InfoBionicIncMember2022-06-30 0000086115sfe:LumesisIncMember2022-06-30 0000086115sfe:meQuilibriumMember2022-06-30 0000086115sfe:MoxeHealthCorporationMember2022-06-30 0000086115sfe:PrognosHealthIncMember2022-06-30 0000086115sfe:SyapseIncMember2022-06-30 0000086115sfe:TriceMedicalIncMember2022-06-30 0000086115us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2022-04-012022-06-30 0000086115us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-04-012021-06-30 0000086115us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2022-01-012022-06-30 0000086115us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-01-012021-06-30 0000086115sfe:PrognosHealthIncMember2022-01-012022-06-30 0000086115sfe:ClutchHoldingsMember2022-01-012022-06-30 0000086115us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-30 0000086115us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-30 0000086115us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-30 0000086115us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-30 0000086115us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000086115us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000086115us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000086115us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31 0000086115us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-30 0000086115us-gaap:GeneralAndAdministrativeExpenseMember2021-04-012021-06-30 0000086115us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-30 0000086115us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-30 0000086115us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-01-012022-06-30 0000086115us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2021-01-012021-06-30 0000086115us-gaap:ShareBasedPaymentArrangementEmployeeMember2022-04-012022-06-30 0000086115us-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-04-012022-06-30 0000086115us-gaap:EmployeeStockOptionMember2022-01-012022-06-30 0000086115us-gaap:EmployeeStockOptionMember2021-01-012021-06-30 0000086115us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-06-30 0000086115us-gaap:EmployeeStockOptionMembersrt:MaximumMember2022-01-012022-06-30 0000086115us-gaap:EmployeeStockOptionMembersrt:MinimumMember2021-01-012021-06-30 0000086115us-gaap:EmployeeStockOptionMembersrt:MaximumMember2021-01-012021-06-30 0000086115sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember2022-01-012022-06-30 0000086115sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember2021-01-012021-06-30 0000086115srt:MinimumMember2022-01-012022-06-30 0000086115srt:MaximumMember2022-01-012022-06-30 0000086115sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member2015-07-31 0000086115sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member2021-01-012021-06-30 0000086115sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member2022-01-012022-06-30 0000086115sfe:ShareRepurchaseProgramAuthorizedInMay2021Member2022-03-31 0000086115sfe:ShareRepurchaseProgramAuthorizedInMay2021Member2022-01-012022-06-30
 

 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549      

______________________________________________________________________________________________

 

FORM 10-Q

(Mark One)

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2022

or

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period From ____________ to ___________

 

Commission File Number 1-5620      

______________________________________________________________________________________________

 

Safeguard Scientifics, Inc.

(Exact name of registrant as specified in its charter)      

______________________________________________________________________________________________

 

Pennsylvania

   

(State or other jurisdiction of

23-1609753

incorporation or organization)

(I.R.S. Employer ID No.)

   

   

150 N. Radnor Chester Road

   

Suite F-200

   

Radnor, PA

19087

(Address of principal executive offices)

(Zip Code)

(610) 293-0600

Registrant’s telephone number, including area code      

______________________________________________________________________________________________

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

common stock, par value $0.10

SFE

New York Stock Exchange

 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  ☑    No  ☐

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).

 

Yes  ☑    No  ☐

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

   

Large accelerated filer  ☐

Accelerated filer  ☐

 

Smaller reporting company  

Non-accelerated filer  ☐

 

 

  Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes      No  ☑

 

Number of shares outstanding as of August 8, 2022

Common Stock 16,387,126



 

 

 

 
 

SAFEGUARD SCIENTIFICS, INC.

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

   

   

PART I – FINANCIAL INFORMATION

   

   

Page

Item 1 – Financial Statements:

   

   

   

Consolidated Balance Sheets – June 30, 2022 (unaudited) and December 31, 2021

3

   

   

Consolidated Statements of Operations (unaudited) – Three and Six Months Ended June 30, 2022 and 2021

4

   

   

Condensed Consolidated Statements of Cash Flows (unaudited) – Six Months Ended June 30, 2022 and 2021

5

 

 

Consolidated Statements of Changes in Equity (unaudited) – Three and Six Months Ended June 30, 2022 and 2021

6

 

 

Notes to Consolidated Financial Statements (unaudited)

8

   

   

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

   

   

Item 3 – Quantitative and Qualitative Disclosures About Market Risk

28

   

   

Item 4 – Controls and Procedures

28

   

   

PART II – OTHER INFORMATION

   

   

   

Item 1 – Legal Proceedings

29

 

 

Item 1A – Risk Factors

29

 

 

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds

29

 

 

Item 3 – Defaults Upon Senior Securities

29

 

 

Item 4 – Mine Safety Disclosures

29

 

 

Item 5 – Other Information

29

 

 

Item 6 – Exhibits

30

   

   

Signatures

31

 

2

 

 

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

 

   (Unaudited)     
  

June 30, 2022

  

December 31, 2021

 

ASSETS

        

Current Assets:

        

Cash and cash equivalents

 $17,510  $24,739 

Restricted cash

  25   25 

Ownership interests

  2,407   4,549 

Prepaid expenses and other current assets

  1,126   965 

Total current assets

  21,068   30,278 

Right-of-use asset, net

  1,431   1,561 

Ownership interests and advances

  23,192   21,972 

Other assets

  267   217 

Total Assets

 $45,958  $54,028 

LIABILITIES AND EQUITY

        

Current Liabilities:

        

Accounts payable

 $56  $41 

Accrued compensation and benefits

  167   794 

Accrued expenses and other current liabilities

  518   524 

Lease liability - current

  401   375 

Total current liabilities

  1,142   1,734 

Lease liability - non-current

  1,471   1,678 

Other long-term liabilities

  50   50 

Total Liabilities

  2,663   3,462 

Commitments and contingencies (Note 9)

          

Equity:

        

Preferred stock, $0.10 par value; 1,000 shares authorized

      

Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued and outstanding at June 30, 2022 and December 31, 2021

  2,157   2,157 

Additional paid-in capital

  805,441   806,638 

Treasury stock, at cost; 5,261 and 5,068 shares at June 30, 2022 and December 31, 2021, respectively

  (48,417)  (48,569)

Accumulated deficit

  (715,861)  (709,635)

Accumulated other comprehensive loss

  (25)  (25)

Total Equity

  43,295   50,566 

Total Liabilities and Equity

 $45,958  $54,028 

 

See Notes to Consolidated Financial Statements.

 

3

 

 

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited - In thousands, except share and per share data)

 

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2022

  

2021

  

2022

  

2021

 

General and administrative expense

 $1,146  $1,991  $2,380  $4,454 

Operating loss

  (1,146)  (1,991)  (2,380)  (4,454)

Other income (loss), net

  30   6,733   (1,967)  7,439 

Interest income

  145   74   246   127 

Equity income (loss), net

  1,454   (5,136)  (2,125)  14,193 

Net income (loss) before income taxes

  483   (320)  (6,226)  17,305 

Income tax benefit (expense)

            

Net income (loss)

 $483  $(320) $(6,226) $17,305 
                 

Net income (loss) per share:

                

Basic

 $0.03  $(0.02) $(0.38) $0.83 

Diluted

 $0.03  $(0.02) $(0.38) $0.83 

Weighted average shares used in computing income (loss) per share:

                

Basic

  16,356   20,856   16,468   20,879 

Diluted

  16,356   20,856   16,468   20,879 

   

See Notes to Consolidated Financial Statements.

 

4

 

 

SAFEGUARD SCIENTIFICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited – In thousands)

   

  

Six Months Ended June 30,

 
  

2022

  

2021

 

Cash Flows from Operating Activities:

        

Net cash used in operating activities

 $(2,099) $(4,734)

Cash Flows from Investing Activities:

        

Proceeds from sales of ownership interests

  485   13,151 

Advances and loans to ownership interests

  (3,400)  (1,000)

Net cash (used in) provided by investing activities

  (2,915)  12,151 

Cash Flows from Financing Activities:

        

Repurchases of Company common stock

  (1,723)  (1,588)

Tax withholdings related to equity-based awards

  (492)  (100)

Net cash used in financing activities

  (2,215)  (1,688)

Net change in cash, cash equivalents and restricted cash

  (7,229)  5,729 

Cash, cash equivalents and restricted cash at beginning of period

  24,764   15,601 

Cash, cash equivalents and restricted cash at end of period

 $17,535  $21,330 

 

See Notes to Consolidated Financial Statements.

 

5

 

 

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited – In thousands, except share data)

   

      

Accumulated

  

Accumulated Other

  

Common Stock

  

Additional Paid-in

  

Treasury Stock

 
  

Total

  

Deficit

  

Comprehensive Loss

  

Shares

  

Amount

  

Capital

  

Shares

  

Amount

 

Balance - December 31, 2021

 $50,566  $(709,635) $(25)  21,573  $2,157  $806,638   5,068  $(48,569)

Net loss

  (6,709)  (6,709)                  

Repurchases of common stock

  (779)                 148   (779)

Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net

  303               (1,019)  (122)  1,322 

Stock-based compensation expense

  168               168       

Balance - March 31, 2022

 $43,549  $(716,344) $(25)  21,573  $2,157  $805,787   5,094  $(48,026)

Net income

  483   483                   

Repurchases of common stock

  (945)                 221   (945)

Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net

  65               (489)  (54)  554 

Stock-based compensation expense

  143               143       

Balance - June 30, 2022

 $43,295  $(715,861) $(25)  21,573  $2,157  $805,441   5,261  $(48,417)

 

See Notes to Consolidated Financial Statements.

 

6

 

SAFEGUARD SCIENTIFICS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited – In thousands)

 

      

Accumulated

  

Accumulated Other

  

Common Stock

  

Additional Paid-in

  

Treasury Stock

 
  

Total

  

Deficit

  

Comprehensive Loss

  

Shares

  

Amount

  

Capital

  

Shares

  

Amount

 

Balance - December 31, 2020

 $62,875  $(736,639) $(25)  21,573  $2,157  $807,582   688  $(10,200)

Net income

  17,625   17,625                   

Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net

  370               (593)  (58)  963 

Stock-based compensation expense

  122               122       

Balance - March 31, 2021

 $80,992  $(719,014) $(25)  21,573  $2,157  $807,111   630  $(9,237)

Net loss

  (320)  (320)                  

Repurchases of common stock

  (1,588)                 229   (1,588)

Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net

  137               (839)  (73)  976 

Stock-based compensation expense

  175               175       

Balance - June 30, 2021

 $79,396  $(719,334) $(25)  21,573  $2,157  $806,447   786  $(9,849)

 

See Notes to Consolidated Financial Statements.

 

7

 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

 

1. General

 

The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not necessarily indicative of the results for a full year or for any interim period. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations relating to interim financial statements. The Consolidated Financial Statements included in this Form 10-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Form 10-Q and with the Company’s Consolidated Financial Statements and Notes thereto included in the Company’s 2021 Annual Report on Form 10-K.

 

Liquidity

 

As of June 30, 2022 the Company had $17.5 million of cash and cash equivalents.

 

In January 2018, Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders. We have considered and taken action on various initiatives including the sale of individual ownership interests, the sale of certain or all ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value.  As we seek to provide additional funding to existing companies where we have an ownership interest, we may be required to expend our cash or incur debt, which will decrease our liquidity.  From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.  Accordingly, the Company could also pursue other sources of capital in order to maintain its liquidity.    

 

The Company believes that its cash and cash equivalents at June 30, 2022 will be sufficient to fund operations past one year from the issuance of these Consolidated Financial Statements.

 

8

 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

 

Principles of Accounting for Ownership Interests

 

The Company accounts for its ownership interests using one of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.

 

In addition to holding voting and non-voting equity securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests and advances on the Consolidated Balance Sheets.

 

Equity Method. The Company accounts for ownership interests whose results are not consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an ownership interest depends on the evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a 20% to 50% interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost. Under the equity method of accounting, the Company does not reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations. The Company also adjusts the carrying value to reflect third party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a one quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.

 

When the Company’s carrying value in an equity method company is reduced to zero, the Company records no further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will not record its share of such income until it exceeds the amount of the Company’s share of losses not previously recognized.

 

Other Method. We account for ownership interests in companies that are not accounted for under the equity method that do not have a readily determinable fair value under the fair value measurement alternative. Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interest of the same issuer. Under this method, our share of the income or losses of such companies is not included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets.

 

The Company accounts for ownership interests that are not accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  As of June 30, 2022 those ownership interests consist of approximately 1.3 million shares of Bright Health Group ("Bright Health") common shares valued at $2.4 million.  

 

Comprehensive Income (loss)

 

During the quarter and six month periods ended June 30, 2022 and 2021, there were no items of comprehensive income (loss). 

 

Impairment of Ownership Interests and Advances

 

On a periodic basis, but no less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated fair value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are not primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.

 

Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.

 

The estimated fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.

 

Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies are included in Other income (loss), net in the Consolidated Statements of Operations.

 

The reduced cost basis of a previously impaired company accounted for using the Equity method is not written-up even if circumstances suggest the value of the company has subsequently recovered.

 

9

 

 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

 

2. Ownership Interests and Advances

 

The following summarizes the carrying value of the Company’s ownership interests and advances. 

  

  

June 30, 2022

  

December 31, 2021

 
  

(Unaudited - In thousands)

 

Equity Method:

        

Companies

 $18,738  $21,091 

Private equity funds

  117   117 
   18,855   21,208 

Other Method:

        

Companies, fair value

  2,407   4,549 

Companies, fair value measurement alternative

  687   514 

Private equity funds, fair value measurement alternative

  250   250 
   3,344   5,313 

Advances to companies

  3,400    
  $25,599  $26,521 

 

There were no impairments recorded during the three and six months ended June 30, 2022, respectively. During the three and six months ended June 30, 2021, the Company recorded impairment of $2.5 million related to reduced expectations for certain Other ownership interests, which is reflected in Other income (loss) in the consolidated Statement of Operations.

 

As of  June 30, 2022, the Company held ownership interests accounted for using the equity method in 9 non-consolidated companies.  Certain of the Company's ownership interests as of June 30, 2022 included the following:

 

Company Name

 

Safeguard Primary Ownership as of June 30, 2022

 

Accounting Method

Aktana, Inc.

 

13.4%

 

Equity

Clutch Holdings, Inc.

 

41.7%

 

Equity

InfoBionic, Inc.

 

25.2%

 

Equity

Lumesis, Inc.

 

43.2%

 

Equity

meQuilibrium

 

31.5%

 

Equity

Moxe Health Corporation

 

19.4%

 

Equity

Prognos Health Inc.

 

28.5%

 

Equity

Syapse, Inc.

 

11.0%

 

Equity

Trice Medical, Inc.

 

12.6%

 

Equity

 

 

10

 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

 

Summarized Financial Information

 

The following table summarizes the statement of operations data for the companies accounted for under the equity method for the three and six months ended June 30, 2022 and 2021, respectively. These results have been compiled from the respective companies' financial statements, reflect certain historical adjustments, and are reported on a one quarter lag basis. Results of operations of the companies are excluded for periods prior to their acquisition, subsequent to their disposition and subsequent to the discontinuation of the equity method of accounting. Historical results are not adjusted when the Company exits, writes-off or discontinues the equity method of accounting. 

 

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2022

  

2021

  

2022

  

2021

 
  

(Unaudited - In thousands)

 

Results of Operations:

                

Revenue

 $36,479  $30,482  $75,290  $70,650 

Gross profit

 $22,653  $17,873  $47,573  $46,101 

Net loss

 $(34,325) $(28,681) $(65,187) $(51,702)

 

 

3. Acquisitions of Ownership Interests

 

The following is a summary of additional deployments during the six month period ended  June 30, 2022:

 

The Company funded $2.0 million of convertible loans to Prognos Health Inc.  The Company had previously deployed an aggregate of $12.6 million.  Prognos is a healthcare platform company transforming the ability to access, manage and analyze healthcare data in partnership with Life Sciences brands, payers, and clinical diagnostics organizations.  Prognos' innovations enhance the value of laboratory results and clinical diagnostic data through advanced analytics and artificial intelligence techniques.

 

The Company funded $1.4 million of convertible loans to Clutch Holdings, Inc. The Company had previously deployed an aggregate of $16.9 million.  Clutch provides customer intelligence and personalized engagements that empower consumer-focused businesses to identify, understand and motivate each segment of their customer base. 

 

11

 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

 

4. Fair Value Measurements

 

The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. 

 

Cash, cash equivalents and restricted cash approximate fair value due to their short term nature.  The Company did not have any Level 2 or Level 3 financial assets or liabilities measured at fair value on a recurring basis as of June 30, 2022 or December 31, 2021.

 

  

Carrying

  

Fair Value Measurement at June 30, 2022

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(Unaudited - In thousands)

 

Cash and cash equivalents

 $17,510  $17,510  $  $ 
                 

Restricted cash

 $25  $25  $  $ 
                 

Ownership interests

 $2,407  $2,407  $  $ 

 

  

Carrying

  

Fair Value Measurement at December 31, 2021

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(Unaudited - In thousands)

 

Cash and cash equivalents

 $24,739  $24,739  $  $ 
                 

Restricted cash

 $25  $25  $  $ 
                 

Ownership interests

 $4,549  $4,549  $  $ 

 

Ownership interests accounted for at fair value as of June 30, 2022 consist of approximately 1.3 million common shares of Bright Health.  The securities are carried at fair value based on the closing stock price on the last trading day of the reporting period.  

 

 

5. Stock-Based Compensation

 

Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:  

 

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2022

  

2021

  

2022

  

2021

 
  

(Unaudited - In thousands)

 

General and administrative expense

 $262  $740  $576  $985 
  $262  $740  $576  $985 

 

Stock-based compensation consists of time based awards to employees, liability based awards to employees to be settled in stock, performance based awards to employees, other non-employee grants and liability based awards to Directors for quarterly and annual services.  During the six months ended June 30, 2022 and 2021, the Company awarded 25 thousand and 64 thousand restricted stock awards, respectively to non-employee directors for compensation.  The Company also issued 162 thousand shares for employee services and 15 thousand shares for non-employee services during the three months ended June 30, 2022, respectively, based on the terms of service agreements.

 

 

6. Income Taxes

 

The Company recorded no consolidated income tax benefit (expense) for the three and six months ended June 30, 2022 and 2021. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the tax provision that would have been recognized in the three and six months ended June 30, 2022 was offset by changes in the valuation allowance. During the three and six months ended June 30, 2022, the Company had no material changes in uncertain tax positions.

 

12

 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

 

 

7. Net Income (Loss) Per Share

 

The calculations of net income (loss) per share were as follows:

 

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2022

  

2021

  

2022

  

2021

 
  

(Unaudited - In thousands, except per share data)

 

Basic:

                

Net income (loss)

 $483  $(320) $(6,226) $17,305 

Weighted average common shares outstanding

  16,356   20,856   16,468   20,879 

Net income (loss) per share

 $0.03  $(0.02) $(0.38) $0.83 
                 

Diluted:

                

Net income (loss) for dilutive share computation

 $483  $(320) $(6,226) $17,305 
                 

Number of shares used in basic per share computation

  16,356   20,856   16,468   20,879 

Unvested restricted stock and DSU's

            

Employee stock options

            

Weighted average common shares outstanding

  16,356   20,856   16,468   20,879 
                 

Net income (loss) per dilutive share

 $0.03  $(0.02) $(0.38) $0.83 

 

Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).

 

If an equity method company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net income (loss) per share is computed by first deducting the income attributable to the potential exercise of the dilutive securities of the company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.

 

Diluted earnings per share do not reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:

 

 

At June 30, 2022 and 2021, options to purchase 18 thousand and 43 thousand shares of common stock, respectively, at prices ranging from $10.37 to $17.11 and $10.37 to $17.11, respectively, were excluded from the calculations.

   
 

At June 30, 2022 and 2021, unvested restricted stock and performance-based stock units convertible into 0.1 million and 0.3 million shares of stock, respectively, were excluded from the calculations.

 

13

 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

 

 

8. Segment Reporting

 

The Company operates as one operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources. 

 

As of June 30, 2022 and December 31, 2021, all of the Company’s assets were located in the United States.

 

14

 

SAFEGUARD SCIENTIFICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

 

 

9. Commitments and Contingencies

 

In March 2019, the Company entered into a sublease of its prior corporate headquarters office space beginning in June 2019. The term of the sublease is through April 2026, the same as the Company's underlying lease. Fixed sublease payments to the Company are escalating over the term of the sublease and are reported as a component of general and administrative expenses.

 

A summary of the Company's operating lease cash flows at June 30, 2022 follows:

 

  

Operating lease payments

  

Expected sublease receipts

 
  

(Unaudited - In thousands)

 

2022 (six months ending December 31)

 $302  $273 

2023

  607   557 

2024

  613   573 

2025

  619   590 

2026

  207   199 

2027

      

Thereafter

      

Total future minimum lease payments

  2,348  $2,192 

Less imputed interest

  (476)    

Total operating lease liabilities

 $1,872     

 

The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, it is not reasonably possible that the ultimate disposition of these matters will have a material adverse effect on the Company’s consolidated financial position or results of operations, however, no assurance can be given as to the outcome of these actions, and one or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its companies. The Company records costs associated with legal fees as such services are rendered.

 

The Company has provided a guarantee, which is fully funded by escrowed funds held by a third party, of $3.8 million at June 30, 2022 which related to one of the Company's private equity fund interests.

 

In 2018, the Board of Directors (the “Board”) of the Company adopted a long-term incentive plan, which was amended in February 2019 and June 2020, known as the Amended and Restated Safeguard Scientifics Transaction Bonus Plan, (the “LTIP”). The purpose of the LTIP is to promote the interests of the Company and its shareholders by providing an additional incentive to employees to maximize the value of the Company in connection with the execution of the business strategy that the Company adopted and announced in January 2018. The June 2020 amendment lowered the level of the first threshold and the resulting bonus pool percentage as an incentive to employees to accelerate actions consisent with the business strategy.  Under the LTIP, participants, which include certain current and former employees, have received awards that may result in cash payments in connection with sales of the Company’s ownership interests (“Sale Transaction(s)”). The LTIP provides for a bonus pool corresponding to certain specified vesting thresholds (some of which have already been met and paid) or specified events. The remaining bonus pool will range from an amount equal to 1.0% of incremental proceeds received at the next threshold to 1.3% at higher thresholds.  A minimum pool will also be created and paid under specified events. The bonus pool will be allocated and paid to participants in the LTIP based on the product of (i) the participant’s applicable bonus pool percentage and (ii) the bonus pool calculated as of the vesting date, minus any previously paid portion of the bonus pool. Any portion of the bonus pool available as of the applicable vesting date that is reserved will be allocated in connection with each vesting date so that the entire bonus pool available as of such vesting date is allocated and payable to participants. Subject to the terms of the LTIP, payments under the LTIP will be paid in cash within 60 days of the applicable vesting date. All current officers and employees of the Company are eligible to participate in the LTIP. The Board, in its sole discretion, will determine the participants to whom awards are granted under the LTIP. The Company did not make any payments during the six months ended June 30, 2022 and has no amounts accrued as of June 30, 2022

 

The Company has agreements with certain remaining employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under employment and severance agreements for remaining employees was approximately $0.8 million at June 30, 2022.

 

In June 2011, the Company's former ownership interest, Advanced BioHealing, Inc. (“ABH”) was acquired by Shire plc (“Shire”).  Prior to the expiration of the escrow period in March 2012, Shire filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (“DOJ”) false claims act investigation relating to ABH (the “Investigation”). In connection with the Investigation, in July 2015 the Company received a Civil Investigation Demand-Documentary Material (“CID”) from the DOJ regarding ABH and Safeguard’s relationship with ABH. Pursuant to the CID, the Company provided the requested materials and information.  To the Company’s knowledge, the CID was related to multiple qui tam (“whistleblower”) actions, one of which was filed in 2014 by an ex-employee of ABH that named the Company and one of the Company’s employees along with other entities and individuals as defendants.  At this time, the DOJ has declined to pursue the qui tam action as it relates to the Company and such Company employee.

 

15

 
 

10. Equity

 

In July 2015, the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. The Company has not repurchased any shares under such authorization during 2021 or the six months ended June 30, 2022.

 

In March 2022, the Company's Board of Directors replaced a previously existing share repurchase plan that was authorized in May 2021 with a newly authorized $3.0 million share repurchase plan using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended. During the six months ended June 30, 2022, the Company repurchased 369,274 shares for an aggregate price of $1.7 million at an average cost at $4.67 per share pursuant to this plan.

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Note Concerning Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about Safeguard Scientifics, Inc. (“Safeguard” or “we”), the industries in which we operate and other matters, as well as management's beliefs and assumptions and other statements regarding matters that are not historical facts. These statements include, in particular, statements about our plans, strategies and prospects. For example, when we use words such as “projects,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “should,” “would,” “could,” “will,” “opportunity,” “potential” or “may,” variations of such words or other words that convey uncertainty of future events or outcomes, we are making forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our forward-looking statements are subject to risks and uncertainties. Factors that could cause actual results to differ materially, include, among others, our ability to make good decisions about the deployment of capital, the fact that our ownership interests may vary from period to period, our substantial capital requirements and absence of liquidity from our holdings, fluctuations in the market prices of our publicly traded holdings, competition, our inability to obtain maximum value for our ownership interests, or at all, and the return of value to our shareholders, our ability to attract and retain qualified employees, our ability to execute our strategy, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our ownership interests and their performance, including the fact that most of our ownership interests have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which Safeguard's ownership interests operate, including the impact of COVID-19, compliance with government regulation and legal liabilities, all of which are discussed in Item 1A. “Risk Factors” in Safeguard's Annual Report on Form 10-K and updated, as applicable, in “Factors that May Affect Future Results” and Item 1A. “Risk Factors” below. Many of these factors are beyond our ability to predict or control. In addition, as a result of these and other factors, our past financial performance should not be relied on as an indication of future performance. All forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by this cautionary statement. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report might not occur.

 

16

 

Business Overview

 

Over the recent past, Safeguard has provided capital and relevant expertise to fuel the growth of technology-driven businesses. In many, but not all cases, we are actively involved, influencing development through board representation and management support, in addition to the influence we exert through our equity ownership. We also continue to hold relatively small equity interests in other enterprises where we do not exert significant influence and do not participate in management activities. In some cases, those ownership interests relate to residual interests from prior larger interests or from companies that acquired companies in which we had ownership interests.

 

In January 2018, Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders. We have considered and taken action on various initiatives including the sale of individual ownership interests, the sale of certain or all ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value.  In December 2019, we declared and paid a $1.00 per share special dividend.  In 2021, we repurchased 4.5 million shares through a combination of open market purchases and a tender offer for an aggregate of $40.7 million resulting in an average price of $8.95 per share.  We will continue to actively work with our ownership interests to seek monetization opportunities while we also evaluate additional strategic alternatives.  These strategic alternatives could include the sale of all of our ownership interests in a single transaction or a series of transactions, merger, business combinations or other strategic transactions.   

 

Results of Operations

 

We operate as one operating segment based upon the similar nature of our technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources.

 

There is intense competition in the markets in which our companies operate. Additionally, the markets in which these companies operate are characterized by rapidly changing technology, evolving industry standards, frequent introduction of new products and services, shifting distribution channels, evolving government regulation, frequently changing intellectual property landscapes and changing customer demands. Their future success depends on each company’s ability to execute its business plan and to adapt to its respective rapidly changing market.

 

The following is a listing of certain of our ownership interests as of  June 30, 2022 and 2021, respectively.  The ownership percentages indicated below are presented as of June 30, 2022 for certain companies in which we held ownership interests and reflects the percentage of the vote we were entitled to cast at that date based on issued and outstanding voting securities (on a common stock equivalent basis), excluding the effect of options, warrants and convertible debt (primary ownership).

 

   

Safeguard Primary Ownership as of June 30,

   

Company Name

 

2022

   

2021

 

Accounting Method

Aktana, Inc.

  13.4%     15.0%  

Equity

Clutch Holdings, Inc.

  41.7%     41.8%  

Equity

InfoBionic, Inc.

  25.2%     25.2%  

Equity

Lumesis, Inc.

  43.2%     43.4%  

Equity

meQuilibrium

  31.5%     32.0%  

Equity

Moxe Health Corporation

  19.4%     27.6%  

Equity

Prognos Health Inc.

  28.5%     28.5%  

Equity

Syapse, Inc.

  11.0%     11.1%  

Equity

Trice Medical, Inc.

  12.6%     16.6%  

Equity

 

17

 

Three months ended June 30, 2022 versus the three months ended June 30, 2021

 

   

Three Months Ended June 30,

 
   

2022

   

2021

   

Variance

 
   

(In thousands)

 

General and administrative expense

  $ (1,146 )   $ (1,991 )   $ 845  

Other income (loss), net

    30       6,733       (6,703 )

Interest income

    145       74       71  

Equity income (loss), net

    1,454       (5,136 )     6,590  
    $ 483     $ (320 )   $ 803  

 

General and Administrative Expense. Our general and administrative expenses consist primarily of employee compensation, stock based compensation, insurance, office costs, and professional services.  General and administrative expense decreased for the three months ended June 30, 2022 as compared to the prior year quarter due to lower employee compensation of $0.3 million, lower insurance costs of $0.1 million and various other lower costs. General and administrative expense includes stock based compensation of $0.3 million for the three months ended June 30, 2022 as compared to $0.7 million in the comparable prior year quarter.  General and administrative expenses for the three months ended June 30, 2021 included $0.3 million estimated for the Transaction Bonus Plan (the "LTIP"), which is a component of employee compensation.  There was no expense recognized pursuant to the LTIP for the three month period ended June 30, 2022.  The Company did not make any payments during the quarter.  

 

Other Income (loss), net. Other income (loss), net decreased $6.7 million for the three months ended June 30, 2022 compared to the prior year quarter.  During the three months ended June 30, 2022, the Company recorded an unrealized loss of $0.1 million related to the decline in the fair value of Bright Health common stock that was offset by a non-cash gain at an Other ownership interest.  During the three months ended June 30, 2021, the Company recorded an unrealized gain of $7.4 million related to the observable price change and additional price movements in Bright Health common stock resulting from the initial public offering and subsequent trading activity.  The Company also recorded a $1.8 million gain resulting from the acquisition of Velano Vascular by another entity during the quarter.  During the period ended June 30, 2021, the Company recorded an impairment of $2.5 million related to reduced expectation for certain Other ownership interests.    

 

Interest Income. Interest income increased during the three months ended June 30, 2022 as compared to the prior year period primarily attributable to a higher average balance of advances to ownership interests.

 

Equity Income (loss), net. Equity income (loss), net increased $6.6 million for the three months ended June 30, 2022 compared to the prior year period. The components of equity income (loss), net for the three months ended June 30, 2022 and 2021 were as follows:

 

   

Three Months Ended June 30,

 
   

2022

   

2021

   

Variance

 
   

(In thousands)

 

Gains on sales of ownership interests, net

  $ 88     $ 280     $ (192 )

Unrealized dilution gains

    5,285             5,285  

Share of loss of our equity method companies, net

    (3,919 )     (5,416 )     1,497  
    $ 1,454     $ (5,136 )   $ 6,590  

 

There were no material gains on sales of ownership interests, net, from ownership interests accounted for under the equity method during the three months ended June 30, 2022 and 2021. The unrealized dilution gains for the three months ended June 30, 2022 was the result of Moxe Health, who raised additional equity capital that diluted the Company's interest.  The change in our share of loss of our equity method companies for the three months ended June 30, 2022 compared to the prior year period of $1.5 million was due to less companies in 2022 and a decrease in losses associated with our ownership interests. 

 

18

 

Six months ended June 30, 2022 versus the six months ended June 30, 2021

 

   

Six Months Ended June 30,

 
   

2022

   

2021

   

Variance

 
   

(In thousands)

 

General and administrative expense

  $ (2,380 )   $ (4,454 )   $ 2,074  

Other income (loss), net

    (1,967 )     7,439       (9,406 )

Interest income

    246       127       119  

Equity income (loss), net

    (2,125 )     14,193       (16,318 )
    $ (6,226 )   $ 17,305     $ (23,531 )

 

General and Administrative Expense. Our general and administrative expenses consist primarily of employee compensation, stock based compensation, insurance, office costs, and professional services.  General and administrative expense decreased for the six months ended June 30, 2022 as compared to the prior year quarter due to lower severance costs of $0.8 million, lower employee compensation of $0.8 million, lower insurance costs of $0.2 million and various other lower costs. General and administrative expense includes stock based compensation of $0.6 million for the six months ended June 30, 2022 as compared to $1.0 million in the comparable prior year quarter.  General and administrative expenses for the six months ended June 30, 2021 included $0.5 million estimated for the Transaction Bonus Plan (the "LTIP"), which is a component of employee compensation.  There was no expense recognized pursuant to the LTIP for the six month period ended June 30, 2022.  The Company did not make any payments during the quarter.  

 

Other Income (loss), net. Other income (loss), net decreased $9.4 million for the six months ended June 30, 2022 compared to the prior year quarter.  During the six months ended June 30, 2022, the Company recorded an unrealized loss of $2.1 million related to the decline in the fair value of Bright Health common stock.  During the six months ended June 30, 2021, the Company recorded an unrealized gain of $7.4 million related to the observable price change and additional price movements in Bright Health common stock resulting from the initial public offering and subsequent trading activity.  The Company also recorded a $1.8 million gain resulting from the acquisition of Velano Vascular and $0.7 million from the acquisition of T-Rex by other entities.  During the six months ended June 30, 2021, the Company recorded an impairment of $2.5 million related to reduced expectations for certain Other ownership interests.

    

 

Interest Income. Interest income increased during the six months ended June 30, 2022 as compared to the prior year period primarily attributable to a higher average balance of advances to ownership interests.

 

Equity Income (loss), net. Equity income (loss), net decreased $16.3.million for the six months ended June 30, 2022 compared to the prior year period. The components of equity income (loss), net for the six months ended June 30, 2022 and 2021 were as follows:

 

   

Six Months Ended June 30,

 
   

2022

   

2021

   

Variance

 
   

(In thousands)

 

Gains on sales of ownership interests

  $ 386     $ 16,788     $ (16,402 )

Unrealized dilution gains

    5,285       7,302       (2,017 )

Share of loss of our equity method companies, net

    (7,796 )     (9,897 )     2,101  
    $ (2,125 )   $ 14,193     $ (16,318 )

 

There were no material gains on sales of ownership interests, net, or impairments from ownership interests accounted for under the equity method during the six months ended June 30, 2022 and 2021  The Company recorded a gain of $17.0 million during the six months ended June 30, 2021 with respect to the Zipnosis transaction where the Company received $3.3 million in cash proceeds and $15.3 million in preferred equity in Bright Health. The unrealized dilution gains for the six months ended June 30, 2022 was the result of Moxe Health, who raised additional equity capital that diluted the Company's interest. The unrealized dilution gains for the six months ended June 30, 2021 was the result of Syapse, who raised additional equity capital that diluted the Company's interest. The change in our share of loss of our equity method companies for the six months ended June 30, 2022 compared to the prior year period of $2.1 million was due to less companies in 2022 and a decrease in losses associated with our ownership interests. 

 

19

 

Income Tax Benefit (Expense)

 

Income tax benefit (expense) was $0.0 million for the three and six months ended June 30, 2022 and 2021. We have recorded a valuation allowance to reduce our net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the income tax provision that would have been recognized in the six months ended June 30, 2022 and 2021 was offset by changes in the valuation allowance.

 

Liquidity and Capital Resources

 

As of June 30, 2022, we had $17.5 million of cash and cash equivalents.

 

In January 2018, Safeguard announced that we will not deploy any capital into new opportunities and will focus on supporting our existing ownership interests and maximizing monetization opportunities to return value to shareholders. In that context, we have, are and will consider initiatives including, among others: the sale of individual ownership interests, the sale of certain ownership interests in secondary market transactions, or a combination thereof, as well as other opportunities to maximize shareholder value. 

 

In 2015, the Company's Board of Directors authorized us, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. During the year ended December 31, 2021 and the six months ended June 30, 2022, we did not repurchase any shares under this authorization.  In March 2022, the Company's Board of Directors replaced a previously existing share repurchase plan that was authorized in May 2021 with a newly authorized $3.0 million share repurchase plan using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended.  The Company purchased 369,274 shares for an aggregate price of $1.7 million at an average cost at $4.67 per share pursuant to this plan.  

 

Our ability to generate liquidity from transactions involving our ownership interests has been adversely affected from time to time by adverse circumstances in the U.S. capital markets and other factors, including the impact of COVID-19.  We may be requested to provide additional capital to our companies, which may cause us to face liquidity issues that will constrain our ability to execute our business strategy and limit our ability to provide financial support to all of our existing companies in the amounts that we desire.  The transactions we enter into in pursuit of our strategy could increase or decrease our liquidity at any point in time. As we seek to provide additional funding to existing companies where we have an ownership interest or commit capital to other initiatives, we may be required to expend our cash or incur debt, which will decrease our liquidity. Conversely, as we dispose of our interests in our ownership interests, we may receive proceeds from such sales, which could increase our liquidity. From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.  Accordingly, the Company could also pursue other sources of capital in order to maintain its liquidity.  The Company believes that its cash and cash equivalents at June 30, 2022 will be sufficient to fund operations past one year from the issuance of these financial statements.

 

20

 

Analysis of Consolidated Cash Flows

 

Cash flow activity was as follows:

 

   

Six Months Ended June 30,

 
   

2022

   

2021

   

Variance

 
   

(In thousands)

 

Net cash used in operating activities

  $ (2,099 )   $ (4,734 )   $ 2,635  

Net cash (used in) provided by investing activities

    (2,915 )     12,151       (15,066 )

Net cash used in financing activities

    (2,215 )     (1,688 )     (527 )
    $ (7,229 )   $ 5,729     $ (12,958 )

 

Net Cash Used In Operating Activities

 

Net cash used in operating activities decreased by $2.6 million for the six months ended June 30, 2022 compared to the prior year period. The activity during the six months ended June 30, 2022 was primarily the result of various non-cash adjustments to net loss, including $2.1 million of equity loss and a $2.1 million unrealized loss on the decrease in fair value of Bright Health common stock.  The activity during the six months ended June 30, 2021 was primarily the result of various non-cash adjustments to net income, including $14.2 million of equity income.  

 

Net Cash (Used in) Provided by Investing Activities

 

Net cash (used in) provided by investing activities decreased by $15.1 million for the six months ended June 30, 2022 compared to the prior year period. During the six months ended June 30, 2022, the Company funded an aggregate of $3.4 million to Prognos Health and Clutch Holdings as compared $1.0 million funded to Trice Medical during the six months ended June 30, 2021.  The Company also received an aggregate of $13.2 million of cash proceeds from the WebLinc, Zipnosis, T-REX and Velano Vascular transactions during the six months ended June 30, 2021.    

 

Net Cash Used In Financing Activities

 

Net cash used in financing activities increased by $0.5 million for the six months ended June 30, 2022 compared to the prior year.  The increase was primarily the result of $1.7 million in repurchases of our common stock.

 

Contractual Cash Obligations and Other Commercial Commitments

 

The following table summarizes our contractual obligations and other commercial commitments as of June 30, 2022, by period due or expiration of the commitment. 

 

   

Payments Due by Period

 
   

Total

    2022 (remainder)    

2023 and 2024

   

2025 and 2026

   

After 2026

 
   

(In millions)

 

Contractual Cash Obligations:

                                       

Operating leases (a)

  $ 2.3       0.3       1.2       0.8        

Total Contractual Cash Obligations (b)

  $ 2.3     $ 0.3     $ 1.2     $ 0.8     $  

 

 

(a)

In 2015, we entered into an agreement for the lease of our former principal executive offices which expires in April 2026. In March 2019, we entered into a sublease for these offices which is expected to result in future aggregate sublease receipts of $2.2 million through April 2026.

 

 

(b)

The maximum aggregate exposure under employment and severance agreements for remaining employees was approximately $0.8 million at June 30, 2022 (not reflected in the table above).

 

21

 

Factors That May Affect Future Results

 

You should carefully consider the information set forth below. The following risk factors describe situations in which our business, financial condition and/or results of operations could be materially harmed, and the value of our securities may be adversely affected. You should also refer to other information included or incorporated by reference in this report. 

 

Our ability to obtain value from our companies and the return of such value to our shareholders are subject to factors beyond our control.

 

In January 2018, we announced that we will not deploy any capital into new companies.  We will instead focus on supporting, and maximizing monetization opportunities for, our existing company interests to return value to shareholders.  In that context, we have considered and continue to consider monetization initiatives including, among others: the sale of our ownership interests, the sale of certain or all ownership interests in secondary market transactions, or a combination thereof, the sale of all of our ownership interests in a single transaction or a series of transactions, business combinations and other strategic transactions as well as other opportunities to maximize shareholder value.  However, this strategic plan may require providing additional capital and operational support to such existing companies and we may not be able to complete any such transaction during any specific time frame or otherwise on desirable terms, if at all, and there can be no assurance as to how long this process will take or the results that this process will yield.  In addition, there can be no assurance that any exploration of a strategic transaction will result in any strategic change or outcome and disclosure of any developments related to such exploration may not be disclosed until required.  Further, if one or more transactions are completed, there can be no assurance as to whether we will realize the value of escrowed proceeds, holdbacks or other contingent consideration, if any, associated with such transaction.  Additionally, there can be no assurance that we will be able to satisfy our liabilities during this process.  The method, timing and amount of any return of value resulting from such a transaction will also be at the discretion of our Board of Directors and may depend on market and business conditions and our overall liabilities, capital structure and liquidity position.

 

A disposition of one or more of our company interests may occur at a time that will yield less value than if we held such interests for a longer period of time.

 

Our companies are at various stages in their lifecycles. The value of our interests in our companies at any point in time is highly dependent on the progress and success such companies have made at such time with respect to the development and marketing of their products and services and that value may fluctuate significantly. In order to effect our strategy of monetizing our interests in our companies, we may dispose of such interests at a time prior to the applicable company reaching its maximum value. Doing so will result in a return of value to shareholders that is less than that which may have been returned if we retained our interests in such company for a longer period of time.

 

The effects of the COVID-19 pandemic may adversely affect the businesses, financial conditions and operating results of the companies in which we have an ownership interest, as well as our ability to monetize such interests, and it may also cause us to increase the amount of additional capital we will need to provide to such companies.

 

To varying degrees, the economic and market conditions caused by the COVID-19 pandemic have negatively impacted, and continue to negatively impact, the companies in which we have ownership interests, including, without limitation, their operations, supply chains, sales infrastructures and the demand for their products and services.  This is negatively affecting their businesses, financial conditions and operating results.  As a result, we may be required to provide additional capital to certain companies, which may cause us to face liquidity issues that will constrain our ability to execute our business strategy and limit our ability to provide financial support to all of our existing companies in the amounts that we desire.  The COVID-19 pandemic is also impacting the mergers and acquisitions market for certain companies, which in some cases has resulted in lower valuation expectations and extended exit timelines for such companies. This, in turn, could negatively affect the amount and timing of the monetization opportunities for such companies and our ability to return value to shareholders.  

 

22

 

Our principal business strategy depends upon our ability to make good decisions regarding the deployment of capital into, and subsequent disposition of, our existing company interests and, ultimately, the performance of such companies, which is uncertain.

 

If we make poor decisions regarding the deployment of capital into, and subsequent disposition of, our existing companies, our business strategy will not succeed. If such companies do not succeed, the value of our assets could be significantly reduced and require substantial impairments or write-offs and our results of operations and the price of our common stock would be adversely affected. The risks relating to our companies include:

 

most of our companies have a history of operating losses and/or limited operating history;

 

 

the intense competition affecting the products and services our companies offer could adversely affect their businesses, financial condition, results of operations and prospects for growth;

 

 

the inability to adapt to changing marketplaces;

 

 

the inability to manage growth;

 

 

the need for additional capital to fund their operations, which we may not be able to fund or which may not be available from third parties on acceptable terms, if at all;

 

 

the inability to protect their proprietary rights and/or infringing on the proprietary rights of others;

 

 

that our companies could face legal liabilities from claims made against them based upon their operations, products or work;

 

 

the impact of economic downturns on their operations, results and growth prospects;

 

 

the inability to attract and retain qualified personnel;

 

 

the existence of government regulations and legal uncertainties may place financial burdens on the businesses of our companies; and

 

 

the inability to plan for and manage catastrophic events.

 

These and other risks are discussed in detail under the caption “Risks Related to Our Companies” below.

 

As we execute against our strategy, a significant amount of our deployed capital may be concentrated in fewer companies.  These remaining companies may also operate in the same or similar industries.  This will limit our diversification and make us more susceptible to a single negative event. 

 

As we execute against our strategy, our capital deployments will be deployed in a decreasing number of companies.  Further, our remaining companies could be concentrated in the same or similar industries. Fewer companies, as well as potential industry concentration, may cause us to be more susceptible to any single economic, regulatory or other occurrence affecting a single company or a particular industry than we would have otherwise been if we had a larger number of companies and our companies operated in more diversified industries.

 

Our business model does not rely upon, or plan for, the receipt of operating cash flows from our companies. Our companies do not provide us with cash flow from their operations. We rely on cash on hand, liquidity events and our ability to generate cash from capital raising activities to finance our operations.

 

We need capital to fund the capital needs of our existing companies. We also need cash to finance our corporate overhead and meet our existing funding commitments. As a result, we have substantial cash requirements. Our companies do not provide us with cash flow from their operations. To the extent our companies generate any cash from operations, they generally retain the funds to develop their own businesses. As a result, we must rely on cash on hand, company liquidity events and new capital raising activities to meet our cash needs. If we are unable to find ways of monetizing our holdings of company interests or raising additional capital on attractive terms, we may face liquidity issues that will require us to constrain our ability to execute our business strategy and limit our ability to provide financial support to our existing companies.

 

23

 

We may be unable to obtain maximum value for our holdings or to sell our holdings on a timely basis.

 

We hold significant positions in our companies. If we were to divest all or part of our holdings in a company, we may have to sell our interests at a relative discount to intrinsic value. For companies with publicly traded stock, we may be unable to sell our holdings at then-quoted market prices. The trading volume and public float in the common stock of a publicly traded company in which we have an interest may be small relative to our holdings. As a result, any significant open-market divestiture by us of our holdings in such a company, if possible at all, would likely have a material adverse effect on the market price of its common stock and on our proceeds from such a divestiture. Additionally, we may not be able to take our companies public as a means of monetizing our position or creating shareholder value. Registration and other requirements under applicable securities laws and contractual restrictions also may adversely affect our ability to dispose of our company holdings on a timely basis.

 

Our success is dependent on our senior management.

 

Our success is dependent on our senior management team’s ability to execute our strategy. In connection with our strategy announced in 2018, we made a series of management changes intended to streamline our organizational structure and reduce our operating costs and since then we have made, and may make, further management changes from time to time.  A loss of one or more of the remaining members of our senior management team without adequate replacement could have a material adverse effect on us.

 

Our business strategy may not be successful if valuations in the market sectors in which our companies participate decline.

 

Our strategy involves creating value for our shareholders by helping our companies build value and, if appropriate, access the public and private capital markets. Therefore, our success is dependent on the value of our companies as determined by the public and private capital markets. Many factors, including reduced market interest, may cause the market value of our companies to decline. If valuations in the market sectors in which our companies participate decline, their access to the public and private capital markets on terms acceptable to them may be limited.

 

Our companies could make business decisions that are not in our best interests or with which we do not agree, which could impair the value of our holdings.

 

Although we currently own a significant, influential interest in some of our companies, we do not maintain a controlling interest in any of our companies. Acquisitions of interests in companies in which we share or have no control, and the dilution of our interests in or a further reduction of our control of companies, will involve additional risks that could cause the performance of our interests and our operating results to suffer, including:

 

the management teams or other equity or debt holders of our companies having economic or business interests or objectives that are different from ours; and

 

the companies not taking our advice with respect to the financial or operating issues they may encounter.

 

Our inability to control our companies also could prevent us from assisting them, financially or otherwise, or could prevent us from liquidating our interests in them at a time or at a price that is favorable to us. Additionally, our companies may not act in ways that are consistent with our business strategy. These factors could hamper our ability to maximize returns on our interests and cause us to incur losses on our interests in these companies.

 

We may have to buy, sell or retain assets when we would otherwise not wish to do so in order to avoid registration under the Investment Company Act.

 

The Investment Company Act of 1940 regulates companies which are engaged primarily in the business of investing, reinvesting, owning, holding or trading in securities. Under the Investment Company Act, a company may be deemed to be an investment company if it owns investment securities with a value exceeding 40% of the value of its total assets (excluding government securities and cash items) on an unconsolidated basis, unless an exemption or safe harbor applies. We refer to this test as the “40% Test.” Securities issued by companies other than consolidated companies are generally considered “investment securities” for purposes of the Investment Company Act, unless other circumstances exist which actively involve the company holding such interests in the management of the underlying company. We are a company that partners with growth-stage companies to build value; we are not engaged primarily in the business of investing, reinvesting or trading in securities. We are in compliance with the 40% Test. Consequently, we do not believe that we are an investment company under the Investment Company Act.

 

We monitor our compliance with the 40% Test and seek to conduct our business activities to comply with this test. It is not feasible for us to be regulated as an investment company because the Investment Company Act rules are inconsistent with our strategy of actively helping our companies in their efforts to build value. In order to continue to comply with the 40% Test, we may need to take various actions which we would otherwise not pursue. For example, we may be limited in the manner or timing in which we sell our interests in a company. Our ownership levels also may be affected if our companies are acquired by third parties or if our companies issue stock which dilutes our ownership interest. The actions we may need to take to address these issues while maintaining compliance with the 40% Test could adversely affect our ability to create and realize value at our companies.

 

The COVID-19 pandemic may adversely affect parties with obligations to us, including the subtenant of our previous office space.

 

In March 2019, we entered into a sublease of our prior corporate headquarters office space beginning in June 2019. The term of the sublease is through April 2026, the same as our underlying lease. Fixed sublease payments to us are escalating over the term of the sublease.  We remain obligated under the original lease for such office space and, in the event the subtenant of such office space fails to satisfy its obligations under the sublease, we would be required to satisfy our obligations directly to the landlord under such original lease.

 

24

 

Risks Related to Our Companies

 

Most of our companies have a history of operating losses and/or limited operating history and may never be profitable.

 

Most of our companies have a history of operating losses and/or limited operating history, have significant historical losses and may never be profitable. Many have incurred substantial costs to develop and market their products, have incurred net losses and cannot fund their cash needs from operations. We expect that the operating expenses of certain of our companies will increase substantially in the foreseeable future as they continue to develop products and services, increase sales and marketing efforts, and expand operations.

 

Our companies face intense competition, which could adversely affect their business, financial condition, results of operations and prospects for growth.

 

There is intense competition in the technology marketplaces, and we expect competition to intensify in the future. Our business, financial condition, and results of operations will be materially adversely affected if our companies are not able to compete successfully. Many of the present and potential competitors may have greater financial, technical, marketing and other resources than those of our companies. This may place our companies at a disadvantage in responding to the offerings of their competitors, technological changes or changes in client requirements. Also, our companies may be at a competitive disadvantage because many of their competitors have greater name recognition, more extensive client bases and a broader range of product offerings. In addition, our companies may compete against one another.

 

The success or failure of many of our companies is dependent upon the ultimate effectiveness of newly-created technologies, medical devices, financial services, healthcare diagnostics, etc.

 

Our companies’ business strategies are often highly dependent upon the successful launch and commercialization of an innovative technology or device, including, without limitation, technologies or devices used in healthcare, financial services or digital media.  Despite all of our efforts to understand the research and development underlying the innovation or creation of such technologies and devices before we deploy capital into a company, sometimes the performance of the technology or device does not match our expectations or those of such company. In those situations, it is likely that we will incur a partial or total loss of the capital which we deployed in such company.

 

Our companies may fail if they do not adapt to changing marketplaces.

 

If our companies fail to adapt to changes in technology and customer and supplier demands, they may not become or remain profitable. There is no assurance that the products and services of our companies will achieve or maintain market penetration or commercial success, or that the businesses of our companies will be successful.

 

The technology marketplaces are characterized by:

 

rapidly changing technology;

 

 

evolving industry standards;

 

 

frequent introduction of new products and services;

 

 

shifting distribution channels;

 

 

evolving government regulation;

 

 

frequently changing intellectual property landscapes; and

 

 

changing customer demands.

 

Our future success will depend on our companies’ ability to adapt to these evolving marketplaces. They may not be able to adequately or economically adapt their products and services, develop new products and services or establish and maintain effective distribution channels for their products and services. If our companies are unable to offer competitive products and services or maintain effective distribution channels, they will sell fewer products and services and forego potential revenue, possibly causing them to lose money. In addition, we and our companies may not be able to respond to the marketplace changes in an economically efficient manner, and our companies may become or remain unprofitable.

 

25

 

Our companies may grow rapidly, including through acquisitions of other businesses, and may be unable to manage their growth.

 

We expect some of our companies to grow rapidly, including through acquisitions of other businesses. Such growth often places considerable operational, managerial, integration and financial strain on a business. To successfully manage such growth, our companies must, among other things:

 

improve, upgrade and expand their business infrastructures;

 

 

successfully integrate and operate any newly acquired businesses;

 

 

scale up production operations;

 

 

develop appropriate financial reporting controls;

 

 

attract and retain qualified personnel; and

 

 

maintain appropriate levels of liquidity.

 

If our companies are unable to manage their growth successfully, their ability to respond effectively to competition and to achieve or maintain profitability will be adversely affected. Further, a material weakness in any of our companies’ internal controls over their financial reporting could result in material misstatements in our Consolidated Financial Statements. These misstatements could result in a restatement of our Consolidated Financial Statements, cause us to fail to meet our reporting obligations and/or cause investors to lose confidence in our reported financial information, leading to a decline in our stock price.

 

Based on our business model, some or all of our companies will need to raise additional capital to fund their operations at any given time. We may not be able to, or decline to, fund some or all of such amounts and such amounts may not be available from third parties on acceptable terms, if at all. Further, if our companies do raise additional capital from third parties, either debt or equity, such capital may rank senior to, or dilute, our interests in such companies.

 

We cannot be certain that our companies will be able to obtain additional financing on favorable terms when needed, if at all. We may not be able to, or decline to, provide our companies with sufficient capital resources to enable them to reach a cash-flow positive position or a sale of the company. General economic disruptions and downturns may also negatively affect the ability of some of our companies to fund their operations from other stockholders and capital sources. We also may fail to accurately project the capital needs of companies. If our companies need capital, but are not able to raise capital from us or other outside sources, or our companies are unable to service their debt obligations, they may need to, or be forced to, cease or scale back operations. In such event, our interest in any such company will become less valuable. If our companies raise additional capital from third parties, either debt or equity, such capital may be dilutive, making our interests less valuable or if such capital ranks senior to the capital we have deployed, such capital may entitle its holders to receive returns of capital before we are entitled to receive any return of our deployed capital. Also, in the event of any insolvency, liquidation, dissolution, reorganization or bankruptcy of one or more our companies, holders of such company’s instruments that rank senior to our deployed capital will typically be entitled to receive payment in full before we receive any return of our deployed capital. After returning such senior capital, such company may not have any remaining assets to use for returning capital to us, causing us to lose some or all of our deployed capital in such company.

 

Economic disruptions and downturns may negatively affect our companies plans and their results of operations.

 

Many of our companies are largely dependent upon outside sources of capital to fund their operations. Disruptions in the availability of capital from such sources will negatively affect the ability of such companies to pursue their business models and will force such companies to revise their growth and development plans accordingly. Any such changes will, in turn, negatively affect our ability to realize the value of our capital deployments in such companies.

 

In addition, downturns in the economy as well as possible governmental responses to such downturns and/or to specific situations in the economy could affect the business prospects of certain of our companies, including, but not limited to, in the following ways: weaknesses in the financial services industries; reduced business and/or consumer spending; and/or systemic changes in the ways the healthcare system operates in the United States.

 

26

 

Some of our companies may be unable to protect their proprietary rights and may infringe on the proprietary rights of others.

 

Our companies assert various forms of intellectual property protection. Intellectual property may constitute an important part of our companies’ assets and competitive strengths. Federal law, most typically copyright, patent, trademark and trade secret laws, generally protects intellectual property rights. Although we expect that our companies will take reasonable efforts to protect the rights to their intellectual property, third parties may develop similar intellectual property independently. Moreover, the complexity of international trade secret, copyright, trademark and patent law, coupled with the limited resources of our companies and the demands of quick delivery of products and services to market, create a risk that our companies’ efforts to prevent misappropriation of their technology will prove inadequate.

 

Some of our companies also license intellectual property from third parties and it is possible that they could become subject to infringement actions based upon their use of the intellectual property licensed from those third parties. Our companies generally obtain representations as to the origin and ownership of such licensed intellectual property. However, this may not adequately protect them. Any claims against our companies’ proprietary rights, with or without merit, could subject the companies to costly litigation and divert their technical and management personnel from other business concerns. If our companies incur costly litigation and their personnel are not effectively deployed, the expenses and losses incurred by our companies will increase and their profits, if any, will decrease.

 

Third parties have and may assert infringement or other intellectual property claims against our companies based on their patents or other intellectual property claims. Even though we believe our companies’ products do not infringe any third party’s patents, they may have to pay substantial damages, possibly including treble damages, if it is ultimately determined that they do. They may have to obtain a license to sell their products if it is determined that their products infringe on another person’s intellectual property. Our companies might be prohibited from selling their products before they obtain a license, which, if available at all, may require them to pay substantial royalties. Even if infringement claims against our companies are without merit, defending these types of lawsuits takes significant time, is expensive and may divert management attention from other business concerns.

 

Certain of our companies could face legal liabilities from claims made against their operations, products or work.

 

Because the manufacture and sale of certain company products entail an inherent risk of product liability, certain of our companies maintain product liability insurance. Although none of our current companies have experienced any material losses in this regard, there can be no assurance that they will be able to maintain or acquire adequate product liability insurance in the future and any product liability claim could have a material adverse effect on a company’s financial stability, revenues and results of operations. In addition, many of the engagements of our companies involve projects that are critical to the operation of their clients’ businesses. If our companies fail to meet their contractual obligations, they could be subject to legal liability, which could adversely affect their business, operating results and financial condition. Our companies’ contracts typically include provisions designed to limit their exposure to legal claims relating to their services and products. However, these provisions may not protect our companies or may not be enforceable. Also, some of our companies depend on their relationships with their clients and their reputation for high-quality services and integrity to retain and attract clients. As a result, claims made against our companies’ work may damage their reputation, which in turn could impact their ability to compete for new work and negatively impact their revenue and profitability.

 

Our companies success depends on their ability to attract and retain qualified personnel.

 

Our companies depend upon their ability to attract and retain senior management and key personnel, including trained technical and marketing personnel. Our companies also will need to continue to hire additional personnel as they expand. Although our current companies have not been the subject of a work stoppage, any future work stoppage could have a material adverse effect on their respective operations. A shortage in the availability of the requisite qualified personnel or work stoppage would limit the ability of our companies to grow, to increase sales of their existing products and services, and to launch new products and services.

 

Government regulations and legal uncertainties may place financial burdens on the businesses of our companies.

 

Manufacturers of medical diagnostic devices and operators of laboratory facilities are subject to strict federal and state regulation regarding validation and the quality of manufacturing and laboratory facilities. Failure to comply with these quality regulation systems requirements could result in civil or criminal penalties or enforcement proceedings, including the recall of a product or a “cease distribution” order. The enactment of any additional laws or regulations that affect healthcare insurance policy and reimbursement (including Medicare reimbursement) could negatively affect some of our companies. If Medicare or private payers change the rates at which our companies or their customers are reimbursed by insurance providers for their products, such changes could adversely impact our companies.

 

Some of our companies may be subject to significant environmental, health, data security and safety regulation.

 

Some of our companies may be subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety, including laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials, as well as to the safety and health of manufacturing and laboratory employees. In addition, some of our companies are subject to federal, state and local financial securities and data security regulations, including, without limitation, the Health Insurance Portability and Accountability Act of 1996, as amended, the California Consumer Privacy Act and the European General Data Protection Regulation, which impose varying degrees of additional obligations, costs and risks upon such companies, including the imposition of significant penalties in the event of any non-compliance. Further, the federal Occupational Safety and Health Administration has established extensive requirements relating to workplace safety. Compliance with such regulations could increase operating costs at certain of our companies, and the failure to comply could negatively affect the operations and results of some of our companies.

 

Catastrophic events may disrupt our companies businesses.

 

Some of our companies are highly automated businesses and rely on their network infrastructure, various software applications and many internal technology systems and data networks for their customer support, development, sales and marketing and accounting and finance functions. Further, some of our companies provide services to their customers from data center facilities in multiple locations. Some of these data centers are operated by third parties, and the companies have limited control over those facilities. A disruption or failure of these systems or data centers in the event of a natural disaster, telecommunications failure, power outage, cyber-attack, war, terrorist attack or other catastrophic event could cause system interruptions, reputational harm, delays in product development, breaches of data security and loss of critical data. Such an event could also prevent the companies from fulfilling customer orders or maintaining certain service level requirements, particularly in respect of their SaaS offerings. While certain of our companies have developed certain disaster recovery plans and maintain backup systems to reduce the potentially adverse effect of such events, a catastrophic event that resulted in the destruction or disruption of any of their data centers or their critical business or information technology systems could severely affect their ability to conduct normal business operations and, as a result, their business, operating results and financial condition could be adversely affected.

 

27

 

We cannot provide assurance that our companies’ disaster recovery plans will address all of the issues they may encounter in the event of a disaster or other unanticipated issue, and their business interruption insurance may not adequately compensate them for losses that may occur from any of the foregoing. In the event that a natural disaster, terrorist attack or other catastrophic event were to destroy any part of their facilities or interrupt their operations for any extended period of time, or if harsh weather or health conditions prevent them from delivering products in a timely manner, their business, financial condition and operating results could be adversely affected.

 

Risks Related to an Investment in our Securities

 

Fluctuations in the price of the common stock of our publicly traded holdings may affect the price of our common stock.

 

From time to time, we may hold equity interests in companies that are publicly traded. Fluctuations in the market prices of the common stock of publicly traded holdings may affect the price of our common stock. Historically, the market prices of our publicly traded holdings have been highly volatile and subject to fluctuations unrelated or disproportionate to operating performance.

 

The continuing costs and burdens associated with being a public company will constitute a much larger percentage of our expenses and we may in the future delist our common stock with the New York Stock Exchange and seek to deregister our common stock with the SEC.

 

We will remain a public company and will continue to be subject to the listing standards of the New York Stock Exchange and SEC rules and regulations, including the Dodd-Frank Wall Street Reform and Consumer Protection Act and the Sarbanes-Oxley Act of 2002.  The costs and burdens of being a public company will be a significant and continually increasing portion of our expenses if we are able to monetize our company interests.  As part of such monetization efforts, we will likely in the future, once the majority of our company interests have been monetized, delist our common stock from the New York Stock Exchange and seek to deregister our common stock with the SEC.  However, there can be no assurance as to the timing of such transactions, or whether such transactions will be completed at all, and we will continue to face the costs and burdens of being a public company until such time as our common stock is delisted with the New York Stock Exchange and deregistered with the SEC.

 

Economic disruptions and downturns may have negative repercussions for us.

 

Events in the United States and international capital markets, debt markets and economies may negatively impact our stock price and our ability to pursue certain tactical and strategic initiatives, such as accessing additional public or private equity or debt financing for us or for our companies and selling our interests in companies on terms acceptable to us and in time frames consistent with our expectations.

 

We cannot provide assurance that material weaknesses in our internal control over financial reporting will not be identified in the future.

 

We cannot assure you that material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in a material weakness, or could result in material misstatements in our Consolidated Financial Statements. These misstatements could result in a restatement of our Consolidated Financial Statements, cause us to fail to meet our reporting obligations and/or cause investors to lose confidence in our reported financial information, leading to a decline in our stock price.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

There have been no material changes to the information we previously disclosed under Item 7A of Part II of our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 11, 2022.

 

Item 4.  Controls and Procedures

 

(a) Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of June 30, 2022 are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

 

(b) Change in Internal Control over Financial Reporting

 

No change in our internal control over financial reporting occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

28

 

PART II

 

OTHER INFORMATION

 

Item 1. Legal Proceedings

 

None.  

 

Item 1A. Risk Factors

 

Except as included under the heading “Factors That May Affect Future Results” above, there have been no material changes in our risk factors from the information set forth in our Annual Report on Form 10-K for the year ended December 31, 2021.

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

The following table provides information about purchases of equity securities by the Company and affiliated purchasers of the Company, during the quarter ended June 30, 2022, which equity securities are registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"):

 

Period

 

Total Number of Shares Purchased (a)

   

Average Price Paid Per Share

   

Total Number of Shares Purchased as Part of Publicly Announced Plan (b)

   

Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plan (b)

 

April 1, 2022 - April 30, 2022

    85,351     $ 4.81       80,687     $ 16,469,533  

May 1, 2022 - May 31, 2022

    88,571     $ 3.92       86,029     $ 16,131,902  

June 1, 2022 - June 30, 2022

    57,305     $ 3.99       54,763     $ 15,912,749  

Total

    231,227     $ 4.27       221,479          

 

 

(a)

During the second quarter of 2022, the Company repurchased an aggregate of 10 thousand shares of its common stock initially issued as restricted stock awards to employees and subsequently withheld from employees to satisfy the statutory withholding tax liability upon the vesting of such restricted stock awards.

 

 

(b)

In July 2015, our Board of Directors authorized the Company to repurchase shares of its outstanding common stock with an aggregate value of up to $25.0 million. These repurchases may be made in open market or privately negotiated transactions, including under plans complying with Rule 10b5-1 of the Exchange Act, based on market conditions, stock price, and other factors. In March 2022, the Company's Board of Directors replaced a previously existing share repurchase plan that was authorized in May 2021 with a newly authorized $3.0 million share repurchase plan using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The share repurchase programs does not obligate the Company to acquire any specific number of shares. 

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

29

 

Item 6.  Exhibits

 

(a) Exhibits.

 

The following is a list of exhibits required by Item 601 of Regulation S-K to be filed as part of this Report. For exhibits that previously have been filed, the Registrant incorporates those exhibits herein by reference. Documents which are incorporated by reference to filings by parties other than the Registrant are identified in a footnote to this table.

 

Exhibit Number

      

Description

   

 

 

 

 

31.1 †

      

Certification of Eric C. Salzman pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934.

      

   

   

   

   

31.2 †

      

Certification of Mark A. Herndon pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934.

      

   

   

   

   

32.1 ‡

      

Certification of Eric C. Salzman pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

      

   

   

   

   

32.2 ‡

      

Certification of Mark A. Herndon pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

      

   

   

   

   

101   The following materials from Safeguard Scientifics, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language); (i) Consolidated Balance Sheets (unaudited); (ii) Consolidated Statements of Operations (unaudited); (iii) Consolidated Statements of Comprehensive Income (Loss) (unaudited); (iv) Condensed Consolidated Statements of Cash Flows (unaudited); (v) Consolidated Statement of Changes in Equity (unaudited); and (vi) Notes to Consolidated Financial Statements (unaudited).  
       
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  

 

Filed herewith

   

Furnished herewith

   
* This exhibit relates to management contracts or compensatory plans, contracts or arrangement in which directors and/or executive officers of the Registrant may participate.  Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K.

 

30

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

   

   

     

   

 

SAFEGUARD SCIENTIFICS, INC.

Date:

August 12, 2022

/s/    Eric C. Salzman  

   

 

Eric C. Salzman

   

 

Chief Executive Officer

Date:

August 12, 2022

/s/    Mark A. Herndon

   

 

Mark A. Herndon

   

 

Senior Vice President and Chief Financial Officer

 

 

 

31
EX-31.1 2 ex_380086.htm EXHIBIT 31.1 ex_380086.htm

Exhibit 31.1

   

CERTIFICATION

   

I, Eric C. Salzman, certify that:

   

1.

I have reviewed this Quarterly Report on Form 10-Q of Safeguard Scientifics, Inc.;

   

   

   

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

   

   

   

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

   

   

   

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

   

   

   

   

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   

   

   

   

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   

   

   

   

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   

   

   

   

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

   

   

   

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

   

   

   

   

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

   

   

   

   

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

   

   

   

 

SAFEGUARD SCIENTIFICS, INC.

   

 

   

Date:

August 12, 2022

/s/ Eric C. Salzman

   

 

Eric C. Salzman

   

 

Chief Executive Officer

 
EX-31.2 3 ex_380087.htm EXHIBIT 31.2 ex_380087.htm

Exhibit 31.2

   

CERTIFICATION

   

I, Mark A. Herndon, certify that:

   

1.

I have reviewed this Quarterly Report on Form 10-Q of Safeguard Scientifics, Inc.;

   

   

   

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

   

   

   

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

   

   

   

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

   

   

   

   

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   

   

   

   

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   

   

   

   

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   

   

   

   

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

   

   

   

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

   

   

   

   

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

   

   

   

   

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

   

   

   

 

SAFEGUARD SCIENTIFICS, INC.

   

 

   

Date:

August 12, 2022

/s/ Mark A. Herndon

   

 

Mark A. Herndon

   

 

Senior Vice President and Chief Financial Officer

 

 
EX-32.1 4 ex_380088.htm EXHIBIT 32.1 ex_380088.htm

Exhibit 32.1

   

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906

of the Sarbanes-Oxley Act of 2002

   

In connection with the Quarterly Report of Safeguard Scientifics, Inc. (“Safeguard”) on Form 10-Q for the six months ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Eric C. Salzman, Chief Executive Officer of Safeguard, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

   

 

1.

The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934, (15 U.S.C. 78m(a)); and

 

   

   

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Safeguard.

   

   

   

 

SAFEGUARD SCIENTIFICS, INC.

   

 

   

Date:

August 12, 2022

/s/ Eric C. Salzman

   

 

Eric C. Salzman

   

 

Chief Executive Officer 

 
EX-32.2 5 ex_380089.htm EXHIBIT 32.2 ex_380089.htm

Exhibit 32.2

   

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906

of the Sarbanes-Oxley Act of 2002

   

In connection with the Quarterly Report of Safeguard Scientifics, Inc. (“Safeguard”) on Form 10-Q for the six months ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark A. Herndon, Senior Vice President and Chief Financial Officer of Safeguard, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

   

 

1.

The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934, (15 U.S.C. 78m(a)); and

 

   

   

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Safeguard.

   

   

   

 

SAFEGUARD SCIENTIFICS, INC.

   

 

   

Date:

August 12, 2022

/s/ Mark A. Herndon

   

 

Mark A. Herndon

   

 

Senior Vice President and Chief Financial Officer

 

 
EX-101.SCH 6 sfe-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Changes in Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - General link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Ownership Interests and Advances link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Acquisitions of Ownership Interests link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Stock-Based Compensation link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Net Income (Loss) Per Share link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Segment Reporting link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Equity link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 2 - Ownership Interests and Advances (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 4 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 5 - Stock-Based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 7 - Net Income (Loss) Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 9 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 1 - General (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 2 - Ownership Interests and Advances (Details Textual) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 3 - Acquisitions of Ownership Interests (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 4 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 5 - Stock-Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 5 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 7 - Net Income (Loss) Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 8 - Segment Reporting (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 10 - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 sfe-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 sfe-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 sfe-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Significant Accounting Policies 2023, Operating lease payments us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Note 2 - Ownership Interests and Advances 2024, Operating lease payments us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Note 4 - Fair Value Measurements Note 5 - Stock-Based Compensation Note 7 - Net Income (Loss) Per Share Note 9 - Commitments and Contingencies Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details) Share-Based Payment Arrangement, Employee [Member] Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) Income Tax Disclosure [Text Block] Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) Note 5 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) us-gaap_GuaranteeObligationsCurrentCarryingValue Guarantor Obligations, Current Carrying Value Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) Lessee, Operating Lease, Liability, Maturity [Table Text Block] Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details) Other assets Share-Based Payment Arrangement, Nonemployee [Member] 2022 (six months ending December 31) us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear us-gaap_LiabilitiesCurrent Total current liabilities Notes To Financial Statements Notes To Financial Statements [Abstract] Schedule of Other Ownership Interests [Table Text Block] Revenue Comprehensive Income, Policy [Policy Text Block] Share-Based Payment Arrangement, Activity [Table Text Block] Ownership interests Debt Securities, Trading, and Equity Securities, FV-NI, Total us-gaap_AssetsCurrent Total current assets us-gaap_CashAndCashEquivalentsFairValueDisclosure Cash and cash equivalents Stockholders' Equity Note Disclosure [Text Block] us-gaap_PaymentsForAdvanceToAffiliate Advances and loans to ownership interests us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Total Equity Balance Balance Treasury stock, shares (in shares) Private Equity Funds [Member] Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued and outstanding at June 30, 2022 and December 31, 2021 Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Liquidity, Policy [Policy Text Block] Disclosure of accounting policy for liquidity. Accrued expenses and other current liabilities Accrued compensation and benefits Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Accounts payable Statistical Measurement [Axis] Investment, Name [Domain] Preferred stock, $0.10 par value; 1,000 shares authorized us-gaap_PolicyTextBlockAbstract Accounting Policies Investment, Name [Axis] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Preferred stock, shares authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) Employee stock options (in shares) Portion at Fair Value Measurement [Member] [Default] Preferred stock, par value (in dollars per share) sfe_EmployeeAndSeveranceAgreementMaximumAggregateExposure Employee and Severance Agreement, Maximum Aggregate Exposure Represents maximum aggregate exposure for employee and severance agreement. Estimate of Fair Value Measurement [Member] Measurement Basis [Axis] Fair Value, Inputs, Level 3 [Member] Unvested restricted stock and DSU's (in shares) Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Grantee Status [Domain] sfe_LongtermIncentivePlanBonusPoolPercent Long-term Incentive Plan, Bonus Pool Percent Represents bonus pool percent for long-term incentive plan. Weighted average shares used in computing income (loss) per share: Grantee Status [Axis] Fair Value Hierarchy and NAV [Axis] Current Liabilities: us-gaap_Assets Total Assets Cash Flows from Operating Activities: Statement [Line Items] us-gaap_NumberOfOperatingSegments Number of Operating Segments Share-Based Payment Arrangement [Text Block] AOCI Attributable to Parent [Member] Additional paid-in capital Other income (loss), net Segment Reporting Disclosure [Text Block] Equity: Bright Health [Member] Represents Bright Health. Award Type [Domain] Restricted cash Current Assets: Fair Value Disclosures [Text Block] Award Type [Axis] Net loss us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net The value of shares issued for restricted stock awards withheld for taxes. sfe_LongTermIncentivePlanPayments Long-term Incentive Plan, Payments Represents amount of payments under long-term incentive plan. Interest income Restricted Stock [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares) The number of shares issued for restricted stock awards and withheld for taxes. us-gaap_Liabilities Total Liabilities us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Net change in cash, cash equivalents and restricted cash Commitments and contingencies (Note 9) us-gaap_OperatingIncomeLoss Operating loss Share-Based Payment Arrangement, Option [Member] Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) provided by investing activities Prepaid expenses and other current assets Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Gross profit us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent Deferred Compensation Liability, Current and Noncurrent, Total Commitments and Contingencies Disclosure [Text Block] Partnership Interest [Member] sfe_ConvertibleBridgeLoan Convertible Bridge Loan The amount of funding for convertible bridge loans in the period. sfe_LesseeSubleaseexpectedReceiptsYearFour 2026, Expected sublease receipts Amount of expected sublease receipts for year four. Clutch Holdings [Member] Related to the entity Clutch Holdings. sfe_LesseeSubleaseexpectedReceiptsYearThree 2025, Expected sublease receipts Amount of expected sublease receipts for year three. sfe_LesseeSubleaseexpectedReceiptsYearTwo 2024, Expected sublease receipts Amount of expected sublease receipts for year two. sfe_LesseeSubleaseexpectedReceiptsRemainderOfFiscalYear 2022 (six months ending December 31) Amount of expected sublease receipts for remainder of fiscal year. Investment, Policy [Policy Text Block] Syapse, Inc. [Member] Related to the entity Syapse, Inc. 2027, Expected sublease receipts Amount of expected sublease receipts for year five. Moxe Health Corporation [Member] Related to the entity Moxe Health Corporation. Aktana, Inc. [Member] Related to the entity Aktana, Inc. us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Tax withholdings related to equity-based awards sfe_LesseeSubleaseExpectedReceiptsTotal Total future minimum lease payments, Expected sublease receipt Total amount of sublease expected receipts. Share Repurchase Program Authorized in July 2015 [Member] Represents share repurchase program authorized in July 2015. meQuilibrium [Member] Related to the entity meQuilibrium. sfe_LesseeSubleaseexpectedReceiptsThereafter Thereafter, Expected sublease receipt Amount of expected sublease receipts after year six. sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent Investments and Advances to Affiliates, Current and Noncurrent Represents Investments and Advances to Affiliates, Current and Noncurrent. sfe_RestrictedCashAndCashEquivalentsFairValue Restricted cash Fair value portion of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Share Repurchase Program Authorized in May 2021 [Member] Represents share repurchase program authorized in May 2021. Ownership Interest Equity Method Investments [Table Text Block] Net income (loss) Net income (loss) Investments in and Advances to Affiliates, Schedule of Investments [Text Block] Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block] Cash Flows from Investing Activities: us-gaap_PaymentsForRepurchaseOfCommonStock Repurchases of Company common stock Other Method, fair value measurement alternative Net income (loss) per share: Retained Earnings [Member] Earnings Per Share [Text Block] us-gaap_TreasuryStockAcquiredAverageCostPerShare Treasury Stock Acquired, Average Cost Per Share (in dollars per share) Advances to companies Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member] Represents restricted stock, performance-based stock units, and deferred stock units. Ownership interests and advances Treasury Stock [Member] Equity income (loss), net Equity Method Companies Equity Method Investments Additional Paid-in Capital [Member] Share Repurchase Program [Domain] Common Stock [Member] us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount Income tax benefit (expense) Equity Components [Axis] Share Repurchase Program [Axis] Equity Component [Domain] Prognos Health, Inc. [Member] Related to the entity Prognos Health, Inc. Lumesis, Inc. [Member] Related to the entity Lumesis, Inc. InfoBionic, Inc. [Member] Related to the entity InfoBionic, Inc. Trice Medical, Inc. [Member] Related to the entity Trice Medical, Inc. us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Net income (loss) before income taxes General and administrative expense Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total General and administrative expense us-gaap_AllocatedShareBasedCompensationExpense Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code General and Administrative Expense [Member] Accounting Policies [Abstract] Document Transition Report City Area Code Entity Interactive Data Current Repurchases of common stock (in shares) Treasury Stock, Shares, Acquired (in shares) us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common stock, shares outstanding (in shares) Title of 12(b) Security sfe_ImpairmentOfOtherMethodSecurities Impairment of Other Method Securities The amount of impairment of other method securities. Equity Method Investment, Nonconsolidated Investee [Axis] Current Fiscal Year End Date Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Equity Method Investment, Nonconsolidated Investee [Domain] Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Income Statement Location [Axis] sfe_TradingSecuritiesFairValueDisclosure Ownership interests Amount of fair value for investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Income Statement Location [Domain] Entity File Number Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Equity Method and Other Investments Disclosure [Text Block] The entire disclosure for equity method and other investments. Document Information [Line Items] Document Information [Table] Entity Filer Category us-gaap_InvestmentOwnedBalanceShares Investment Owned, Balance, Shares (in shares) Entity Current Reporting Status us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Diluted (in shares) 2027, Operating lease payments Stock-based compensation expense Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Entity [Domain] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Diluted (in dollars per share) Basic (in shares) us-gaap_TreasuryStockValueAcquiredCostMethod Treasury Stock, Value, Acquired, Cost Method Repurchases of common stock Diluted: Entity Address, City or Town Entity Address, Postal Zip Code Basic (in dollars per share) Entity Address, State or Province us-gaap_TreasuryStockValue Treasury stock, at cost; 5,261 and 5,068 shares at June 30, 2022 and December 31, 2021, respectively Basic: Statement of Cash Flows [Abstract] Entity Common Stock, Shares Outstanding Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Investments [Domain] Trading Symbol Investment Type [Axis] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Local Phone Number us-gaap_TableTextBlock Notes Tables sfe_LesseeSubleaseExpectedReceiptsYearOne 2023, Expected sublease receipts Amount of expected sublease receipts for year one. Cash Flows from Financing Activities: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Other long-term liabilities us-gaap_LiabilitiesAndStockholdersEquity Total Liabilities and Equity Reported Value Measurement [Member] Proceeds from sales of ownership interests Accumulated deficit Accumulated other comprehensive loss us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Lease liability - non-current Class of Stock [Axis] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Total operating lease liabilities, Operating lease payments Lease liability - current us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share) Right-of-use asset, net us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total future minimum lease payments, Operating lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less imputed interest, Operating lease payments 2025, Operating lease payments us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2026, Operating lease payments us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) Thereafter, Operating lease payments us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive EX-101.PRE 10 sfe-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document And Entity Information - shares
6 Months Ended
Jun. 30, 2022
Aug. 08, 2022
Document Information [Line Items]    
Entity Central Index Key 0000086115  
Entity Registrant Name SAFEGUARD SCIENTIFICS INC  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2022  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 1-5620  
Entity Incorporation, State or Country Code PA  
Entity Tax Identification Number 23-1609753  
Entity Address, Address Line One 150 N. Radnor Chester Road  
Entity Address, City or Town Radnor  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19087  
City Area Code 610  
Local Phone Number 293-0600  
Title of 12(b) Security common stock, par value $0.10  
Trading Symbol SFE  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Small Business true  
Entity Filer Category Non-accelerated Filer  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   16,387,126
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current Assets:    
Cash and cash equivalents $ 17,510 $ 24,739
Restricted cash 25 25
Ownership interests 2,407 4,549
Prepaid expenses and other current assets 1,126 965
Total current assets 21,068 30,278
Right-of-use asset, net 1,431 1,561
Ownership interests and advances 23,192 21,972
Other assets 267 217
Total Assets 45,958 54,028
Current Liabilities:    
Accounts payable 56 41
Accrued compensation and benefits 167 794
Accrued expenses and other current liabilities 518 524
Lease liability - current 401 375
Total current liabilities 1,142 1,734
Lease liability - non-current 1,471 1,678
Other long-term liabilities 50 50
Total Liabilities 2,663 3,462
Commitments and contingencies (Note 9)
Equity:    
Preferred stock, $0.10 par value; 1,000 shares authorized 0 0
Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued and outstanding at June 30, 2022 and December 31, 2021 2,157 2,157
Additional paid-in capital 805,441 806,638
Treasury stock, at cost; 5,261 and 5,068 shares at June 30, 2022 and December 31, 2021, respectively (48,417) (48,569)
Accumulated deficit (715,861) (709,635)
Accumulated other comprehensive loss (25) (25)
Total Equity 43,295 50,566
Total Liabilities and Equity $ 45,958 $ 54,028
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
shares in Thousands
Jun. 30, 2022
Dec. 31, 2021
Preferred stock, par value (in dollars per share) $ 0.10 $ 0.10
Preferred stock, shares authorized (in shares) 1,000 1,000
Common stock, par value (in dollars per share) $ 0.10 $ 0.10
Common stock, shares authorized (in shares) 83,333 83,333
Common stock, shares issued (in shares) 21,573 21,573
Common stock, shares outstanding (in shares) 21,573 21,573
Treasury stock, shares (in shares) 5,261 5,068
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
General and administrative expense $ 1,146 $ 1,991 $ 2,380 $ 4,454
Operating loss (1,146) (1,991) (2,380) (4,454)
Other income (loss), net 30 6,733 (1,967) 7,439
Interest income 145 74 246 127
Equity income (loss), net 1,454 (5,136) (2,125) 14,193
Net income (loss) before income taxes 483 (320) (6,226) 17,305
Income tax benefit (expense) 0 0 0 0
Net income (loss) $ 483 $ (320) $ (6,226) $ 17,305
Net income (loss) per share:        
Basic (in dollars per share) $ 0.03 $ (0.02) $ (0.38) $ 0.83
Diluted (in dollars per share) $ 0.03 $ (0.02) $ (0.38) $ 0.83
Weighted average shares used in computing income (loss) per share:        
Basic (in shares) 16,356 20,856 16,468 20,879
Diluted (in shares) 16,356 20,856 16,468 20,879
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash Flows from Operating Activities:    
Net cash used in operating activities $ (2,099) $ (4,734)
Cash Flows from Investing Activities:    
Proceeds from sales of ownership interests 485 13,151
Advances and loans to ownership interests (3,400) (1,000)
Net cash (used in) provided by investing activities (2,915) 12,151
Cash Flows from Financing Activities:    
Repurchases of Company common stock (1,723) (1,588)
Tax withholdings related to equity-based awards (492) (100)
Net cash used in financing activities (2,215) (1,688)
Net change in cash, cash equivalents and restricted cash (7,229) 5,729
Cash, cash equivalents and restricted cash at beginning of period 24,764 15,601
Cash, cash equivalents and restricted cash at end of period $ 17,535 $ 21,330
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Changes in Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock [Member]
Total
Balance at Dec. 31, 2020 $ (736,639) $ (25) $ 2,157 $ 807,582 $ (10,200) $ 62,875
Balance (in shares) at Dec. 31, 2020     21,573   688  
Net income (loss) 17,625 0 $ 0 0 $ 0 17,625
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net 0 0 $ 0 (593) $ 963 370
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)     0   (58)  
Stock-based compensation expense 0 0 $ 0 122 $ 0 122
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (0) (0) (0) 593 (963) (370)
Balance at Mar. 31, 2021 (719,014) (25) $ 2,157 807,111 $ (9,237) 80,992
Balance (in shares) at Mar. 31, 2021     21,573   630  
Balance at Dec. 31, 2020 (736,639) (25) $ 2,157 807,582 $ (10,200) 62,875
Balance (in shares) at Dec. 31, 2020     21,573   688  
Net income (loss)           17,305
Balance at Jun. 30, 2021 (719,334) (25) $ 2,157 806,447 $ (9,849) 79,396
Balance (in shares) at Jun. 30, 2021     21,573   786  
Balance at Mar. 31, 2021 (719,014) (25) $ 2,157 807,111 $ (9,237) 80,992
Balance (in shares) at Mar. 31, 2021     21,573   630  
Net income (loss) (320) 0 $ 0 0 $ 0 (320)
Repurchases of common stock 0 0 $ 0 0 $ (1,588) (1,588)
Repurchases of common stock (in shares)     0   229  
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net 0 0 $ 0 839 $ (976) (137)
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)     0   (73)  
Stock-based compensation expense 0 0 $ 0 175 $ 0 175
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net 0 0 0 (839) 976 137
Balance at Jun. 30, 2021 (719,334) (25) $ 2,157 806,447 $ (9,849) 79,396
Balance (in shares) at Jun. 30, 2021     21,573   786  
Balance at Dec. 31, 2021 (709,635) (25) $ 2,157 806,638 $ (48,569) 50,566
Balance (in shares) at Dec. 31, 2021     21,573   5,068  
Net income (loss) (6,709) 0 $ 0 0 $ 0 (6,709)
Repurchases of common stock 0 0 $ 0 0 $ (779) (779)
Repurchases of common stock (in shares)     0   148  
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net 0 0 $ 0 (1,019) $ 1,322 303
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)     0   (122)  
Stock-based compensation expense 0 0 $ 0 168 $ 0 168
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (0) (0) (0) 1,019 (1,322) (303)
Balance at Mar. 31, 2022 (716,344) (25) $ 2,157 805,787 $ (48,026) 43,549
Balance (in shares) at Mar. 31, 2022     21,573   5,094  
Balance at Dec. 31, 2021 (709,635) (25) $ 2,157 806,638 $ (48,569) 50,566
Balance (in shares) at Dec. 31, 2021     21,573   5,068  
Net income (loss)           (6,226)
Balance at Jun. 30, 2022 (715,861) (25) $ 2,157 805,441 $ (48,417) 43,295
Balance (in shares) at Jun. 30, 2022     21,573   5,261  
Balance at Mar. 31, 2022 (716,344) (25) $ 2,157 805,787 $ (48,026) 43,549
Balance (in shares) at Mar. 31, 2022     21,573   5,094  
Net income (loss) 483 0 $ 0 0 $ 0 483
Repurchases of common stock 0 0 $ 0 0 $ (945) (945)
Repurchases of common stock (in shares)     0   221  
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net 0 0 $ 0 489 $ (554) (65)
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)     0   (54)  
Stock-based compensation expense 0 0 $ 0 143 $ 0 143
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net 0 0 0 (489) 554 65
Balance at Jun. 30, 2022 $ (715,861) $ (25) $ 2,157 $ 805,441 $ (48,417) $ 43,295
Balance (in shares) at Jun. 30, 2022     21,573   5,261  
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Note 1 - General
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. General

 

The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not necessarily indicative of the results for a full year or for any interim period. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations relating to interim financial statements. The Consolidated Financial Statements included in this Form 10-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Form 10-Q and with the Company’s Consolidated Financial Statements and Notes thereto included in the Company’s 2021 Annual Report on Form 10-K.

 

Liquidity

 

As of June 30, 2022 the Company had $17.5 million of cash and cash equivalents.

 

In January 2018, Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders. We have considered and taken action on various initiatives including the sale of individual ownership interests, the sale of certain or all ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value.  As we seek to provide additional funding to existing companies where we have an ownership interest, we may be required to expend our cash or incur debt, which will decrease our liquidity.  From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.  Accordingly, the Company could also pursue other sources of capital in order to maintain its liquidity.    

 

The Company believes that its cash and cash equivalents at June 30, 2022 will be sufficient to fund operations past one year from the issuance of these Consolidated Financial Statements.

 

 

Principles of Accounting for Ownership Interests

 

The Company accounts for its ownership interests using one of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.

 

In addition to holding voting and non-voting equity securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests and advances on the Consolidated Balance Sheets.

 

Equity Method. The Company accounts for ownership interests whose results are not consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an ownership interest depends on the evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a 20% to 50% interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost. Under the equity method of accounting, the Company does not reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations. The Company also adjusts the carrying value to reflect third party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a one quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.

 

When the Company’s carrying value in an equity method company is reduced to zero, the Company records no further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will not record its share of such income until it exceeds the amount of the Company’s share of losses not previously recognized.

 

Other Method. We account for ownership interests in companies that are not accounted for under the equity method that do not have a readily determinable fair value under the fair value measurement alternative. Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interest of the same issuer. Under this method, our share of the income or losses of such companies is not included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets.

 

The Company accounts for ownership interests that are not accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  As of June 30, 2022 those ownership interests consist of approximately 1.3 million shares of Bright Health Group ("Bright Health") common shares valued at $2.4 million.  

 

Comprehensive Income (loss)

 

During the quarter and six month periods ended June 30, 2022 and 2021, there were no items of comprehensive income (loss). 

 

Impairment of Ownership Interests and Advances

 

On a periodic basis, but no less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated fair value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are not primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.

 

Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.

 

The estimated fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.

 

Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies are included in Other income (loss), net in the Consolidated Statements of Operations.

 

The reduced cost basis of a previously impaired company accounted for using the Equity method is not written-up even if circumstances suggest the value of the company has subsequently recovered.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Note 2 - Ownership Interests and Advances
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]

2. Ownership Interests and Advances

 

The following summarizes the carrying value of the Company’s ownership interests and advances. 

  

  

June 30, 2022

  

December 31, 2021

 
  

(Unaudited - In thousands)

 

Equity Method:

        

Companies

 $18,738  $21,091 

Private equity funds

  117   117 
   18,855   21,208 

Other Method:

        

Companies, fair value

  2,407   4,549 

Companies, fair value measurement alternative

  687   514 

Private equity funds, fair value measurement alternative

  250   250 
   3,344   5,313 

Advances to companies

  3,400    
  $25,599  $26,521 

 

There were no impairments recorded during the three and six months ended June 30, 2022, respectively. During the three and six months ended June 30, 2021, the Company recorded impairment of $2.5 million related to reduced expectations for certain Other ownership interests, which is reflected in Other income (loss) in the consolidated Statement of Operations.

 

As of  June 30, 2022, the Company held ownership interests accounted for using the equity method in 9 non-consolidated companies.  Certain of the Company's ownership interests as of June 30, 2022 included the following:

 

Company Name

 

Safeguard Primary Ownership as of June 30, 2022

 

Accounting Method

Aktana, Inc.

 

13.4%

 

Equity

Clutch Holdings, Inc.

 

41.7%

 

Equity

InfoBionic, Inc.

 

25.2%

 

Equity

Lumesis, Inc.

 

43.2%

 

Equity

meQuilibrium

 

31.5%

 

Equity

Moxe Health Corporation

 

19.4%

 

Equity

Prognos Health Inc.

 

28.5%

 

Equity

Syapse, Inc.

 

11.0%

 

Equity

Trice Medical, Inc.

 

12.6%

 

Equity

 

Summarized Financial Information

 

The following table summarizes the statement of operations data for the companies accounted for under the equity method for the three and six months ended June 30, 2022 and 2021, respectively. These results have been compiled from the respective companies' financial statements, reflect certain historical adjustments, and are reported on a one quarter lag basis. Results of operations of the companies are excluded for periods prior to their acquisition, subsequent to their disposition and subsequent to the discontinuation of the equity method of accounting. Historical results are not adjusted when the Company exits, writes-off or discontinues the equity method of accounting. 

 

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2022

  

2021

  

2022

  

2021

 
  

(Unaudited - In thousands)

 

Results of Operations:

                

Revenue

 $36,479  $30,482  $75,290  $70,650 

Gross profit

 $22,653  $17,873  $47,573  $46,101 

Net loss

 $(34,325) $(28,681) $(65,187) $(51,702)

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Note 3 - Acquisitions of Ownership Interests
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Equity Method and Other Investments Disclosure [Text Block]

3. Acquisitions of Ownership Interests

 

The following is a summary of additional deployments during the six month period ended  June 30, 2022:

 

The Company funded $2.0 million of convertible loans to Prognos Health Inc.  The Company had previously deployed an aggregate of $12.6 million.  Prognos is a healthcare platform company transforming the ability to access, manage and analyze healthcare data in partnership with Life Sciences brands, payers, and clinical diagnostics organizations.  Prognos' innovations enhance the value of laboratory results and clinical diagnostic data through advanced analytics and artificial intelligence techniques.

 

The Company funded $1.4 million of convertible loans to Clutch Holdings, Inc. The Company had previously deployed an aggregate of $16.9 million.  Clutch provides customer intelligence and personalized engagements that empower consumer-focused businesses to identify, understand and motivate each segment of their customer base. 

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Note 4 - Fair Value Measurements
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

4. Fair Value Measurements

 

The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. 

 

Cash, cash equivalents and restricted cash approximate fair value due to their short term nature.  The Company did not have any Level 2 or Level 3 financial assets or liabilities measured at fair value on a recurring basis as of June 30, 2022 or December 31, 2021.

 

  

Carrying

  

Fair Value Measurement at June 30, 2022

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(Unaudited - In thousands)

 

Cash and cash equivalents

 $17,510  $17,510  $  $ 
                 

Restricted cash

 $25  $25  $  $ 
                 

Ownership interests

 $2,407  $2,407  $  $ 

 

  

Carrying

  

Fair Value Measurement at December 31, 2021

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(Unaudited - In thousands)

 

Cash and cash equivalents

 $24,739  $24,739  $  $ 
                 

Restricted cash

 $25  $25  $  $ 
                 

Ownership interests

 $4,549  $4,549  $  $ 

 

Ownership interests accounted for at fair value as of June 30, 2022 consist of approximately 1.3 million common shares of Bright Health.  The securities are carried at fair value based on the closing stock price on the last trading day of the reporting period.  

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Note 5 - Stock-Based Compensation
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

5. Stock-Based Compensation

 

Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:  

 

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2022

  

2021

  

2022

  

2021

 
  

(Unaudited - In thousands)

 

General and administrative expense

 $262  $740  $576  $985 
  $262  $740  $576  $985 

 

Stock-based compensation consists of time based awards to employees, liability based awards to employees to be settled in stock, performance based awards to employees, other non-employee grants and liability based awards to Directors for quarterly and annual services.  During the six months ended June 30, 2022 and 2021, the Company awarded 25 thousand and 64 thousand restricted stock awards, respectively to non-employee directors for compensation.  The Company also issued 162 thousand shares for employee services and 15 thousand shares for non-employee services during the three months ended June 30, 2022, respectively, based on the terms of service agreements.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Note 6 - Income Taxes
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

6. Income Taxes

 

The Company recorded no consolidated income tax benefit (expense) for the three and six months ended June 30, 2022 and 2021. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the tax provision that would have been recognized in the three and six months ended June 30, 2022 was offset by changes in the valuation allowance. During the three and six months ended June 30, 2022, the Company had no material changes in uncertain tax positions.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Note 7 - Net Income (Loss) Per Share
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Earnings Per Share [Text Block]

7. Net Income (Loss) Per Share

 

The calculations of net income (loss) per share were as follows:

 

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2022

  

2021

  

2022

  

2021

 
  

(Unaudited - In thousands, except per share data)

 

Basic:

                

Net income (loss)

 $483  $(320) $(6,226) $17,305 

Weighted average common shares outstanding

  16,356   20,856   16,468   20,879 

Net income (loss) per share

 $0.03  $(0.02) $(0.38) $0.83 
                 

Diluted:

                

Net income (loss) for dilutive share computation

 $483  $(320) $(6,226) $17,305 
                 

Number of shares used in basic per share computation

  16,356   20,856   16,468   20,879 

Unvested restricted stock and DSU's

            

Employee stock options

            

Weighted average common shares outstanding

  16,356   20,856   16,468   20,879 
                 

Net income (loss) per dilutive share

 $0.03  $(0.02) $(0.38) $0.83 

 

Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).

 

If an equity method company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net income (loss) per share is computed by first deducting the income attributable to the potential exercise of the dilutive securities of the company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.

 

Diluted earnings per share do not reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:

 

 

At June 30, 2022 and 2021, options to purchase 18 thousand and 43 thousand shares of common stock, respectively, at prices ranging from $10.37 to $17.11 and $10.37 to $17.11, respectively, were excluded from the calculations.

   
 

At June 30, 2022 and 2021, unvested restricted stock and performance-based stock units convertible into 0.1 million and 0.3 million shares of stock, respectively, were excluded from the calculations.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Note 8 - Segment Reporting
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

8. Segment Reporting

 

The Company operates as one operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources. 

 

As of June 30, 2022 and December 31, 2021, all of the Company’s assets were located in the United States.

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Note 9 - Commitments and Contingencies
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

9. Commitments and Contingencies

 

In March 2019, the Company entered into a sublease of its prior corporate headquarters office space beginning in June 2019. The term of the sublease is through April 2026, the same as the Company's underlying lease. Fixed sublease payments to the Company are escalating over the term of the sublease and are reported as a component of general and administrative expenses.

 

A summary of the Company's operating lease cash flows at June 30, 2022 follows:

 

  

Operating lease payments

  

Expected sublease receipts

 
  

(Unaudited - In thousands)

 

2022 (six months ending December 31)

 $302  $273 

2023

  607   557 

2024

  613   573 

2025

  619   590 

2026

  207   199 

2027

      

Thereafter

      

Total future minimum lease payments

  2,348  $2,192 

Less imputed interest

  (476)    

Total operating lease liabilities

 $1,872     

 

The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, it is not reasonably possible that the ultimate disposition of these matters will have a material adverse effect on the Company’s consolidated financial position or results of operations, however, no assurance can be given as to the outcome of these actions, and one or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its companies. The Company records costs associated with legal fees as such services are rendered.

 

The Company has provided a guarantee, which is fully funded by escrowed funds held by a third party, of $3.8 million at June 30, 2022 which related to one of the Company's private equity fund interests.

 

In 2018, the Board of Directors (the “Board”) of the Company adopted a long-term incentive plan, which was amended in February 2019 and June 2020, known as the Amended and Restated Safeguard Scientifics Transaction Bonus Plan, (the “LTIP”). The purpose of the LTIP is to promote the interests of the Company and its shareholders by providing an additional incentive to employees to maximize the value of the Company in connection with the execution of the business strategy that the Company adopted and announced in January 2018. The June 2020 amendment lowered the level of the first threshold and the resulting bonus pool percentage as an incentive to employees to accelerate actions consisent with the business strategy.  Under the LTIP, participants, which include certain current and former employees, have received awards that may result in cash payments in connection with sales of the Company’s ownership interests (“Sale Transaction(s)”). The LTIP provides for a bonus pool corresponding to certain specified vesting thresholds (some of which have already been met and paid) or specified events. The remaining bonus pool will range from an amount equal to 1.0% of incremental proceeds received at the next threshold to 1.3% at higher thresholds.  A minimum pool will also be created and paid under specified events. The bonus pool will be allocated and paid to participants in the LTIP based on the product of (i) the participant’s applicable bonus pool percentage and (ii) the bonus pool calculated as of the vesting date, minus any previously paid portion of the bonus pool. Any portion of the bonus pool available as of the applicable vesting date that is reserved will be allocated in connection with each vesting date so that the entire bonus pool available as of such vesting date is allocated and payable to participants. Subject to the terms of the LTIP, payments under the LTIP will be paid in cash within 60 days of the applicable vesting date. All current officers and employees of the Company are eligible to participate in the LTIP. The Board, in its sole discretion, will determine the participants to whom awards are granted under the LTIP. The Company did not make any payments during the six months ended June 30, 2022 and has no amounts accrued as of June 30, 2022

 

The Company has agreements with certain remaining employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under employment and severance agreements for remaining employees was approximately $0.8 million at June 30, 2022.

 

In June 2011, the Company's former ownership interest, Advanced BioHealing, Inc. (“ABH”) was acquired by Shire plc (“Shire”).  Prior to the expiration of the escrow period in March 2012, Shire filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (“DOJ”) false claims act investigation relating to ABH (the “Investigation”). In connection with the Investigation, in July 2015 the Company received a Civil Investigation Demand-Documentary Material (“CID”) from the DOJ regarding ABH and Safeguard’s relationship with ABH. Pursuant to the CID, the Company provided the requested materials and information.  To the Company’s knowledge, the CID was related to multiple qui tam (“whistleblower”) actions, one of which was filed in 2014 by an ex-employee of ABH that named the Company and one of the Company’s employees along with other entities and individuals as defendants.  At this time, the DOJ has declined to pursue the qui tam action as it relates to the Company and such Company employee.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Note 10 - Equity
6 Months Ended
Jun. 30, 2022
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

10. Equity

 

In July 2015, the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. The Company has not repurchased any shares under such authorization during 2021 or the six months ended June 30, 2022.

 

In March 2022, the Company's Board of Directors replaced a previously existing share repurchase plan that was authorized in May 2021 with a newly authorized $3.0 million share repurchase plan using existing funds in accordance with the requirements of Rule 10b5-1 and Rule 10b-18 under the Securities Exchange Act of 1934, as amended. During the six months ended June 30, 2022, the Company repurchased 369,274 shares for an aggregate price of $1.7 million at an average cost at $4.67 per share pursuant to this plan.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Liquidity, Policy [Policy Text Block]

Liquidity

 

As of June 30, 2022 the Company had $17.5 million of cash and cash equivalents.

 

In January 2018, Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders. We have considered and taken action on various initiatives including the sale of individual ownership interests, the sale of certain or all ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value.  As we seek to provide additional funding to existing companies where we have an ownership interest, we may be required to expend our cash or incur debt, which will decrease our liquidity.  From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.  Accordingly, the Company could also pursue other sources of capital in order to maintain its liquidity.    

 

The Company believes that its cash and cash equivalents at June 30, 2022 will be sufficient to fund operations past one year from the issuance of these Consolidated Financial Statements.

 

Investment, Policy [Policy Text Block]

Principles of Accounting for Ownership Interests

 

The Company accounts for its ownership interests using one of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.

 

In addition to holding voting and non-voting equity securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests and advances on the Consolidated Balance Sheets.

 

Equity Method. The Company accounts for ownership interests whose results are not consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an ownership interest depends on the evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a 20% to 50% interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost. Under the equity method of accounting, the Company does not reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations. The Company also adjusts the carrying value to reflect third party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a one quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.

 

When the Company’s carrying value in an equity method company is reduced to zero, the Company records no further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will not record its share of such income until it exceeds the amount of the Company’s share of losses not previously recognized.

 

Other Method. We account for ownership interests in companies that are not accounted for under the equity method that do not have a readily determinable fair value under the fair value measurement alternative. Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interest of the same issuer. Under this method, our share of the income or losses of such companies is not included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets.

 

The Company accounts for ownership interests that are not accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  As of June 30, 2022 those ownership interests consist of approximately 1.3 million shares of Bright Health Group ("Bright Health") common shares valued at $2.4 million.  

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income (loss)

 

During the quarter and six month periods ended June 30, 2022 and 2021, there were no items of comprehensive income (loss). 

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Ownership Interests and Advances

 

On a periodic basis, but no less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated fair value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are not primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.

 

Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.

 

The estimated fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.

 

Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies are included in Other income (loss), net in the Consolidated Statements of Operations.

 

The reduced cost basis of a previously impaired company accounted for using the Equity method is not written-up even if circumstances suggest the value of the company has subsequently recovered.

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Note 2 - Ownership Interests and Advances (Tables)
6 Months Ended
Jun. 30, 2022
Notes Tables  
Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block]
  

June 30, 2022

  

December 31, 2021

 
  

(Unaudited - In thousands)

 

Equity Method:

        

Companies

 $18,738  $21,091 

Private equity funds

  117   117 
   18,855   21,208 

Other Method:

        

Companies, fair value

  2,407   4,549 

Companies, fair value measurement alternative

  687   514 

Private equity funds, fair value measurement alternative

  250   250 
   3,344   5,313 

Advances to companies

  3,400    
  $25,599  $26,521 
Schedule of Other Ownership Interests [Table Text Block]

Company Name

 

Safeguard Primary Ownership as of June 30, 2022

 

Accounting Method

Aktana, Inc.

 

13.4%

 

Equity

Clutch Holdings, Inc.

 

41.7%

 

Equity

InfoBionic, Inc.

 

25.2%

 

Equity

Lumesis, Inc.

 

43.2%

 

Equity

meQuilibrium

 

31.5%

 

Equity

Moxe Health Corporation

 

19.4%

 

Equity

Prognos Health Inc.

 

28.5%

 

Equity

Syapse, Inc.

 

11.0%

 

Equity

Trice Medical, Inc.

 

12.6%

 

Equity

Equity Method Investments [Table Text Block]
  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2022

  

2021

  

2022

  

2021

 
  

(Unaudited - In thousands)

 

Results of Operations:

                

Revenue

 $36,479  $30,482  $75,290  $70,650 

Gross profit

 $22,653  $17,873  $47,573  $46,101 

Net loss

 $(34,325) $(28,681) $(65,187) $(51,702)
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Note 4 - Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2022
Notes Tables  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
  

Carrying

  

Fair Value Measurement at June 30, 2022

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(Unaudited - In thousands)

 

Cash and cash equivalents

 $17,510  $17,510  $  $ 
                 

Restricted cash

 $25  $25  $  $ 
                 

Ownership interests

 $2,407  $2,407  $  $ 
  

Carrying

  

Fair Value Measurement at December 31, 2021

 
  

Value

  

Level 1

  

Level 2

  

Level 3

 
  

(Unaudited - In thousands)

 

Cash and cash equivalents

 $24,739  $24,739  $  $ 
                 

Restricted cash

 $25  $25  $  $ 
                 

Ownership interests

 $4,549  $4,549  $  $ 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Note 5 - Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2022
Notes Tables  
Share-Based Payment Arrangement, Activity [Table Text Block]
  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2022

  

2021

  

2022

  

2021

 
  

(Unaudited - In thousands)

 

General and administrative expense

 $262  $740  $576  $985 
  $262  $740  $576  $985 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Note 7 - Net Income (Loss) Per Share (Tables)
6 Months Ended
Jun. 30, 2022
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2022

  

2021

  

2022

  

2021

 
  

(Unaudited - In thousands, except per share data)

 

Basic:

                

Net income (loss)

 $483  $(320) $(6,226) $17,305 

Weighted average common shares outstanding

  16,356   20,856   16,468   20,879 

Net income (loss) per share

 $0.03  $(0.02) $(0.38) $0.83 
                 

Diluted:

                

Net income (loss) for dilutive share computation

 $483  $(320) $(6,226) $17,305 
                 

Number of shares used in basic per share computation

  16,356   20,856   16,468   20,879 

Unvested restricted stock and DSU's

            

Employee stock options

            

Weighted average common shares outstanding

  16,356   20,856   16,468   20,879 
                 

Net income (loss) per dilutive share

 $0.03  $(0.02) $(0.38) $0.83 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Note 9 - Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2022
Notes Tables  
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
  

Operating lease payments

  

Expected sublease receipts

 
  

(Unaudited - In thousands)

 

2022 (six months ending December 31)

 $302  $273 

2023

  607   557 

2024

  613   573 

2025

  619   590 

2026

  207   199 

2027

      

Thereafter

      

Total future minimum lease payments

  2,348  $2,192 

Less imputed interest

  (476)    

Total operating lease liabilities

 $1,872     
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Note 1 - General (Details Textual) - USD ($)
$ in Thousands, shares in Millions
Jun. 30, 2022
Dec. 31, 2021
Cash and Cash Equivalents, at Carrying Value, Total $ 17,510 $ 24,739
Debt Securities, Trading, and Equity Securities, FV-NI, Total $ 2,407 $ 4,549
Bright Health [Member]    
Investment Owned, Balance, Shares (in shares) 1.3  
Debt Securities, Trading, and Equity Securities, FV-NI, Total $ 2,400  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Note 2 - Ownership Interests and Advances (Details Textual)
$ in Millions
6 Months Ended
Jun. 30, 2022
USD ($)
Impairment of Other Method Securities $ 2.5
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Equity Method Companies $ 18,855 $ 21,208
Ownership interests 2,407 4,549
Other Method, fair value measurement alternative 3,344 5,313
Advances to companies 3,400 0
Investments and Advances to Affiliates, Current and Noncurrent 25,599 26,521
Partnership Interest [Member]    
Equity Method Companies 18,738 21,091
Ownership interests 2,407 4,549
Other Method, fair value measurement alternative 687 514
Private Equity Funds [Member]    
Equity Method Companies 117 117
Other Method, fair value measurement alternative $ 250 $ 250
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details)
Jun. 30, 2022
Aktana, Inc. [Member]  
Ownership Interest 13.40%
Clutch Holdings [Member]  
Ownership Interest 41.70%
InfoBionic, Inc. [Member]  
Ownership Interest 25.20%
Lumesis, Inc. [Member]  
Ownership Interest 43.20%
meQuilibrium [Member]  
Ownership Interest 31.50%
Moxe Health Corporation [Member]  
Ownership Interest 19.40%
Prognos Health, Inc. [Member]  
Ownership Interest 28.50%
Syapse, Inc. [Member]  
Ownership Interest 11.00%
Trice Medical, Inc. [Member]  
Ownership Interest 12.60%
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) - Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue $ 36,479 $ 30,482 $ 75,290 $ 70,650
Gross profit 22,653 17,873 47,573 46,101
Net loss $ (34,325) $ (28,681) $ (65,187) $ (51,702)
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Note 3 - Acquisitions of Ownership Interests (Details Textual) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Equity Method Investments $ 18,855 $ 21,208
Prognos Health, Inc. [Member]    
Convertible Bridge Loan 2,000  
Equity Method Investments 12,600  
Clutch Holdings [Member]    
Convertible Bridge Loan 1,400  
Equity Method Investments $ 16,900  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Note 4 - Fair Value Measurements (Details Textual)
shares in Millions
Jun. 30, 2022
shares
Bright Health [Member]  
Investment Owned, Balance, Shares (in shares) 1.3
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Reported Value Measurement [Member]    
Cash and cash equivalents $ 17,510 $ 24,739
Restricted cash 25 25
Ownership interests 2,407 4,549
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash and cash equivalents 17,510 24,739
Restricted cash 25 25
Ownership interests 2,407 4,549
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash and cash equivalents 0 0
Restricted cash 0 0
Ownership interests 0 0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Cash and cash equivalents 0 0
Restricted cash 0 0
Ownership interests $ 0 $ 0
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Note 5 - Stock-Based Compensation (Details Textual) - shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2022
Jun. 30, 2021
Share-Based Payment Arrangement, Nonemployee [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) 15    
Share-Based Payment Arrangement, Employee [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) 162    
Restricted Stock [Member] | Share-Based Payment Arrangement, Nonemployee [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares)   25 64
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Note 5 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
General and administrative expense $ 262 $ 740 $ 576 $ 985
General and Administrative Expense [Member]        
General and administrative expense $ 262 $ 740 $ 576 $ 985
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Note 7 - Net Income (Loss) Per Share (Details Textual) - $ / shares
shares in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 18 43
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]    
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) $ 10.37 $ 10.37
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]    
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share) $ 17.11 $ 17.11
Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 100 300
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Basic:            
Net income (loss) $ 483 $ (6,709) $ (320) $ 17,625 $ (6,226) $ 17,305
Basic (in shares) 16,356   20,856   16,468 20,879
Basic (in dollars per share) $ 0.03   $ (0.02)   $ (0.38) $ 0.83
Diluted:            
Net income (loss) $ 483 $ (6,709) $ (320) $ 17,625 $ (6,226) $ 17,305
Basic (in shares) 16,356   20,856   16,468 20,879
Unvested restricted stock and DSU's (in shares) 0   0   0 0
Employee stock options (in shares) 0   0   0 0
Diluted (in shares) 16,356   20,856   16,468 20,879
Diluted (in dollars per share) $ 0.03   $ (0.02)   $ (0.38) $ 0.83
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Note 8 - Segment Reporting (Details Textual)
6 Months Ended
Jun. 30, 2022
Number of Operating Segments 1
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Note 9 - Commitments and Contingencies (Details Textual)
$ in Thousands
6 Months Ended
Jun. 30, 2022
USD ($)
Long-term Incentive Plan, Payments $ 0
Deferred Compensation Liability, Current and Noncurrent, Total 0
Employee and Severance Agreement, Maximum Aggregate Exposure $ 800
Minimum [Member]  
Long-term Incentive Plan, Bonus Pool Percent 1.00%
Maximum [Member]  
Long-term Incentive Plan, Bonus Pool Percent 1.30%
Private Equity Funds [Member]  
Guarantor Obligations, Current Carrying Value $ 3,800
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details)
$ in Thousands
Jun. 30, 2022
USD ($)
2022 (six months ending December 31) $ 302
2022 (six months ending December 31) 273
2023, Operating lease payments 607
2023, Expected sublease receipts 557
2024, Operating lease payments 613
2024, Expected sublease receipts 573
2025, Operating lease payments 619
2025, Expected sublease receipts 590
2026, Operating lease payments 207
2026, Expected sublease receipts 199
2027, Operating lease payments 0
2027, Expected sublease receipts 0
Thereafter, Operating lease payments 0
Thereafter, Expected sublease receipt 0
Total future minimum lease payments, Operating lease payments 2,348
Total future minimum lease payments, Expected sublease receipt 2,192
Less imputed interest, Operating lease payments (476)
Total operating lease liabilities, Operating lease payments $ 1,872
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Note 10 - Equity (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Jul. 31, 2015
Treasury Stock, Value, Acquired, Cost Method $ 945 $ 779 $ 1,588      
Share Repurchase Program Authorized in July 2015 [Member]            
Stock Repurchase Program, Authorized Amount           $ 25,000
Treasury Stock, Shares, Acquired (in shares)       0 0  
Share Repurchase Program Authorized in May 2021 [Member]            
Stock Repurchase Program, Authorized Amount   $ 3,000        
Treasury Stock, Shares, Acquired (in shares)       369,274    
Treasury Stock, Value, Acquired, Cost Method       $ 1,700    
Treasury Stock Acquired, Average Cost Per Share (in dollars per share)       $ 4.67    
XML 49 sfe20220630_10q_htm.xml IDEA: XBRL DOCUMENT 0000086115 2022-01-01 2022-06-30 0000086115 2022-08-08 0000086115 2022-06-30 0000086115 2021-12-31 0000086115 2022-04-01 2022-06-30 0000086115 2021-04-01 2021-06-30 0000086115 2021-01-01 2021-06-30 0000086115 2020-12-31 0000086115 2021-06-30 0000086115 us-gaap:RetainedEarningsMember 2021-12-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000086115 us-gaap:CommonStockMember 2021-12-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000086115 us-gaap:TreasuryStockMember 2021-12-31 0000086115 2022-01-01 2022-03-31 0000086115 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000086115 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000086115 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0000086115 2022-03-31 0000086115 us-gaap:RetainedEarningsMember 2022-03-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000086115 us-gaap:CommonStockMember 2022-03-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000086115 us-gaap:TreasuryStockMember 2022-03-31 0000086115 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000086115 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000086115 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000086115 us-gaap:TreasuryStockMember 2022-04-01 2022-06-30 0000086115 us-gaap:RetainedEarningsMember 2022-06-30 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000086115 us-gaap:CommonStockMember 2022-06-30 0000086115 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000086115 us-gaap:TreasuryStockMember 2022-06-30 0000086115 us-gaap:RetainedEarningsMember 2020-12-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000086115 us-gaap:CommonStockMember 2020-12-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000086115 us-gaap:TreasuryStockMember 2020-12-31 0000086115 2021-01-01 2021-03-31 0000086115 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000086115 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000086115 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000086115 2021-03-31 0000086115 us-gaap:RetainedEarningsMember 2021-03-31 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000086115 us-gaap:CommonStockMember 2021-03-31 0000086115 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000086115 us-gaap:TreasuryStockMember 2021-03-31 0000086115 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000086115 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000086115 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000086115 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0000086115 us-gaap:RetainedEarningsMember 2021-06-30 0000086115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000086115 us-gaap:CommonStockMember 2021-06-30 0000086115 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000086115 us-gaap:TreasuryStockMember 2021-06-30 0000086115 sfe:BrightHealthMember 2022-06-30 0000086115 srt:PartnershipInterestMember 2022-06-30 0000086115 srt:PartnershipInterestMember 2021-12-31 0000086115 us-gaap:PrivateEquityFundsMember 2022-06-30 0000086115 us-gaap:PrivateEquityFundsMember 2021-12-31 0000086115 sfe:AktanaIncMember 2022-06-30 0000086115 sfe:ClutchHoldingsMember 2022-06-30 0000086115 sfe:InfoBionicIncMember 2022-06-30 0000086115 sfe:LumesisIncMember 2022-06-30 0000086115 sfe:meQuilibriumMember 2022-06-30 0000086115 sfe:MoxeHealthCorporationMember 2022-06-30 0000086115 sfe:PrognosHealthIncMember 2022-06-30 0000086115 sfe:SyapseIncMember 2022-06-30 0000086115 sfe:TriceMedicalIncMember 2022-06-30 0000086115 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2022-04-01 2022-06-30 0000086115 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-04-01 2021-06-30 0000086115 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2022-01-01 2022-06-30 0000086115 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-01-01 2021-06-30 0000086115 sfe:PrognosHealthIncMember 2022-01-01 2022-06-30 0000086115 sfe:ClutchHoldingsMember 2022-01-01 2022-06-30 0000086115 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000086115 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000086115 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000086115 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000086115 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000086115 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000086115 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000086115 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000086115 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0000086115 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0000086115 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0000086115 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0000086115 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-06-30 0000086115 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-06-30 0000086115 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-04-01 2022-06-30 0000086115 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-04-01 2022-06-30 0000086115 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0000086115 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0000086115 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0000086115 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0000086115 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0000086115 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0000086115 sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember 2022-01-01 2022-06-30 0000086115 sfe:RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember 2021-01-01 2021-06-30 0000086115 srt:MinimumMember 2022-01-01 2022-06-30 0000086115 srt:MaximumMember 2022-01-01 2022-06-30 0000086115 sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member 2015-07-31 0000086115 sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member 2021-01-01 2021-06-30 0000086115 sfe:ShareRepurchaseProgramAuthorizedInJuly2015Member 2022-01-01 2022-06-30 0000086115 sfe:ShareRepurchaseProgramAuthorizedInMay2021Member 2022-03-31 0000086115 sfe:ShareRepurchaseProgramAuthorizedInMay2021Member 2022-01-01 2022-06-30 shares thunderdome:item iso4217:USD iso4217:USD shares pure 0000086115 SAFEGUARD SCIENTIFICS INC false --12-31 Q2 2022 0.10 0.10 1000000 1000000 0.10 0.10 83333000 83333000 21573000 21573000 21573000 21573000 2157000 5261000 5068000 17510000 17510000 0 0 25000 25000 0 0 2407000 2407000 0 0 24739000 24739000 0 0 25000 25000 0 0 4549000 4549000 0 0 1 0 0 0 10-Q true 2022-06-30 false 1-5620 PA 23-1609753 150 N. Radnor Chester Road Radnor PA 19087 610 293-0600 common stock, par value $0.10 SFE NYSE Yes Yes true Non-accelerated Filer false false 16387126 17510000 24739000 25000 25000 2407000 4549000 1126000 965000 21068000 30278000 1431000 1561000 23192000 21972000 267000 217000 45958000 54028000 56000 41000 167000 794000 518000 524000 401000 375000 1142000 1734000 1471000 1678000 50000 50000 2663000 3462000 0 0 2157000 805441000 806638000 48417000 48569000 -715861000 -709635000 -25000 -25000 43295000 50566000 45958000 54028000 1146000 1991000 2380000 4454000 -1146000 -1991000 -2380000 -4454000 30000 6733000 -1967000 7439000 145000 74000 246000 127000 1454000 -5136000 -2125000 14193000 483000 -320000 -6226000 17305000 0 0 0 0 483000 -320000 -6226000 17305000 0.03 -0.02 -0.38 0.83 0.03 -0.02 -0.38 0.83 16356000 20856000 16468000 20879000 16356000 20856000 16468000 20879000 -2099000 -4734000 485000 13151000 3400000 1000000 -2915000 12151000 1723000 1588000 492000 100000 -2215000 -1688000 -7229000 5729000 24764000 15601000 17535000 21330000 50566000 -709635000 -25000 21573000 2157000 806638000 5068000 -48569000 -6709000 -6709000 0 0 0 0 779000 -0 -0 0 -0 -0 148000 779000 -303000 -0 -0 0 -0 1019000 -122000 -1322000 168000 0 0 0 168000 0 43549000 -716344000 -25000 21573000 2157000 805787000 5094000 -48026000 483000 483000 0 0 0 0 945000 -0 -0 0 -0 -0 221000 945000 65000 0 0 0 0 -489000 -54000 554000 143000 0 0 0 143000 0 43295000 -715861000 -25000 21573000 2157000 805441000 5261000 -48417000 62875000 -736639000 -25000 21573000 2157000 807582000 688000 -10200000 17625000 17625000 0 0 0 0 -370000 -0 -0 0 -0 593000 -58000 -963000 122000 0 0 0 122000 0 80992000 -719014000 -25000 21573000 2157000 807111000 630000 -9237000 -320000 -320000 0 0 0 0 1588000 -0 -0 0 -0 -0 229000 1588000 137000 0 0 0 0 -839000 -73000 976000 175000 0 0 0 175000 0 79396000 -719334000 -25000 21573000 2157000 806447000 786000 -9849000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">1.</em> General</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are <em style="font: inherit;">not</em> necessarily indicative of the results for a full year or for any interim period. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations relating to interim financial statements. The Consolidated Financial Statements included in this Form <em style="font: inherit;">10</em>-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Form <em style="font: inherit;">10</em>-Q and with the Company’s Consolidated Financial Statements and Notes thereto included in the Company’s <em style="font: inherit;">2021</em> Annual Report on Form <em style="font: inherit;">10</em>-K.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b/></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Liquidity</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.75pt;">As of <em style="font: inherit;"> June 30, 2022</em> the Company had $17.5 million of cash and cash equivalents.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">In <em style="font: inherit;"> January 2018, </em>Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders. We have considered and taken action on various initiatives including the sale of individual ownership interests, the sale of certain or all ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value.  As we seek to provide additional funding to existing companies where we have an ownership interest, we <em style="font: inherit;"> may </em>be required to expend our cash or incur debt, which will decrease our liquidity.  From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.  Accordingly, the Company could also pursue other sources of capital in order to maintain its liquidity.    </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company believes that its cash and cash equivalents at <em style="font: inherit;"> June 30, 2022</em> will be sufficient to fund operations past <em style="font: inherit;">one</em> year from the issuance of these Consolidated Financial Statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -18pt; text-align: left; text-indent: 27pt;"><b/></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -18pt; text-align: left; text-indent: 27pt;"><b>Principles of Accounting for Ownership Interests</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The Company accounts for its ownership interests using <em style="font: inherit;">one</em> of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">In addition to holding voting and non-voting equity securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests and advances on the Consolidated Balance Sheets.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"><i>Equity Method.</i> The Company accounts for ownership interests whose results are <em style="font: inherit;">not</em> consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or <em style="font: inherit;">not</em> the Company exercises significant influence with respect to an ownership interest depends on the evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a <em style="font: inherit;">20%</em> to <em style="font: inherit;">50%</em> interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost. Under the equity method of accounting, the Company does <em style="font: inherit;">not</em> reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations. The Company also adjusts the carrying value to reflect <em style="font: inherit;">third</em> party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a <em style="font: inherit;">one</em> quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">When the Company’s carrying value in an equity method company is reduced to zero, the Company records <em style="font: inherit;">no</em> further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will <em style="font: inherit;">not</em> record its share of such income until it exceeds the amount of the Company’s share of losses <em style="font: inherit;">not</em> previously recognized.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"><i>Other Method. </i>We account for ownership interests in companies that are <em style="font: inherit;">not</em> accounted for under the equity method that do <em style="font: inherit;">not</em> have a readily determinable fair value under the fair value measurement alternative. Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interest of the same issuer. Under this method, our share of the income or losses of such companies is <em style="font: inherit;">not</em> included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The Company accounts for ownership interests that are <em style="font: inherit;">not</em> accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  As of <em style="font: inherit;"> June 30, 2022 </em>those ownership interests consist of approximately 1.3 million shares of Bright Health Group ("Bright Health") common shares valued at $2.4 million.  </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 16pt; text-align: left;"><b/></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 16pt; text-align: left;"><b>Comprehensive Income (loss)</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 16pt; text-align: left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">During the quarter and <em style="font: inherit;">six</em> month periods ended <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021,</em> there were <em style="font: inherit;">no</em> items of comprehensive income (loss). </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"/> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 16pt; text-align: left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 16pt; text-align: left;"><b/></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 16pt; text-align: left;"><b>Impairment of Ownership Interests and Advances</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: left;">On a periodic basis, but <em style="font: inherit;">no</em> less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated fair value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are <em style="font: inherit;">not</em> primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -2pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: left;">Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -2pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: left;">The estimated fair value of privately held companies is generally determined based on the value at which independent <em style="font: inherit;">third</em> parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -11pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: left;">Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies are included in Other income (loss), net in the Consolidated Statements of Operations.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -11pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: left;">The reduced cost basis of a previously impaired company accounted for using the Equity method is <em style="font: inherit;">not</em> written-up even if circumstances suggest the value of the company has subsequently recovered.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Liquidity</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.75pt;">As of <em style="font: inherit;"> June 30, 2022</em> the Company had $17.5 million of cash and cash equivalents.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">In <em style="font: inherit;"> January 2018, </em>Safeguard ceased deploying capital into new opportunities in order to focus on supporting the existing ownership interests and maximizing monetization opportunities to enable returning value to shareholders. We have considered and taken action on various initiatives including the sale of individual ownership interests, the sale of certain or all ownership interests in secondary market transactions as well as other opportunities to maximize shareholder value.  As we seek to provide additional funding to existing companies where we have an ownership interest, we <em style="font: inherit;"> may </em>be required to expend our cash or incur debt, which will decrease our liquidity.  From time to time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.  Accordingly, the Company could also pursue other sources of capital in order to maintain its liquidity.    </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">The Company believes that its cash and cash equivalents at <em style="font: inherit;"> June 30, 2022</em> will be sufficient to fund operations past <em style="font: inherit;">one</em> year from the issuance of these Consolidated Financial Statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> 17500000 <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -18pt; text-align: left; text-indent: 27pt;"><b>Principles of Accounting for Ownership Interests</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The Company accounts for its ownership interests using <em style="font: inherit;">one</em> of the following methods: Equity or Other. The accounting method applied is generally determined by the degree of the Company's influence over the entity, primarily determined by our voting interest in the entity.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">In addition to holding voting and non-voting equity securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests and advances on the Consolidated Balance Sheets.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"><i>Equity Method.</i> The Company accounts for ownership interests whose results are <em style="font: inherit;">not</em> consolidated, but over which it exercises significant influence, under the equity method of accounting. Whether or <em style="font: inherit;">not</em> the Company exercises significant influence with respect to an ownership interest depends on the evaluation of several factors including, among others, representation on the board of directors and our ownership level, which is generally a <em style="font: inherit;">20%</em> to <em style="font: inherit;">50%</em> interest in the voting securities of a company, including voting rights associated with the Company’s holdings in common, preferred and other convertible instruments in the company. The Company records the initial ownership interest at cost. Under the equity method of accounting, the Company does <em style="font: inherit;">not</em> reflect a company’s financial statements within our Consolidated Financial Statements; however, our share of the income or loss of such company is reflected in Equity income (loss), net in the Consolidated Statements of Operations. The Company also adjusts the carrying value to reflect <em style="font: inherit;">third</em> party investments in the ownership interests, which typically result in a dilution gain. The Company includes the carrying value of equity method companies in Ownership interests and advances on the Consolidated Balance Sheets. Any excess of the Company’s cost over its underlying interest in the net assets of equity method companies that is allocated to intangible assets is amortized over the estimated useful lives of the related intangible assets. The Company reflects its share of the income or loss of the equity method companies on a <em style="font: inherit;">one</em> quarter lag. This reporting lag could result in a delay in recognition of the impact of changes in the business or operations of these companies.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">When the Company’s carrying value in an equity method company is reduced to zero, the Company records <em style="font: inherit;">no</em> further losses in its Consolidated Statements of Operations unless the Company has an outstanding guarantee obligation or has committed additional funding to such equity method company. If such equity method company subsequently reports income, the Company will <em style="font: inherit;">not</em> record its share of such income until it exceeds the amount of the Company’s share of losses <em style="font: inherit;">not</em> previously recognized.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"><i>Other Method. </i>We account for ownership interests in companies that are <em style="font: inherit;">not</em> accounted for under the equity method that do <em style="font: inherit;">not</em> have a readily determinable fair value under the fair value measurement alternative. Under the fair value measurement alternative, these ownership interests are based on our original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar interest of the same issuer. Under this method, our share of the income or losses of such companies is <em style="font: inherit;">not</em> included in our Consolidated Statements of Operations, however, the result of observable price changes, if any, are reflected in Other income (loss), net. We include the carrying value of these interests in Ownership interests and advances on the Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The Company accounts for ownership interests that are <em style="font: inherit;">not</em> accounted for under the equity method and have a readily determinable fair value at fair value based on the closing stock price on the last trading day of the reporting period.  As of <em style="font: inherit;"> June 30, 2022 </em>those ownership interests consist of approximately 1.3 million shares of Bright Health Group ("Bright Health") common shares valued at $2.4 million.  </p> 1300000 2400000 <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 16pt; text-align: left;"><b>Comprehensive Income (loss)</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 16pt; text-align: left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">During the quarter and <em style="font: inherit;">six</em> month periods ended <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021,</em> there were <em style="font: inherit;">no</em> items of comprehensive income (loss). </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 16pt; text-align: left;"><b>Impairment of Ownership Interests and Advances</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: left;">On a periodic basis, but <em style="font: inherit;">no</em> less frequently than quarterly, the Company evaluates the carrying value of its ownership interests and advances for possible impairment based on achievement of business plan objectives and milestones, the estimated fair value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. The business plan objectives and milestones the Company considers include, among others, those related to financial performance, such as achievement of planned financial results or completion of capital raising activities, and those that are <em style="font: inherit;">not</em> primarily financial in nature, such as hiring of key employees or the establishment of strategic relationships.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -2pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: left;">Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -2pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: left;">The estimated fair value of privately held companies is generally determined based on the value at which independent <em style="font: inherit;">third</em> parties have invested or have committed to invest in these companies or based on other valuation methods, including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -11pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: left;">Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies are included in Other income (loss), net in the Consolidated Statements of Operations.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt -11pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: left;">The reduced cost basis of a previously impaired company accounted for using the Equity method is <em style="font: inherit;">not</em> written-up even if circumstances suggest the value of the company has subsequently recovered.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">2.</em> Ownership Interests and Advances</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The following summarizes the carrying value of the Company’s ownership interests and advances. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">  </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">June 30, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Equity Method:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Companies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,738</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Private equity funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,855</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,208</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other Method:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Companies, fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,407</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Companies, fair value measurement alternative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">687</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">514</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Private equity funds, fair value measurement alternative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,344</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Advances to companies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,599</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,521</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">There were <em style="font: inherit;">no</em> impairments recorded during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022, </em>respectively. During the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2021, </em>the Company recorded impairment of $2.5 million related to reduced expectations for certain Other ownership interests, which is reflected in Other income (loss) in the consolidated Statement of Operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">As of <em style="font: inherit;"> June 30, 2022</em>, the Company held ownership interests accounted for using the equity method in <em style="font: inherit;">9</em> non-consolidated companies.  Certain of the Company's ownership interests as of <em style="font: inherit;"> June 30, 2022</em> included the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91%;margin-left:auto;margin-right:auto;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Company Name</b></p> </td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:1.4%;"> </td><td style="border-bottom:solid 1px #000000;vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Safeguard Primary Ownership as of June 30, 2022</em></b></p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="border-bottom:solid 1px #000000;vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accounting Method</em></b></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Aktana, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">13.4%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clutch Holdings, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">41.7%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">InfoBionic, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">25.2%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lumesis, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">43.2%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">meQuilibrium</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">31.5%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Moxe Health Corporation</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19.4%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prognos Health Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">28.5%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Syapse, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11.0%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Trice Medical, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:bottom;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12.6%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"><i><b>Summarized Financial Information</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:12pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The following table summarizes the statement of operations data for the companies accounted for under the equity method for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em>, respectively. These results have been compiled from the respective companies' financial statements, reflect certain historical adjustments, and are reported on a <em style="font: inherit;">one</em> quarter lag basis. Results of operations of the companies are excluded for periods prior to their acquisition, subsequent to their disposition and subsequent to the discontinuation of the equity method of accounting. Historical results are <em style="font: inherit;">not</em> adjusted when the Company exits, writes-off or discontinues the equity method of accounting. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Results of Operations:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,479</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,482</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">70,650</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,873</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,573</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(34,325</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(28,681</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(65,187</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(51,702</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">June 30, 2022</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2021</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Equity Method:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Companies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,738</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Private equity funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,855</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,208</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other Method:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Companies, fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,407</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Companies, fair value measurement alternative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">687</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">514</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Private equity funds, fair value measurement alternative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,344</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Advances to companies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,599</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,521</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 18738000 21091000 117000 117000 18855000 21208000 2407000 4549000 687000 514000 250000 250000 3344000 5313000 3400000 0 25599000 26521000 2500000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91%;margin-left:auto;margin-right:auto;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Company Name</b></p> </td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:1.4%;"> </td><td style="border-bottom:solid 1px #000000;vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Safeguard Primary Ownership as of June 30, 2022</em></b></p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="border-bottom:solid 1px #000000;vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accounting Method</em></b></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Aktana, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">13.4%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clutch Holdings, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">41.7%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">InfoBionic, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">25.2%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lumesis, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">43.2%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">meQuilibrium</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">31.5%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Moxe Health Corporation</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19.4%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prognos Health Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">28.5%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Syapse, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11.0%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="vertical-align:middle;width:25.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Trice Medical, Inc.</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:bottom;width:51.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12.6%</p> </td><td style="vertical-align:middle;width:1.4%;"> </td><td style="vertical-align:middle;width:20.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Equity</em></p> </td></tr> </tbody></table> 0.134 0.417 0.252 0.432 0.315 0.194 0.285 0.110 0.126 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Results of Operations:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,479</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,482</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">70,650</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,873</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,573</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(34,325</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(28,681</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(65,187</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(51,702</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> </tbody></table> 36479000 30482000 75290000 70650000 22653000 17873000 47573000 46101000 -34325000 -28681000 -65187000 -51702000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">3.</em> Acquisitions of Ownership Interests</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The following is a summary of additional deployments during the <em style="font: inherit;">six</em> month period ended <em style="font: inherit;"> June 30, 2022</em>:</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The Company funded $2.0 million of convertible loans to Prognos Health Inc.  The Company had previously deployed an aggregate of $12.6 million.  Prognos is a healthcare platform company transforming the ability to access, manage and analyze healthcare data in partnership with Life Sciences brands, payers, and clinical diagnostics organizations.  Prognos' innovations enhance the value of laboratory results and clinical diagnostic data through advanced analytics and artificial intelligence techniques.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The Company funded $1.4 million of convertible loans to Clutch Holdings, Inc. The Company had previously deployed an aggregate of $16.9 million.  Clutch provides customer intelligence and personalized engagements that empower consumer-focused businesses to identify, understand and motivate each segment of their customer base. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> 2000000.0 12600000 1400000 16900000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">4.</em> Fair Value Measurements</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">The Company categorizes its financial instruments into a <em style="font: inherit;">three</em>-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level <em style="font: inherit;">1</em>) and the lowest priority to unobservable inputs (Level <em style="font: inherit;">3</em>). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">Cash, cash equivalents and restricted cash approximate fair value due to their short term nature.  The Company did <em style="font: inherit;">not</em> have any Level <em style="font: inherit;">2</em> or Level <em style="font: inherit;">3</em> financial assets or liabilities measured at fair value on a recurring basis as of <em style="font: inherit;"> June 30, 2022</em> or <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurement at June 30, 2022</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 1</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 2</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 3</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463511">17,510</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463512">17,510</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463513">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463514">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463515">25</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463516">25</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463517">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463518">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Ownership interests</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463519">2,407</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463520">2,407</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463521">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463522">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurement at December 31, 2021</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 1</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 2</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 3</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463531">24,739</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463532">24,739</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463533">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463534">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt">Restricted cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463535">25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463536">25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463537">—</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463538">—</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt">Ownership interests</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463539">4,549</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463540">4,549</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463541">—</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463542">—</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 24.75pt;">Ownership interests accounted for at fair value as of <em style="font: inherit;"> June 30, 2022</em> consist of approximately 1.3 million common shares of Bright Health.  The securities are carried at fair value based on the closing stock price on the last trading day of the reporting period.  </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurement at June 30, 2022</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 1</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 2</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 3</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463511">17,510</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463512">17,510</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463513">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463514">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463515">25</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463516">25</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463517">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463518">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Ownership interests</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463519">2,407</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463520">2,407</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463521">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463522">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Carrying</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Fair Value Measurement at December 31, 2021</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 1</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 2</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level 3</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463531">24,739</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463532">24,739</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463533">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463534">—</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt">Restricted cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463535">25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463536">25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463537">—</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463538">—</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%; padding: 0; margin: 0"> <p style="margin-top: 0pt; margin-bottom: 0pt">Ownership interests</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463539">4,549</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463540">4,549</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463541">—</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c86463542">—</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 1300000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">5.</em> Stock-Based Compensation</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">262</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">576</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">262</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">576</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">Stock-based compensation consists of time based awards to employees, liability based awards to employees to be settled in stock, performance based awards to employees, other non-employee grants and liability based awards to Directors for quarterly and annual services.  During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em>, the Company awarded 25 thousand and 64 thousand restricted stock awards, respectively to non-employee directors for compensation.  The Company also issued 162 thousand shares for employee services and 15 thousand shares for non-employee services during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2022, </em>respectively, based on the terms of service agreements.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">262</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">576</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">262</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">576</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 262000 740000 576000 985000 262000 740000 576000 985000 25000 64000 162000 15000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">6.</em> Income Taxes</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">The Company recorded <em style="font: inherit;">no</em> consolidated income tax benefit (expense) for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em>. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than <em style="font: inherit;">not</em> to be realized in future years. Accordingly, the tax provision that would have been recognized in the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em> was offset by changes in the valuation allowance. During the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em>, the Company had <em style="font: inherit;">no</em> material changes in uncertain tax positions.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">7.</em> Net Income (Loss) Per Share</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">The calculations of net income (loss) per share were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited - In thousands, except per share data)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Basic:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(320</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(6,226</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,305</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,356</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,856</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,468</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,879</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) per share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.03</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Diluted:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) for dilutive share computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(320</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,226</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,305</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Number of shares used in basic per share computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,356</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,856</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,468</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,879</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested restricted stock and DSU's</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,356</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,856</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,468</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,879</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) per dilutive share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.03</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">If an equity method company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net income (loss) per share is computed by <em style="font: inherit;">first</em> deducting the income attributable to the potential exercise of the dilutive securities of the company from net income (loss). Any impact is shown as an adjustment to net income (loss) for purposes of calculating diluted net income (loss) per share.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">Diluted earnings per share do <em style="font: inherit;">not</em> reflect the following potential shares of common stock that would have an anti-dilutive effect or have unsatisfied performance or market conditions:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 9pt;"> </td><td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">•</p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">At <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em>, options to purchase 18 thousand and 43 thousand shares of common stock, respectively, at prices ranging from $10.37 to $17.11 and $10.37 to $17.11, respectively, were excluded from the calculations.</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 9pt;"> </td><td style="width: 18pt;"> </td><td> </td></tr> <tr style="vertical-align: top;"><td style="width: 9pt;"> </td><td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">•</p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">At <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em>, unvested restricted stock and performance-based stock units convertible into 0.1 million and 0.3 million shares of stock, respectively, were excluded from the calculations.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Six Months Ended June 30,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited - In thousands, except per share data)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Basic:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(320</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(6,226</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,305</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,356</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,856</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,468</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,879</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) per share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.03</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Diluted:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) for dilutive share computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(320</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,226</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,305</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Number of shares used in basic per share computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,356</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,856</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,468</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,879</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested restricted stock and DSU's</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,356</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,856</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,468</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,879</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) per dilutive share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.03</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 483000 -320000 -6226000 17305000 16356000 20856000 16468000 20879000 0.03 -0.02 -0.38 0.83 483000 -320000 -6226000 17305000 16356000 20856000 16468000 20879000 0 0 0 0 0 0 0 0 16356000 20856000 16468000 20879000 0.03 -0.02 -0.38 0.83 18000 43000 10.37 17.11 10.37 17.11 100000 300000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">8.</em> Segment Reporting</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">The Company operates as <span style="-sec-ix-hidden:c86463725">one</span> operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.75pt;">As of <em style="font: inherit;"> June 30, 2022</em> and <em style="font: inherit;"> December 31, 2021</em>, all of the Company’s assets were located in the United States.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">9.</em> Commitments and Contingencies</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> March 2019, </em>the Company entered into a sublease of its prior corporate headquarters office space beginning in <em style="font: inherit;"> June 2019. </em>The term of the sublease is through <em style="font: inherit;"> April 2026, </em>the same as the Company's underlying lease. Fixed sublease payments to the Company are escalating over the term of the sublease and are reported as a component of general and administrative expenses.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">A summary of the Company's operating lease cash flows at <em style="font: inherit;"> June 30, 2022</em> follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 54pt;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Operating lease payments</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Expected sublease receipts</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 31%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022 (six months ending December 31)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">302</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">273</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">607</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">557</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">613</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">573</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,192</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,872</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, it is <em style="font: inherit;">not</em> reasonably possible that the ultimate disposition of these matters will have a material adverse effect on the Company’s consolidated financial position or results of operations, however, <em style="font: inherit;">no</em> assurance can be given as to the outcome of these actions, and <em style="font: inherit;">one</em> or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its companies. The Company records costs associated with legal fees as such services are rendered.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The Company has provided a guarantee, which is fully funded by escrowed funds held by a <em style="font: inherit;">third</em> party, of $3.8 million at <em style="font: inherit;"> June 30, 2022</em> which related to <em style="font: inherit;">one</em> of the Company's private equity fund interests.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In <em style="font: inherit;">2018,</em> the Board of Directors (the “Board”) of the Company adopted a long-term incentive plan, which was amended in <em style="font: inherit;"> February 2019 </em>and <em style="font: inherit;"> June 2020, </em>known as the Amended and Restated Safeguard Scientifics Transaction Bonus Plan, (the “LTIP”). The purpose of the LTIP is to promote the interests of the Company and its shareholders by providing an additional incentive to employees to maximize the value of the Company in connection with the execution of the business strategy that the Company adopted and announced in <em style="font: inherit;"> January 2018. </em>The <em style="font: inherit;"> June 2020 </em>amendment lowered the level of the <em style="font: inherit;">first</em> threshold and the resulting bonus pool percentage as an incentive to employees to accelerate actions consisent with the business strategy.  Under the LTIP, participants, which include certain current and former employees, have received awards that <em style="font: inherit;"> may </em>result in cash payments in connection with sales of the Company’s ownership interests (“Sale Transaction(s)”). The LTIP provides for a bonus pool corresponding to certain specified vesting thresholds (some of which have already been met and paid) or specified events. The remaining bonus pool will range from an amount equal to 1.0% of incremental proceeds received at the next threshold to 1.3% at higher thresholds.  A minimum pool will also be created and paid under specified events. The bonus pool will be allocated and paid to participants in the LTIP based on the product of (i) the participant’s applicable bonus pool percentage and (ii) the bonus pool calculated as of the vesting date, minus any previously paid portion of the bonus pool. Any portion of the bonus pool available as of the applicable vesting date that is reserved will be allocated in connection with each vesting date so that the entire bonus pool available as of such vesting date is allocated and payable to participants. Subject to the terms of the LTIP, payments under the LTIP will be paid in cash within <em style="font: inherit;">60</em> days of the applicable vesting date. All current officers and employees of the Company are eligible to participate in the LTIP. The Board, in its sole discretion, will determine the participants to whom awards are granted under the LTIP. The Company did <span style="-sec-ix-hidden:c86463739">not</span> make any payments during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022 </em>and has no amounts accrued as of <em style="font: inherit;"> June 30, 2022</em>. </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The Company has agreements with certain remaining employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under employment and severance agreements for remaining employees was approximately $0.8 million at <em style="font: inherit;"> June 30, 2022</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In <em style="font: inherit;"> June 2011, </em>the Company's former ownership interest, Advanced BioHealing, Inc. (“ABH”) was acquired by Shire plc (“Shire”).  Prior to the expiration of the escrow period in <em style="font: inherit;"> March 2012, </em>Shire filed a claim against all amounts held in escrow related to the sale based principally upon a United States Department of Justice (“DOJ”) false claims act investigation relating to ABH (the “Investigation”). In connection with the Investigation, in <em style="font: inherit;"> July 2015 </em>the Company received a Civil Investigation Demand-Documentary Material (“CID”) from the DOJ regarding ABH and Safeguard’s relationship with ABH. Pursuant to the CID, the Company provided the requested materials and information.  To the Company’s knowledge, the CID was related to multiple qui tam (“whistleblower”) actions, <em style="font: inherit;">one</em> of which was filed in <em style="font: inherit;">2014</em> by an ex-employee of ABH that named the Company and <em style="font: inherit;">one</em> of the Company’s employees along with other entities and individuals as defendants.  At this time, the DOJ has declined to pursue the qui tam action as it relates to the Company and such Company employee.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 54pt;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Operating lease payments</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">Expected sublease receipts</em></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 31%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Unaudited - In thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022 (six months ending December 31)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">302</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">273</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">607</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">557</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">613</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">573</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,192</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 27%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,872</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 27%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> </tbody></table> 302000 273000 607000 557000 613000 573000 619000 590000 207000 199000 0 0 0 0 2348000 2192000 476000 1872000 3800000 0.010 0.013 0 800000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">10.</em> Equity</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In <em style="font: inherit;"> July 2015, </em>the Company's Board of Directors authorized the Company, from time to time and depending on market conditions, to repurchase up to $25.0 million of the Company's outstanding common stock. The Company has<span style="-sec-ix-hidden:c86463806"> <span style="-sec-ix-hidden:c86463749">not</span></span> repurchased any shares under such authorization during <em style="font: inherit;">2021</em> or the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:22.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In <em style="font: inherit;"> March 2022, </em>the Company's Board of Directors replaced a previously existing share repurchase plan that was authorized in <em style="font: inherit;"> May 2021 </em>with a newly authorized $3.0 million share repurchase plan using existing funds in accordance with the requirements of Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> and Rule <em style="font: inherit;">10b</em>-<em style="font: inherit;">18</em> under the Securities Exchange Act of <em style="font: inherit;">1934,</em> as amended. During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em>, the Company repurchased 369,274 shares for an aggregate price of $1.7 million at an average cost at $4.67 per share pursuant to this plan.</p> 25000000.0 3000000.0 369274 1700000 4.67 EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 114 157 1 false 34 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.safeguard.com/20220630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Changes in Equity (Unaudited) Sheet http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited Consolidated Statements of Changes in Equity (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - General Sheet http://www.safeguard.com/20220630/role/statement-note-1-general Note 1 - General Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Ownership Interests and Advances Sheet http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances- Note 2 - Ownership Interests and Advances Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Acquisitions of Ownership Interests Sheet http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests Note 3 - Acquisitions of Ownership Interests Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements Note 4 - Fair Value Measurements Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Stock-Based Compensation Sheet http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation Note 5 - Stock-Based Compensation Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Income Taxes Sheet http://www.safeguard.com/20220630/role/statement-note-6-income-taxes Note 6 - Income Taxes Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Net Income (Loss) Per Share Sheet http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share Note 7 - Net Income (Loss) Per Share Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Segment Reporting Sheet http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting Note 8 - Segment Reporting Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Commitments and Contingencies Sheet http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies Note 9 - Commitments and Contingencies Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Equity Sheet http://www.safeguard.com/20220630/role/statement-note-10-equity Note 10 - Equity Notes 16 false false R17.htm 016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies 17 false false R18.htm 017 - Disclosure - Note 2 - Ownership Interests and Advances (Tables) Sheet http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables Note 2 - Ownership Interests and Advances (Tables) Tables http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances- 18 false false R19.htm 018 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-tables Note 4 - Fair Value Measurements (Tables) Tables http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements 19 false false R20.htm 019 - Disclosure - Note 5 - Stock-Based Compensation (Tables) Sheet http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-tables Note 5 - Stock-Based Compensation (Tables) Tables http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation 20 false false R21.htm 020 - Disclosure - Note 7 - Net Income (Loss) Per Share (Tables) Sheet http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-tables Note 7 - Net Income (Loss) Per Share (Tables) Tables http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share 21 false false R22.htm 021 - Disclosure - Note 9 - Commitments and Contingencies (Tables) Sheet http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-tables Note 9 - Commitments and Contingencies (Tables) Tables http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies 22 false false R23.htm 022 - Disclosure - Note 1 - General (Details Textual) Sheet http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual Note 1 - General (Details Textual) Details http://www.safeguard.com/20220630/role/statement-note-1-general 23 false false R24.htm 023 - Disclosure - Note 2 - Ownership Interests and Advances (Details Textual) Sheet http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-details-textual Note 2 - Ownership Interests and Advances (Details Textual) Details http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables 24 false false R25.htm 024 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) Sheet http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) Details 25 false false R26.htm 025 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details) Sheet http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details) Details 26 false false R27.htm 026 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) Sheet http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) Details 27 false false R28.htm 027 - Disclosure - Note 3 - Acquisitions of Ownership Interests (Details Textual) Sheet http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual Note 3 - Acquisitions of Ownership Interests (Details Textual) Details http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests 28 false false R29.htm 028 - Disclosure - Note 4 - Fair Value Measurements (Details Textual) Sheet http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-details-textual Note 4 - Fair Value Measurements (Details Textual) Details http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-tables 29 false false R30.htm 029 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) Sheet http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) Details 30 false false R31.htm 030 - Disclosure - Note 5 - Stock-Based Compensation (Details Textual) Sheet http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual Note 5 - Stock-Based Compensation (Details Textual) Details http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-tables 31 false false R32.htm 031 - Disclosure - Note 5 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) Sheet http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details Note 5 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) Details 32 false false R33.htm 032 - Disclosure - Note 7 - Net Income (Loss) Per Share (Details Textual) Sheet http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual Note 7 - Net Income (Loss) Per Share (Details Textual) Details http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-tables 33 false false R34.htm 033 - Disclosure - Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) Sheet http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) Details http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-tables 34 false false R35.htm 034 - Disclosure - Note 8 - Segment Reporting (Details Textual) Sheet http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting-details-textual Note 8 - Segment Reporting (Details Textual) Details http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting 35 false false R36.htm 035 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual) Sheet http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual Note 9 - Commitments and Contingencies (Details Textual) Details http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-tables 36 false false R37.htm 036 - Disclosure - Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details) Sheet http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details) Details 37 false false R38.htm 037 - Disclosure - Note 10 - Equity (Details Textual) Sheet http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual Note 10 - Equity (Details Textual) Details http://www.safeguard.com/20220630/role/statement-note-10-equity 38 false false All Reports Book All Reports sfe20220630_10q.htm ex_380086.htm ex_380087.htm ex_380088.htm ex_380089.htm sfe-20220630.xsd sfe-20220630_cal.xml sfe-20220630_def.xml sfe-20220630_lab.xml sfe-20220630_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sfe20220630_10q.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 114, "dts": { "calculationLink": { "local": [ "sfe-20220630_cal.xml" ] }, "definitionLink": { "local": [ "sfe-20220630_def.xml" ] }, "inline": { "local": [ "sfe20220630_10q.htm" ] }, "labelLink": { "local": [ "sfe-20220630_lab.xml" ] }, "presentationLink": { "local": [ "sfe-20220630_pre.xml" ] }, "schema": { "local": [ "sfe-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 256, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 28, "http://www.safeguard.com/20220630": 17, "http://xbrl.sec.gov/dei/2022": 6, "total": 51 }, "keyCustom": 20, "keyStandard": 137, "memberCustom": 13, "memberStandard": 21, "nsprefix": "sfe", "nsuri": "http://www.safeguard.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.safeguard.com/20220630/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Fair Value Measurements", "role": "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements", "shortName": "Note 4 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Stock-Based Compensation", "role": "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "shortName": "Note 5 - Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Income Taxes", "role": "http://www.safeguard.com/20220630/role/statement-note-6-income-taxes", "shortName": "Note 6 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Net Income (Loss) Per Share", "role": "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "shortName": "Note 7 - Net Income (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Segment Reporting", "role": "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting", "shortName": "Note 8 - Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Commitments and Contingencies", "role": "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "shortName": "Note 9 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Equity", "role": "http://www.safeguard.com/20220630/role/statement-note-10-equity", "shortName": "Note 10 - Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "sfe:LiquidityPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "sfe:LiquidityPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 2 - Ownership Interests and Advances (Tables)", "role": "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables", "shortName": "Note 2 - Ownership Interests and Advances (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 4 - Fair Value Measurements (Tables)", "role": "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-tables", "shortName": "Note 4 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)", "role": "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited", "shortName": "Consolidated Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 5 - Stock-Based Compensation (Tables)", "role": "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-tables", "shortName": "Note 5 - Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 7 - Net Income (Loss) Per Share (Tables)", "role": "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-tables", "shortName": "Note 7 - Net Income (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 9 - Commitments and Contingencies (Tables)", "role": "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-tables", "shortName": "Note 9 - Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 1 - General (Details Textual)", "role": "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual", "shortName": "Note 1 - General (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-BrightHealthMember", "decimals": "-5", "lang": null, "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": "-5", "first": true, "lang": null, "name": "sfe:ImpairmentOfOtherMethodSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 2 - Ownership Interests and Advances (Details Textual)", "role": "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-details-textual", "shortName": "Note 2 - Ownership Interests and Advances (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": "-5", "first": true, "lang": null, "name": "sfe:ImpairmentOfOtherMethodSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details)", "role": "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "shortName": "Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AktanaIncMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details)", "role": "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "shortName": "Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AktanaIncMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30_EquityMethodInvestmentNonconsolidatedInvesteeAxis-EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details)", "role": "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "shortName": "Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30_EquityMethodInvestmentNonconsolidatedInvesteeAxis-EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 3 - Acquisitions of Ownership Interests (Details Textual)", "role": "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "shortName": "Note 3 - Acquisitions of Ownership Interests (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "sfe:EquityMethodAndOtherInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PrognosHealthIncMember", "decimals": "-6", "lang": null, "name": "sfe:ConvertibleBridgeLoan", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-BrightHealthMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedBalanceShares", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 4 - Fair Value Measurements (Details Textual)", "role": "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-details-textual", "shortName": "Note 4 - Fair Value Measurements (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "role": "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)", "role": "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "shortName": "Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 5 - Stock-Based Compensation (Details Textual)", "role": "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual", "shortName": "Note 5 - Stock-Based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 5 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)", "role": "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "shortName": "Note 5 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 7 - Net Income (Loss) Per Share (Details Textual)", "role": "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual", "shortName": "Note 7 - Net Income (Loss) Per Share (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details)", "role": "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "shortName": "Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R35": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 8 - Segment Reporting (Details Textual)", "role": "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting-details-textual", "shortName": "Note 8 - Segment Reporting (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)", "role": "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual", "shortName": "Note 9 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details)", "role": "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details", "shortName": "Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 10 - Equity (Details Textual)", "role": "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual", "shortName": "Note 10 - Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2015-07-31_ShareRepurchaseProgramAxis-ShareRepurchaseProgramAuthorizedInJuly2015Member", "decimals": "-6", "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations (Unaudited)", "role": "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-04-01_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Changes in Equity (Unaudited)", "role": "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited", "shortName": "Consolidated Statements of Changes in Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember", "decimals": "-3", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - General", "role": "http://www.safeguard.com/20220630/role/statement-note-1-general", "shortName": "Note 1 - General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Ownership Interests and Advances", "role": "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-", "shortName": "Note 2 - Ownership Interests and Advances", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "sfe:EquityMethodAndOtherInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Acquisitions of Ownership Interests", "role": "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests", "shortName": "Note 3 - Acquisitions of Ownership Interests", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sfe20220630_10q.htm", "contextRef": "d_2022-01-01_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "sfe:EquityMethodAndOtherInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 34, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited", "http://www.safeguard.com/20220630/role/statement-document-and-entity-information", "http://www.safeguard.com/20220630/role/statement-note-1-general", "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20220630/role/statement-note-10-equity", "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-tables", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-tables", "http://www.safeguard.com/20220630/role/statement-note-6-income-taxes", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-tables", "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting", "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-tables", "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited", "http://www.safeguard.com/20220630/role/statement-document-and-entity-information", "http://www.safeguard.com/20220630/role/statement-note-1-general", "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20220630/role/statement-note-10-equity", "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-tables", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-tables", "http://www.safeguard.com/20220630/role/statement-note-6-income-taxes", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-tables", "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting", "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-tables", "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "sfe_AktanaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Aktana, Inc.", "label": "Aktana, Inc. [Member]" } } }, "localname": "AktanaIncMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "sfe_BrightHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Bright Health.", "label": "Bright Health [Member]" } } }, "localname": "BrightHealthMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-1-general", "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "sfe_ClutchHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Clutch Holdings.", "label": "Clutch Holdings [Member]" } } }, "localname": "ClutchHoldingsMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "sfe_ConvertibleBridgeLoan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of funding for convertible bridge loans in the period.", "label": "sfe_ConvertibleBridgeLoan", "terseLabel": "Convertible Bridge Loan" } } }, "localname": "ConvertibleBridgeLoan", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_EmployeeAndSeveranceAgreementMaximumAggregateExposure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents maximum aggregate exposure for employee and severance agreement.", "label": "sfe_EmployeeAndSeveranceAgreementMaximumAggregateExposure", "terseLabel": "Employee and Severance Agreement, Maximum Aggregate Exposure" } } }, "localname": "EmployeeAndSeveranceAgreementMaximumAggregateExposure", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_EquityMethodAndOtherInvestmentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method and other investments.", "label": "Equity Method and Other Investments Disclosure [Text Block]" } } }, "localname": "EquityMethodAndOtherInvestmentsDisclosureTextBlock", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests" ], "xbrltype": "textBlockItemType" }, "sfe_ImpairmentOfOtherMethodSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment of other method securities.", "label": "sfe_ImpairmentOfOtherMethodSecurities", "terseLabel": "Impairment of Other Method Securities" } } }, "localname": "ImpairmentOfOtherMethodSecurities", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_InfoBionicIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity InfoBionic, Inc.", "label": "InfoBionic, Inc. [Member]" } } }, "localname": "InfoBionicIncMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents Investments and Advances to Affiliates, Current and Noncurrent.", "label": "sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent", "totalLabel": "Investments and Advances to Affiliates, Current and Noncurrent" } } }, "localname": "InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "monetaryItemType" }, "sfe_LesseeSubleaseExpectedReceiptsTotal": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total amount of sublease expected receipts.", "label": "sfe_LesseeSubleaseExpectedReceiptsTotal", "totalLabel": "Total future minimum lease payments, Expected sublease receipt" } } }, "localname": "LesseeSubleaseExpectedReceiptsTotal", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "sfe_LesseeSubleaseExpectedReceiptsYearOne": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 4.0, "parentTag": "sfe_LesseeSubleaseExpectedReceiptsTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expected sublease receipts for year one.", "label": "sfe_LesseeSubleaseExpectedReceiptsYearOne", "terseLabel": "2023, Expected sublease receipts" } } }, "localname": "LesseeSubleaseExpectedReceiptsYearOne", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "sfe_LesseeSubleaseexpectedReceiptsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 5.0, "parentTag": "sfe_LesseeSubleaseExpectedReceiptsTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expected sublease receipts for remainder of fiscal year.", "label": "sfe_LesseeSubleaseexpectedReceiptsRemainderOfFiscalYear", "terseLabel": "2022 (six months ending December 31)" } } }, "localname": "LesseeSubleaseexpectedReceiptsRemainderOfFiscalYear", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "sfe_LesseeSubleaseexpectedReceiptsThereafter": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 0.0, "parentTag": "sfe_LesseeSubleaseExpectedReceiptsTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expected sublease receipts after year six.", "label": "sfe_LesseeSubleaseexpectedReceiptsThereafter", "terseLabel": "Thereafter, Expected sublease receipt" } } }, "localname": "LesseeSubleaseexpectedReceiptsThereafter", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "sfe_LesseeSubleaseexpectedReceiptsYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expected sublease receipts for year five.", "label": "2027, Expected sublease receipts" } } }, "localname": "LesseeSubleaseexpectedReceiptsYearFive", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "sfe_LesseeSubleaseexpectedReceiptsYearFour": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 1.0, "parentTag": "sfe_LesseeSubleaseExpectedReceiptsTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expected sublease receipts for year four.", "label": "sfe_LesseeSubleaseexpectedReceiptsYearFour", "terseLabel": "2026, Expected sublease receipts" } } }, "localname": "LesseeSubleaseexpectedReceiptsYearFour", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "sfe_LesseeSubleaseexpectedReceiptsYearThree": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 2.0, "parentTag": "sfe_LesseeSubleaseExpectedReceiptsTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expected sublease receipts for year three.", "label": "sfe_LesseeSubleaseexpectedReceiptsYearThree", "terseLabel": "2025, Expected sublease receipts" } } }, "localname": "LesseeSubleaseexpectedReceiptsYearThree", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "sfe_LesseeSubleaseexpectedReceiptsYearTwo": { "auth_ref": [], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 3.0, "parentTag": "sfe_LesseeSubleaseExpectedReceiptsTotal", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expected sublease receipts for year two.", "label": "sfe_LesseeSubleaseexpectedReceiptsYearTwo", "terseLabel": "2024, Expected sublease receipts" } } }, "localname": "LesseeSubleaseexpectedReceiptsYearTwo", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "sfe_LiquidityPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for liquidity.", "label": "Liquidity, Policy [Policy Text Block]" } } }, "localname": "LiquidityPolicyPolicyTextBlock", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "sfe_LongTermIncentivePlanPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents amount of payments under long-term incentive plan.", "label": "sfe_LongTermIncentivePlanPayments", "terseLabel": "Long-term Incentive Plan, Payments" } } }, "localname": "LongTermIncentivePlanPayments", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "sfe_LongtermIncentivePlanBonusPoolPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents bonus pool percent for long-term incentive plan.", "label": "sfe_LongtermIncentivePlanBonusPoolPercent", "terseLabel": "Long-term Incentive Plan, Bonus Pool Percent" } } }, "localname": "LongtermIncentivePlanBonusPoolPercent", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "percentItemType" }, "sfe_LumesisIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Lumesis, Inc.", "label": "Lumesis, Inc. [Member]" } } }, "localname": "LumesisIncMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "sfe_MoxeHealthCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Moxe Health Corporation.", "label": "Moxe Health Corporation [Member]" } } }, "localname": "MoxeHealthCorporationMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "sfe_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_PrognosHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Prognos Health, Inc.", "label": "Prognos Health, Inc. [Member]" } } }, "localname": "PrognosHealthIncMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "domainItemType" }, "sfe_RestrictedCashAndCashEquivalentsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "sfe_RestrictedCashAndCashEquivalentsFairValue", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsFairValue", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "sfe_RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents restricted stock, performance-based stock units, and deferred stock units.", "label": "Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member]" } } }, "localname": "RestrictedStockPerformanceBasedStockUnitsAndDeferredStockUnitsMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual" ], "xbrltype": "domainItemType" }, "sfe_ShareRepurchaseProgramAuthorizedInJuly2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents share repurchase program authorized in July 2015.", "label": "Share Repurchase Program Authorized in July 2015 [Member]" } } }, "localname": "ShareRepurchaseProgramAuthorizedInJuly2015Member", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-10-equity", "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual" ], "xbrltype": "domainItemType" }, "sfe_ShareRepurchaseProgramAuthorizedInMay2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents share repurchase program authorized in May 2021.", "label": "Share Repurchase Program Authorized in May 2021 [Member]" } } }, "localname": "ShareRepurchaseProgramAuthorizedInMay2021Member", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-10-equity", "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual" ], "xbrltype": "domainItemType" }, "sfe_StockIssuedDuringPeriodSharesRestrictedStockWithheldForTaxes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued for restricted stock awards and withheld for taxes.", "label": "Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockWithheldForTaxes", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "sharesItemType" }, "sfe_StockIssuedDuringPeriodValueRestrictedStockAwardWithheldForTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of shares issued for restricted stock awards withheld for taxes.", "label": "Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net", "negatedLabel": "Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardWithheldForTaxes", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "sfe_SyapseIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Syapse, Inc.", "label": "Syapse, Inc. [Member]" } } }, "localname": "SyapseIncMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "sfe_TradingSecuritiesFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of fair value for investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "sfe_TradingSecuritiesFairValueDisclosure", "terseLabel": "Ownership interests" } } }, "localname": "TradingSecuritiesFairValueDisclosure", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "sfe_TriceMedicalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity Trice Medical, Inc.", "label": "Trice Medical, Inc. [Member]" } } }, "localname": "TriceMedicalIncMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "sfe_meQuilibriumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity meQuilibrium.", "label": "meQuilibrium [Member]" } } }, "localname": "meQuilibriumMember", "nsuri": "http://www.safeguard.com/20220630", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "sfe_statement-statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details)" } } }, "localname": "statement-statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details)" } } }, "localname": "statement-statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details)" } } }, "localname": "statement-statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-2-ownership-interests-and-advances-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Ownership Interests and Advances" } } }, "localname": "statement-statement-note-2-ownership-interests-and-advances-tables", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-4-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements" } } }, "localname": "statement-statement-note-4-fair-value-measurements-tables", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)" } } }, "localname": "statement-statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-5-stockbased-compensation-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Stock-Based Compensation" } } }, "localname": "statement-statement-note-5-stockbased-compensation-tables", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details)" } } }, "localname": "statement-statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-7-net-income-loss-per-share-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Net Income (Loss) Per Share" } } }, "localname": "statement-statement-note-7-net-income-loss-per-share-tables", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details)" } } }, "localname": "statement-statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-note-9-commitments-and-contingencies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Commitments and Contingencies" } } }, "localname": "statement-statement-note-9-commitments-and-contingencies-tables", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "sfe_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.safeguard.com/20220630", "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-1-general", "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r137", "r138", "r139", "r140", "r154", "r160", "r187", "r188", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r325", "r326", "r353", "r354" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r137", "r138", "r139", "r140", "r154", "r160", "r187", "r188", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r325", "r326", "r353", "r354" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_PartnershipInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Partnership Interest [Member]" } } }, "localname": "PartnershipInterestMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r132", "r137", "r138", "r139", "r140", "r154", "r160", "r178", "r187", "r188", "r219", "r220", "r221", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r325", "r326", "r353", "r354" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r132", "r137", "r138", "r139", "r140", "r154", "r160", "r178", "r187", "r188", "r219", "r220", "r221", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r325", "r326", "r353", "r354" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-1-general", "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r20", "r292" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r17", "r29", "r30", "r31", "r315", "r331", "r332" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r28", "r31", "r34", "r35", "r36", "r61", "r62", "r63", "r255", "r289", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r15" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r61", "r62", "r63", "r229", "r230", "r231", "r263" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r190", "r232", "r233" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdvancesToAffiliate": { "auth_ref": [ "r334" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details": { "order": 1.0, "parentTag": "sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients.", "label": "Advances to companies" } } }, "localname": "AdvancesToAffiliate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r224" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "verboseLabel": "General and administrative expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r11", "r58", "r102", "r107", "r113", "r126", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r251", "r256", "r277", "r290", "r292", "r305", "r314" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r19", "r58", "r126", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r251", "r256", "r277", "r290", "r292" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r216", "r217", "r218", "r219", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r8", "r55" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r51", "r55", "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r51", "r278" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "totalLabel": "Net change in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r25", "r307", "r318" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r134", "r135", "r136", "r141", "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r61", "r62", "r263" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r172" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r292" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued and outstanding at June 30, 2022 and December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent", "terseLabel": "Deferred Compensation Liability, Current and Noncurrent, Total" } } }, "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r193", "r194", "r225", "r226", "r227", "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-1-general", "http://www.safeguard.com/20220630/role/statement-note-10-equity", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-6-income-taxes", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r41", "r66", "r67", "r68", "r69", "r70", "r74", "r76", "r83", "r84", "r85", "r89", "r90", "r264", "r265", "r312", "r321" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r41", "r66", "r67", "r68", "r69", "r70", "r76", "r83", "r84", "r85", "r89", "r90", "r264", "r265", "r312", "r321" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diluted:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r86", "r87", "r88", "r91" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r34", "r35", "r36", "r61", "r62", "r63", "r65", "r71", "r73", "r92", "r128", "r172", "r173", "r229", "r230", "r231", "r239", "r240", "r263", "r279", "r280", "r281", "r282", "r283", "r284", "r289", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r2", "r58", "r126", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r2", "r58", "r126", "r277" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "auth_ref": [ "r2", "r58", "r126", "r277" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership Interest" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r9", "r103", "r123" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details": { "order": 0.0, "parentTag": "sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Companies", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r122" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details": { "order": 2.0, "parentTag": "sfe_InvestmentsAndAdvancesToAffiliatesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Other Method, fair value measurement alternative" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r155", "r156", "r157", "r274" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r155", "r156", "r157", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r267", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r155", "r156", "r157", "r266", "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r266", "r267", "r268", "r269", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r155", "r179", "r180", "r185", "r186", "r267", "r293" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r155", "r156", "r157", "r179", "r180", "r185", "r186", "r267", "r294" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r155", "r156", "r157", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r267", "r295" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r155", "r156", "r157", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r189", "r191", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r216", "r217", "r218", "r219", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [ "r189", "r191", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r216", "r217", "r218", "r219", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r43", "r58", "r102", "r106", "r109", "r112", "r115", "r126", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "auth_ref": [ "r142" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.", "label": "us-gaap_GuaranteeObligationsCurrentCarryingValue", "terseLabel": "Guarantor Obligations, Current Carrying Value" } } }, "localname": "GuaranteeObligationsCurrentCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r129", "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r38", "r102", "r106", "r109", "r112", "r115", "r304", "r310", "r313", "r323" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Net income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r39", "r53", "r100", "r123", "r309", "r319" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Equity income (loss), net" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r130", "r133" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r59", "r236", "r237", "r238", "r241", "r243", "r245", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-6-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r60", "r72", "r73", "r101", "r235", "r242", "r244", "r324" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax benefit (expense)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r77", "r78", "r79", "r85", "r192" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Unvested restricted stock and DSU's (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToWrittenPutOptions": { "auth_ref": [ "r78", "r80", "r81", "r85" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of outstanding written put options using the reverse treasury stock method.", "label": "Employee stock options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToWrittenPutOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r45", "r99" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r333", "r338" ], "lang": { "en-us": { "role": { "documentation": "Balance held at close of period in number of shares.", "label": "us-gaap_InvestmentOwnedBalanceShares", "terseLabel": "Investment Owned, Balance, Shares (in shares)" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r125", "r322" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r335", "r336", "r337", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r335", "r336", "r337", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r11" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Ownership interests and advances" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.", "label": "Investments in and Advances to Affiliates, Schedule of Investments [Text Block]" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r287" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total future minimum lease payments, Operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r287" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "verboseLabel": "Thereafter, Operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r287" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "verboseLabel": "2023, Operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r287" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "verboseLabel": "2026, Operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r287" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "verboseLabel": "2025, Operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r287" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "verboseLabel": "2024, Operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r287" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "verboseLabel": "2022 (six months ending December 31)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r287" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less imputed interest, Operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2027, Operating lease payments" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r21", "r58", "r108", "r126", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r252", "r256", "r257", "r277", "r290", "r291" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r58", "r126", "r277", "r292", "r306", "r317" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r23", "r58", "r126", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r252", "r256", "r257", "r277", "r290", "r291", "r292" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r51" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r51" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r51", "r52", "r54" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r32", "r33", "r36", "r40", "r54", "r58", "r64", "r66", "r67", "r68", "r69", "r72", "r73", "r82", "r102", "r106", "r109", "r112", "r115", "r126", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r265", "r277", "r311", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r102", "r106", "r109", "r112", "r115" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r286" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total operating lease liabilities, Operating lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r286" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liability - current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r286" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liability - non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r285" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-1-general" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r10" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income (loss), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForAdvanceToAffiliate": { "auth_ref": [ "r48" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).", "label": "us-gaap_PaymentsForAdvanceToAffiliate", "negatedLabel": "Advances and loans to ownership interests" } } }, "localname": "PaymentsForAdvanceToAffiliate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r49" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Repurchases of Company common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r49" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Tax withholdings related to equity-based awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member] [Default]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13", "r158" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13", "r292" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.10 par value; 1,000 shares authorized" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivateEquityFundsMember": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Investments held in private equity funds.", "label": "Private Equity Funds [Member]" } } }, "localname": "PrivateEquityFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "auth_ref": [ "r47" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Proceeds from sales of ownership interests" } } }, "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r32", "r33", "r36", "r50", "r58", "r64", "r72", "r73", "r102", "r106", "r109", "r112", "r115", "r126", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r250", "r253", "r254", "r259", "r260", "r265", "r277", "r313" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r8", "r56" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r173", "r292", "r316", "r330", "r332" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r61", "r62", "r63", "r65", "r71", "r73", "r128", "r229", "r230", "r231", "r239", "r240", "r263", "r327", "r329" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r37", "r58", "r97", "r98", "r105", "r110", "r111", "r117", "r118", "r120", "r126", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r277", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A tabular presentation of the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates, as prescribed by the SEC. It reflects specified information about ownership, financial results from, and financial position in such entities. Includes the tabular presentations that disaggregate investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates.", "label": "Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block]" } } }, "localname": "ScheduleOfInvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other units or shares or classes of ownership in a partnership.", "label": "Schedule of Other Ownership Interests [Table Text Block]" } } }, "localname": "ScheduleOfOtherOwnershipInterestsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r205", "r212", "r215" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r93", "r95", "r96", "r102", "r104", "r109", "r113", "r114", "r115", "r116", "r117", "r119", "r120", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r216", "r217", "r218", "r219", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r191", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r216", "r217", "r218", "r219", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-Based Payment Arrangement, Employee [Member]" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "auth_ref": [ "r189", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r216", "r217", "r218", "r219", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-Based Payment Arrangement, Nonemployee [Member]" } } }, "localname": "ShareBasedPaymentArrangementNonemployeeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-10-equity", "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-10-equity", "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r27", "r34", "r35", "r36", "r61", "r62", "r63", "r65", "r71", "r73", "r92", "r128", "r172", "r173", "r229", "r230", "r231", "r239", "r240", "r263", "r279", "r280", "r281", "r282", "r283", "r284", "r289", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited", "http://www.safeguard.com/20220630/role/statement-note-1-general", "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20220630/role/statement-note-10-equity", "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-tables", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-tables", "http://www.safeguard.com/20220630/role/statement-note-6-income-taxes", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-tables", "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting", "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-tables", "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r61", "r62", "r63", "r92", "r303" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited", "http://www.safeguard.com/20220630/role/statement-note-1-general", "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20220630/role/statement-note-10-equity", "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-ownership-interests-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-results-of-operations-details", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests", "http://www.safeguard.com/20220630/role/statement-note-3-acquisitions-of-ownership-interests-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-details-textual", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-tables", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-details-textual", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-schedule-of-stockbased-compensation-expense-details", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-tables", "http://www.safeguard.com/20220630/role/statement-note-6-income-taxes", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-details-textual", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-tables", "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting", "http://www.safeguard.com/20220630/role/statement-note-8-segment-reporting-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-operating-lease-cash-flow-details", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-tables", "http://www.safeguard.com/20220630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramAuthorizedAmount1", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r35", "r58", "r61", "r62", "r63", "r65", "r71", "r126", "r128", "r173", "r229", "r230", "r231", "r239", "r240", "r248", "r249", "r258", "r263", "r277", "r279", "r280", "r284", "r289", "r328", "r329" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r57", "r159", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r173", "r177", "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-10-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-tables", "http://www.safeguard.com/20220630/role/statement-note-4-fair-value-measurements-tables", "http://www.safeguard.com/20220630/role/statement-note-5-stockbased-compensation-tables", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-tables", "http://www.safeguard.com/20220630/role/statement-note-9-commitments-and-contingencies-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r5", "r12", "r308" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Ownership interests", "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI, Total" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.safeguard.com/20220630/role/statement-note-1-general-details-textual", "http://www.safeguard.com/20220630/role/statement-note-2-ownership-interests-and-advances-schedule-of-carrying-value-of-ownership-interests-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "us-gaap_TreasuryStockAcquiredAverageCostPerShare", "terseLabel": "Treasury Stock Acquired, Average Cost Per Share (in dollars per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r26", "r175" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r26", "r175" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r14", "r172", "r173" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Repurchases of common stock (in shares)", "terseLabel": "Treasury Stock, Shares, Acquired (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited", "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r26", "r175", "r176" ], "calculation": { "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost; 5,261 and 5,068 shares at June 30, 2022 and December 31, 2021, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r172", "r173", "r175" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedLabel": "Repurchases of common stock", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-changes-in-equity-unaudited", "http://www.safeguard.com/20220630/role/statement-note-10-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r75", "r85" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares used in computing income (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r74", "r85" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.safeguard.com/20220630/role/statement-consolidated-statements-of-operations-unaudited", "http://www.safeguard.com/20220630/role/statement-note-7-net-income-loss-per-share-calculations-of-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.2)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r355": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r356": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r357": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r358": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r359": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r360": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "35", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2366-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "36", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2398-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" } }, "version": "2.1" } ZIP 57 0001437749-22-020306-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-020306-xbrl.zip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

,R*6?^F6,WMD M7_!D9!9U$(@'5]&E6-.]V934;#/OZ!=I>M-D5^S73UYKY>]0MW# M5L".(?O,52&Q3Y# C]Z/)&-%![?;A*R/A>,R5G;53;)Y,[-X7E1W;)GV[-/GWWTEUDV]:32U=!K,3=BT0O67?XF9SIW-E^8Y MKGIA#)EH2(7+WRZ.:LQ"U#_.?AU?^JO^*>G+0*3'YZ"ZQ(FQ+G'B3)A!>S=^ 3LD-L] M;*0F\"]@L[_PM" MN'E^DW>>L1TM@0+5 M&U()4HD<09]H3L8B@UX))=MB":/A8D6S'UD9VO\1.Y M9?PZI>DFOZ4TN279_#BFU+@?)'>0#GP?+R%:A!BG$7(S.L!+AW @YJ2@FA;$ MB9D@00[B]*!QC=+Z)>-!C&S-1[:61,B,234KXIH5:P8C0 (EH\5%P=SV=LK\ MC<2/2W87G_$7E$?R<<-/O+($<7ZSRU;>$Q,&!0,\GTS1N=Z.*GH0E@15?M2; M7'HT\I0Y&Q&5%8M2YNAU0O/\FYT?P<]!SCGPK-&AIB*,-M7Q;*%L-X0FY>-I MXE"/"OI-+(\SD_4[;C#[%$8E.MY]S M'LMRPS1BS!7EV9Q=E,3BZ=GPX(" 0FZ.T/D&R8NR7R;T.4=\[E%-"MK1$F;' MM)@<.AS'_05Y M:%SMO+U"0XUYYVV%[!Q?;Q;-T-@R7?,9S8O\R&$F[TM9,A!4X&JSQ.Y\.V^+ MSVZ$<'\)G:UDJ-FCCJ;$9W+9S6HC*+SA6?\YY1E9,N+C)W(ES,N=;@C&_>$I M:/7P.,]*>W-VA9K>=JB@3,:SX+$#YC-!K=GK3TRC*.:+"2>W.&;:^AE>QSL/ MR$*]3>MWA IF+P+G$EE3@-:,A"E_(9)$A)%#?8Y3.!N]29Y8#A]I2BMM1JZ& M"UDO12%U>IV $M<-W+6T">S[#X\3E)(>IP%'LJ;)9PICGK^;OE20[\B:A_ZG MCSM5HD\+->@)M07T8W"N34H24$T#:A3&"JY*FDP!M>"K1[L3P[VD2<0NKC+M M)%LCR88_N]>I*9K!!FPU,385C%^)6$_LPDOROIQ"HH#&." M=31MU,]<6'E0GF;<->4O!"?%LKT$2VL0!*K'I?$DD\Q5F>/$_^X9G;,TXEZ(RD(4/E"Y2BT)(,GYC8]C1AQU M6,]VI]-IDMK0>HZ\+;:[.EZ5/T)VUW+J; L4]U:8KN5UAQ3-&=8@LMK-3&K$ M(<].-GJ^6IUMK5QP GEH2>1A]-QN9AZYO8S#):LEU4OO,Y96'UL?TS;8'EU+ M&^C#FPOT&-[F4=K/17_[4GVLJMV86]M ]Z$F+)_:53@7Y';V42V>^/2[D_;3 M:YHK'4[:VL"]Y7:P7,L!0X:X?3N4KUL+UZ@6*[Q-OU"0V'_<3O.$$ZZ([VM/ M3.O>_Z+14B$N@\ $BI<5;E]^3E9$0GRA/'-E+1+0?RIP5ER;Z8T,\T1<,!#9 M$2#"2;+]"PA/(?U 'N,TY8\)=('6X!H+09ASD48N64/8UYI,<;3[#;,)4"?3 M9&5$%M9M66KA?)-QF[9@LM#O=OA%*W&^_RTNEDN21)[0YE +$A?B1B#RV,H VXRL&:2E<%OCD>(%?D'/G&::\/>' M7..A.RB3?I),2D626L,MXK\:KZS>&>Z7I,SCSO;)DB&QK#C#>7&9UTG,O4$+4'I924SX%>+83)UFG2WQG6^MGNP9,C^JSP!K6 MO[V;K:T/>$I>A0Y,OHQ3G,[W@DW5UE-# ,,&(K<@\A;0ITT1*,+/X7@!D?W< MV"SL+U62IT5%",*:X_0;==TE@?W1UKUL=F%ED5FD#K8'N(7%"-QPUA4MM%^E M944_8WMH9L&M!FD=VJMO-N!\'+'IP&P==)L- /,5(GN2XK!N:6&?'\G7<=M M"3E/K2@&I\+1)MI]$J>VTT_)E*_CB5:N25%Q@NW_%2^N.S#TON@7G' M2Z(M%D3IFA:&B!"/P,;$?A6OQL:C\OZ2ZH'O4*5>(!9I6[4?8;^^-U?X(AWJ MD=92 OQMR'2UBH5A*V?#.:,I#_XC["ZDU"HT>D"W.C5DYTZ^.]1B!\ X#R5J _/Z3UC=IUM8Z3&[*[) *4.'9>PRL=4"V'M #"L ML+8@"OSNUENK?U M>IL1GK*KS#[$K@\B/=%>3*%BH1KT!*Y0#0RNEV9) B*2!GE3I"(!U;P,$L7A M/6Z65S@C,=/ M<,N+#+[?M@/HBA%TCQ$:<>B.,N?QBPW,:(BVVW0 M1>(Q#TJ[I$\0)R%L:A1MSO>*;?"4);]D-,^9#K6(5@8IK MO0Q7H(IFQURC&JSPESB=+ C31_:2[E0OVMLJY44:\0QLG;HJ& XT.;HI/E]7 M3&/"(#=-#Z,'Q'!45*$F6;7[QG:"JJPOHOI;3=L$"3^/,#GBP6)+!YN-,3Q+ MZF>CA0$9_O$R0([:P_?,/7I&E:\6.$EZ+YZ.L]CF6=$09O;73I#9'_^XQ5F1 MLKUI&:^K>)'V3)TZ;4T]=KM@.C>4[!"C.M(GR)N/'FNI$;^L?,&9>#Z1K(@? M$G*:Q=$CN:;X\+K4VP[@O=T*ST?P9RMB4W?J@:@'* H-S$BB1@$' '?TWH5T M+C:B9+7PW)XW1O<@1Y=V1.XG61_YW@[))QO&7MFG6$1'1K(? 2VJU%B7$\M*/Q =8_DXH? M)NBB) 'E)4TH*XD9R]!@.\.LWA6(5A@ ]G9Q[ L,X#CY!RO#' W"$L*/O>[]''W!L M/LZ^@I,VQL-O?TUIGWXMK':];3Q3V*:QZ^=FRWBF(]DPGJF#)049'6RS^,[S M9@$9F9>MXIF.*0R0XWB3O"7Y4C7JOY,L[G..$$&&\9G5 &WT!: ML87?3EK)&G8)#C1RV%;S#KW.XQ>THFFQS'F"6%&%CU$FLAF\/S'.U^!EK(XW MGZRB4ECY!)UB0QK;9M2]0K6V)HT)"9#([98F\7S;]RK9V]XZE=L!7/>YW"K$ M$R11HR_EOZ$?%_MYW9KCK9.!=JF MGB=\PK62@.1H@4D8<\^).>Q7P+=A"?% M_!9L$[*F>4AS4'-$_K/;*.2 :C#*];-'_ 2S_S0[NGGV8 A7P1 MH_+R(L H&YMZ<21H^B\"1WRV6D@?Z N1]33/:+:F&5;& VNV!BR9#JBNUPE' M795N;2 ''PV##F7(8T(Q4/_K0D>$J"$SK5; [+<"I[A+VU&T $CZ 23GOOX" MG:6V8TWSD&+<')%WT57) =5@E+_PR#)C>,F_>WJ/7_ZVRQIY2;/VRK"*BZ M M.&@@)1"M+Z]T*'T0YW0/O+ I@G)_D):4:6#URB6B&/WT0>3:D)DYPX2=VDHQ M'7HZ!KS]7!QHB<+[O_?JT]G+^M[3"MV_R;F5#+N[ST C V?O7&QXHF"TBM-X MM5DA>>FI*F!T7/E&,6J@:Z@8^,XYM!Y:??NK+GVAKWG=BZKUCJ?!63MC'M^, M[NI4TK<9?2)OT^)?X#HF@>OQR:(:_ M7Y*,X$71*LNF70]0A'>%V-$RK&'>9HP IX<=.F>*Z) C=/CX("B2SP]Y M_!):+=5875KO#RIF6^TANQ=M'AD[BYXP&QE3@V>+!=NWV(Z;:Z1-L <$V%]@ M"'WL-C#*3%>FK_$#[LH-TD1H>44T9F*)/*EBEH%AR4\&N4[L-A_^!M"E.%GG"":H4V.'\FW MB(^*EU_E2>C8OO2P*5",7Z)@\00MX\=ELF4_,P!1F5)6;M?% M$LON#XQ"QCT\?"WE#ZGI:4TW^-_3E$J0X0(FZ<5+GBFM*V$RK[; MHO*,X!R)']-X$<\Q^XN-]#%D8]X?6W-#%XWH! MURCKU$MAJFP8\YU:,S.P4.9]H1^ZW085P=Q;((C$CR0!>Q?B+_>8JU&APT&T M^=\KBBJF>DS5SS.Q=M32.FX 3KQ? ?)1IR46-9S0:UYTRBB*;PAR@94K#&AV MEOO_:+)I/TL"A,CE5ZG"3O1IOB31)B$W"X,-=3C UD%W4 +\1>>):V27:;(B ME-\\]W?OT83Q64]S:[S?,'/G;3FU$F4X!'X>]ZTN9WB BVUP>IS?I14+"KP. M1Z%%N1,+ZFVN1U@";?:0%]P$JEB,<$#.2Z)5")TGGN,6U\N$/N>(2R2J24$[ M6GX>>5VPH\D!U0=KY[CW0)A+FNWL1S<+GHB;IJ)2INI2HMW1,KA%C-S'(ZB(6$M@2>Z;/5L:-I5W^'1 M,'13W,DWJG/"G[;BE!]T]3.*=*+JM$!9P+,R30'P.K>6BC=):=Z9H,7NI75% M,*\;($H8XX31EV)>""F@WI M&;N"[4.]CSU][0?:B?P][U32PS CZ280W#+8S^2.[2BT;> ^$SK&5BB8LSD[ MES,2S9Y(AA_)&B#7*W=CA81\E,0@00VJR)F@ MDB#$*6HLQM=QBB*:)#C+=TI"F/F M8:.>BTL^NS*$*6';P4YJP*.!W,V%>#)97-!LQ1&*I!3BR\]I++SAJUJ+NR^5 MWH9#@K5R4H>C=Z_$UD[- O4$-<@LTZ#(C5(0)3V.ZS*?C5_ 'HMAN&3MQMCP M!L\EX]9'C!,_H,V.<5'%N,8O(7V.!U@61^[(0\UB(#>*W>/7YB&/HQAG_&$@ MS^E%R_-E!(X0T-E2 M^D!834&8:U.G#:>CY1"7(3\'W\$U(*CIIHNA*A4^\);)3:?<]>V2#43ARZG< M&@WZ@K= #1R>_';WS,P3E)(PCN-F;*=6O SM,-[Y2C>TK(65KM(K_$SO#NEX M! !KC-*Y?4R>[.KWOK$LA%D4Q?PF@Y-;'#-ZSO Z+G#2>8QK]0&;5#I@NS>N M5,@1QSZ-4U3B#WO,ZS&<@KCHSTNV-;SMG/+*,0I!T^D"]5WM !TLI/.+Q!_( MC52'V13"06\BUO /ZMS E.V PG0$S[GGI73K&L$-1,U*JLT??UL0IZ CPE;Z MU9RH=B.SWM"-20^+K]<]37(@VJ.SD0*T2;F2CK?D23/,7A(49G,VE#UJR6;/ M!H%[_,*3Z*4Y.24I6<0J9[*>UE:7_B.H[B/!Q/V^P"_H06)$KXFD(,PK<1]W MC^[V/2SSN*_C0GB&RKL5O]/25.3 >HE5=WJM/N ]O .VI_O]#BGZPM$&4BJU MN$Q!K M\<^F2K=X.@]Y:?$B5^LX24+CZV=Q[7PDH5@<2WGD3[FQK97\\@.E[ M=PI[Y^UFZY'1KI-75GXL7!I3FLL28%T%NKH; GQ-V@&Z%H,2:UFFS;)LUU!# M&#)7>ML O?MK] @+U6>?7>ITQM4\SKO$6M4$D@K] )1K42[Q6 MF/QG]%8) ]7AE66&[@4]9?R+YUW2VM$*E%O[")K[JV>%TE)L!Z%]2,D]'%F M/,YJV:":3+,2X?LLGI,/)(KG..D2XLYV #%NA>?>&8: !#2G/+ M\+P+=+><4&W>!?(Q.J.,E>DF3A]OUD36U MZ*XWD1)]Z2G>) "53RU!1%V7YQ3(2'\>%ZTIY&?%&J*FLVIX#?H<(4Y3UJ GCP&HF<-2. MQ:!%F)/YMX_TZ4U$8KG^V(?=LF-__..\O-C_^P9G;+M,MG>$E_\Y6&,:+0T7 M5 =$UZ)5H44U7B01>Y4B'992 SXYDH\90QQQY)<)?FR1BM;? ;*P!\>Y2WR% M#'%LWJ>]G6>TEQ&.IOA"F.7XC3!C8B5V(.&POMD MH)*.L"[S9A.A;P((:G2?R2J"[%9T2Y-XWI\_N[\#]-ZA!.S\K*PQHPHU^E(A M#Q0YUL]E:LXZQPKV?8;37,2O]6K8JJ86*O8A2&\Z]@YQ:"5;R55JPBI'4G+& MSN991K!"V6K[&2 -33#.[8-<>>+(PFA(K1RC?6QPK&&SRQOFZ?7).2[PV7ZQ MZQ;EMZNYA4[=!M:;,ETC1QQ[5:@\F +=R6)JRKJA8.HEX/$8/B6^VI7Y,LIM&G F>% MV9HXQ0G/BF:[M <;PD5J6,_$> N8XQ:1?HPM$C-)D>J4EDR8GOQ(LO2?\2K M-H6XJQE -6H#YSSXK,2)*J2(8_6N"75RDNJR)T0V#-T-7*>+?8X,[]OZ64/; MF93;":([_,%W&2V^MR?4"+OWG+Q[N(^+I&O?.6QBL>=4H)Q[E7,D7$T^>??Z MX1M4H0^VX1RQD.KPQ2X09K7&<2:JO"]$32:9L&Q7INA@QHWZ0()D^F"[E@DM M(HS#9X8?%> "M:."RWRS A<:U=!@D17W2X*PR''"1Q?OC96*L:[D6/.:M !1 M0]I+AX+8&SBQIG23SFD21]R71_Y 2$<*!3"<09-Q=N#SFZ9S1]($'1"%*JI" MIF* 3U=O9DSM.7#UWB#-EY=Q/L?)WPG.V%WV_+C*B$Y3R#N$ J1SE5GB11(Q MXIC1!:_@P'#[?Z'HXRLU8=8X]\*;[)>,;M95Q6Q"NLOA#0K;QYZIHF&$^RC- MD*!U5^^=D, U^H:=;NB>JS>'XUQ?&NEU0)!\K!VOJ7F,-([PR7M@DP9= 8.E MM]7WAI&GV:TPHU^R[PXU9JVV%OXP1S"].<24NH=$C03N8"XQ:LY2(W9Y$1:N M^NB)RE%+:T&I(?H6$Z&BCD%(CGG:*B(*1CD6D-OJ.4YQA>EL9R$<>_"\B4:Y M=02[N'1SDVJSR'/NC#H)YS6?ZIBF'88:C1Y6N2M:(7M*S5OC1A7RD#86'4X? MY3?08)]EMB','YUV=L=+'&9HB M%V,#/!NT5.0;QUA@[P2S^HU@P8A 3YP*M* 9&UUU*4"\HC-Y**JG@BU:"5FJP/HT?LG(G#ZF(IT\^R%M)&,I)"^^$7$K^SB)O)FYP'KY MZ_3CU3H1QN ]*>^ MC!/R<=-B#.YJ O9ZWX'RY.G.$2*),9!S>POWJ Y+G,[ZQ8IDCVR[^R6CS\52 MUNG;*@6@LS58%EJA>A*+"C>2R,M*A?Z=<'3X2PV9YCJ CH'ON-LW?[8)E&-= M_07'L9;AXN&:##N,@3OB@M-=X=,*)\GI)H]3DK>9]SI:@7>!/6B>5K_ B2JD M@19].QNI)F_:I9%P M\FK4B]U=>>[)2W'*0/[68F>! P%87[82 M #",T O4HY&6?KVI9:6&6?1,4.EC$?H$&G:-4*=3ZFU3^AN)'Y<%B69/ M),./Y7OGS>*<#Z=,OZZ100((!;C1&&)S?E65>(/+-W02Z$"<]2:SUR3/:596 M;$H?KPDO[(VWPLQW3T_)'9D3MA2C2_8_[F^MNN2 X0#EUAB?:\EEG/UQ@FJ" M4,(I0NN2I"!"#)\3.ABC_6F$T?_;E.;I>SJ+(I%4%2>W.(ZNTC.\C@NJ1C\ISGK>()>J:".)YQ ML:8N:.TQ;W-.0TVD4S/ /7ZYBOASVB*6[H ]GGD][<&& 5<3Y8 AAWMHP_K MP=?'96K,.K>V)(8]XY5R(_+ROXG:.J]H![<>[4/8B!3>I M-HN<"L4=>10E'=)"D9*('=(PF1P[.4EUV>-4&EI#!U0_@V?? M4V8!.>M!O/^5+*-]?' TO=?D$2<2:TM894<+P"0?0'(]SP(=JF;;?Z1D%_.H M!D?\)=2N8DK:_#>Z&T%3:>\![.[D",?7GYSW6< MDA/E5M_1%KSOM\#T= B4*"?5!\21HYLTE!+0Q5UJQ#+_N\?-XC).<3J/V56: MRD(\/56W3+K:[C0=*/SM/W2!:BI014;HJEQ&L]"V76FSUE\NKH.GK/*A0"&& M/:VA.;7:H?I\]8EHDN L1VN2R1>@, ] ??READP+_0AY]-YTBO-X;O8$V0UC MV ?(=ERN!5$@&>OC8P_[^Y\>=7CJ34[W:O0($W15HN>,YH4,/5"(ITE7H%3J MH/#E7J-#BW75J<'&.$#Y*4'+KOK4!'%ZT&@&^I,<:,KNP6R-F0VUHXA8^,): M?4M)56%+BZ6A]:@>M5ZSU[!ZE2]EOD3W\Y@TJ2XMW8A=/JP,O(CG379/G]7F M9&5+6PO##J)O^X*HJDHSQ'&'M2VT<+7-LJ!BE0\18;?( B?_)UXKJNKV-[85 ME#V@OF5%(D<,>Y@2O!KL;9.8#IX%.["Z;F:=;0KC38Y6._ M$9:LF^PVHT]Q.N_=<13-;?>< ["^=QV!GA]1%0%A]QT5D]MVGD[.!;R%:]^Y M![]AA[M/#W.I]'2%K&_+93%&7+!K9%[\ 7T_>??#BO]V@OC\BQ;G9"[J3J#W)^);]G_6=DU$R?'$KWN1AHAUWCS'=&P;WC); M^PQYC/NZ80IDX[A?MO.T[P /_/C3>)J=^=< MJUG"&,++$!N9H&M)DXADN4PHI;^C]?>UW]K4.+SN<4TR?H?*?&OCV>TT9J)] MV]-E;Z@,XSW"V--ZF*SBO@3N*)]X8/GJ8ZXZA7AP&:HRJ?"LM64NHOA?(@:F ML]JD?D?K5$ J!.Z%;)<2,G":>FU>MR;)T6.@([VM*M&P73W0I$5%:_T=H(WM MP7$M&B4R)+%YUZ_:>49[&1%H6^FL%:5J.,BVX:BZ,,6P]*R4WEQA P MYN$F>\1IN2.=U:4UN>=J&MTRCI.T2HM2^[;6YZ9&MF/7:( 2.C0YKN6[22]W M76I0+$RO39KWG:MW9,-2*CM:)<[D@?J:9%=Q:)37*5W25%U;1M4$$HEV ,IY M*!H5I6,YPE"1Z4KN41V6^'M$XZ%/?;MJ>R/HX]D>,&\/9WM808]FEG0#G$L_ MTH+D2" .DX5',?%4CRNZ0MQ: ('G[B'DT^9!)".Z>.'O>R02&7O61UIJ=$?X+,9BM(PIFLK>3[B,I^&N6<%J)2'2Z_9R3Z"HM=;+T<<;] M!T3&QA[K*AP0\,0T1^AZ_VF\;8KDGS4I:$=+F!=UB\FAPW'TJR,G\JUM#\G.*!/8$/2XORI MK"16W)1Y.=XJ.$A0+"[4#9I1133;[U%--A)TEXD44.CKM!M1H%[FUY^IBU<< M:A#[D?%5YA]7&:UZ.T#-3TK S@U)HI)40M/'*=/]5BC9$1'&#M3/8FK.-W^9 M;G>TL(5P_#JM$"S=;M \MCW@?=WM^^B W/:''UM!"YR8W8'N>9>],X*?&3J# M,IIM%59)6++FKE!W! M[+?\*ITM%FPIXD)9[VD B$#9ML#L6LXKTN1=-\>)#("GSRG;Q);Q&L4554'$ M?8@YHPXFPMLRN",%9I1%E7/\;#[?K#8)#T\Y)XMX'JL4;_V.0*'N1^!:=AL8 M4211!A%2 U93./^\B5R#$'%9X$G+,[(D:J[\;CLK="!6>Q/B%M^#'M.W1@^@<'9 ]G6-[" ! MIG_G+ M967DVZ(I2FDZ+9&',?AILYR"^>@_,.DLP7E>AJ=T>-KVMK<-0#J$Z_R]D>.K M XY"NMWVL[8MHJB;7P%>"]OCB-.HS%9E^"X(@F;] FB$U>=;7UOM2YDS1J0O M*!/&CNY)#S:+K8]W%E,3^C W.\+='-S.0UK$NP(]J/?7>*,;63' /N;W'^'C MDK$SB+9XYE)5/ NE)XY01SQD=+]TM7+/WZE>[K#[I?-D4/UL4RQY)"")/J<1 MVXRY G*SYK_?LHG)+UY(-H]SI$@4_(_+VN1AA"&0,?T'4] ?[/XG$O7,ZU36M%GD$/Z +;S5WV.;DH7TPU; M!IACG*"4C.&$5C%9>4!WH#E4YZG-E]D+3[E!G+DTTWIRZ-.D! M.7PZ9BR1U);UXUBK[$R+\SEW!"+1QC7,V7;'X'6,Q-,![6,D?G;RG_$&XIPP;J?B5SND:_D/>$ M$KB.CR?@Z[1M7]-GW[9M!FPRY9I_8E]57[']\-V??_']02P,$% @ EVX, M59ERBQWW*0 Y\(# !0 !S9F4M,C R,C V,S!?<')E+GAM;.U]77?C-I+V M_9ZS_Z&W]YKIMCN9I',FNT=VVXGG=;>\;O=D=V]R:!*2L$,1&H"4[?SZ%R E M2[8(H, /D(1PD;0E 6!5L0!4/54H_/4_'Y?)FS6B#)/TE[OP>3K^=75VSE3\^-ST8^N%#T?;DX\>/[XI?GYLR7-60#WKR[K\_ M7W^-%F@9!C@5$HD$+0S_S(HOKTD49H48M2R\D;80GX)MLT!\%9R_7BF2RTOB[B"S?";F__\N']^]$TW>< M[ PM49H%*+E*T-MW>Q2O*&*\;R&B:_[%IKV@JEWJ2PK08X:X.FZ$MB4B(=$+'L5SV59Y M&(J^FY/UNQCAXKGBCT("!??\PQ\7:8:S)Z[A(4ZWCTO">Y3\\E;V$\ <6 M._G/X@VC^)>W&4+(U7)@*3#']N M1U+)N*V&KJV(!J"NI-::TIUT[.B,:FLE.E-@[,QKU)\ + ^P"$[&*@+H2N^* M,D!,(E)GZ]X)Z*_O*MV(5GVBF$1Y\0?W=@-4:"]W,6:$+HOG@?TCX#B6?"4C M:CKQFR;\\;$@X3()YQ5^2N7O'7I.YV)9HB@\)_%KNT?V-%I7/OD$4D_B2?U?E=VK;6J-3R A&Y4%+"S1> M[6:AS&> -K=+;97' &EJ@AK#QW0T@*- M=S1,&19O3TNDK*D-*ODC5)3M_=PA-1LC-X[YGLTV_XC9>2(%"!5M;=$I=K@I MO2,/$FS#)_^*59)?6-[9%:6'E3^D-)6M;YED1>,)IE=$([]0]Y:59 M5JZ _,'B#5>:')#FG5,[E/A%^;B+):)S+H1?*7G(%OQUKL)4KIO*UIW3>HD3 M]"5?WB,J)?"PB16JZ#E?4^:$RB57V:ISVH2G3[F:%Z9@L?"=DYPO+T_*11W4 MRP+MW/H*HPRO$;<1P\VL51"M:MXYM;=HC@7BDF9?PJ5-F&),OV96M.J?M+GR\B@5B,\-E;H%F\=&T'WLLVI0F(L"' M!4GE:[:L28=4?4513KD03D[O[W!6Z47+FEB@ZN(Q6H3I'$G6$%6S#JGC3J:P MY[X^+>])4D%6Y>_NQ"A5T\?Y>!,(5CJ&J).)(."(H:/J<<@M ;NXCBJ*1B0J MPQ LD5,W)**(1X%%\<$-4< B3F"I?.^&5( !+K!8?G!1+)*(&E@H?W%+*(?Q M"+ D?G1+$LK %E@H/[DE%$4\$BR2CVZ)1!U;A)MI3IFN,H 9+@ZGS%8#J!@N M(4?,6 -0$"X;1^Q:8"@>+A='+%M0\!\N%4<,6WC\'BX:1\Q;:!H&7#".6+OR M+%*X*!RQ<=5A%K@X'+%OU?$=.-CFB%VKB-[ 9>&(4:L/L,%%XI05"\F9@HO& M*2,6DG@"%XU3=JPB;0,N$:=L6$4:&%PB3IFN@)1"N&0 M&"8;VSVW&)&4D03'HA1/K4\%B;S[>A'1*"V0F_GN8Y.@&T6**OJ*\ M1L^^."I7F$F>+0C%?Z)8SXFL1[\<7#&6PZE_V;I?RN7G3TRZ6.7A9KO7UID4 M9IU[Y LX-6"=?(T@"+W3V7-YG!M2!F4U1:9,NKI0]ZAU.N\H"EE.G_:T5T*L MHJ4[6="U]*KW>DT^0]R^8AQ?;KBO2%2O:%D=B\@T8G:XFE):P8:F6@HEBJ'%RR2@88F&HH$@*J.,W7<3"Y:J]XNR%R4W#X) MYD7-]^+[#<4)MGB,ZHX?:UNY'Z% MJHF/Z7S,,5_%IO(^7/T3Y@(:7RSM\'L(4B[ MN0ZO0-_58SPB[:O6JPU)7[7>5ZWW&+')A&G+F"#FYM;89:<'E]LUU<8.L+:J M:P W:>SRLAF_&0OR?/3Q&\,;);HUQ7L VDX#\I!RJVF!5P$6"?Y\B6#%#0YA MO!89C"PP@^ ,!K0)SAF3Y6&[#F&[P<-F'HH9&12S,WG8E5B,)YM9?4K7>I=-<$MCN!M^#$_0S>)HM$-V;J/I(:[-!7'*'*^F[H62>$E9"PU=I)'W+ZH8^F\5GLW@( M9; 0BH<,1FCT>LC 0P8>,O 9&@/!&GR&1I<9&A#S>NPI"FW+3.]XCEW+?%Z+ M!T'K@J!M !\] )[?![,0TV M#L$&R^+X6FGPFH&$9:RHR78FYL5-^ 0ZM-32 MJ.-%<,;/04\8U*\T3+GI6%Y[II@YTG;]45NY? -:6J7XEEOF%$?9IM!M99 ! MU-8N1O:\5NRO)A-*Q=V!Q=IQ]G2PGA2+ZVZ%3>.;)$RET0 ;C^I)9ELB=SQ< M<(.*/"&D?/WF PR&OR\D14U9E([AT6R/9GLTVZ/9'LUN72NJ_2%B W.]1()53QJ]U(,E]. M8ISD&5ZCKRC**/49+SY?:2;[IBO\RWE7\O0IJ*LX;;V_G.GJH'4,6E MNW_B "2HC05!NXTWRCM^#GJ*4[]6>5U&A+:]7>HWOFBQ54Y78A8KXV3:]CXF MYF-B/B;F8V(^)M;>A*FTA(G&)!T[US8M4%+7TG-%R("HF"U'P)5PBF6]!1IF MKDA7?6)+@AN,G7GE1J! ;\8>5%+S+/P=]E0 O9_/M M=C+#[Z@WZ.FQ:H]5>ZS:8]4>JQZEMS10E,9[2PV])>,=O >_Z:,H#++$96'B MXO;FB*2"6,3W"&18_1_/@YZ/U6=TTA)WG#'ND]YZO_G%#\9ZA-\(-WM,K/#<5K3DM9 M7/(R3^/JDP+0YA[Y\47<("[1_#OES3T\:D%XYPG@1YO%ST%?.7K6FR+%R?8F6BPW(("O5M+]'TCV2[I'THT32#;;'UQ5'05N1 M,_+1XPA V/L8**9QC1W2)P!XUJ4E\(+!.T0!+W&?%+$?-0; M(?O-_V5>);Q#8[KVE*:V^NQ1W<9P=@N&/A-TLR%#@\OI.]A.D^9KQP*E#*_1 M55&[&Z)A=;O;37)=KD),A0Y-*=])5H2%R71V3=+Y-:;QON2!LU4TK0>'^5] ?,>%!Z?G=W:;ND!51F@"IRE8_?8/)CJ#Z1[ M[&)?$CK#@IB;\ZZ(!L O,7= 79E",.D8VMZN8*-FPJGG6;J2 VNH2(V]TQ[2 M/T\#\I!RTV^!5P%.N1'(YT)92B*,UZ*B* LRL1$9%LLP'M9F^FA-XCRRVB&R M6N5$U7M9&ARSB098\JS+R,MGE"U(O-N=#N].?.5K0[O910FB!8KS!$UG>R1= MI9,TGFPD?4Z>DY/TIIF"T2G6R6]VNHH7 S0 3S& MY4#B(VB*#$"_:] )0V/'Y<:UO#=Y[%"&':I5:>QH@(<,/63H(<-]24BV.&+- M3G1%I4P$:69INH*CZ25DYH_U@/U\'\Q"3(-UF.0H6*)09/B5I43K0#[0T6PB M/68T>8"G#X '^HX@N([9^[;NU%]RXOXN:"NQ8+[I7./PGN\UXJ*GSR6Y\32] M%9<_49S.ST*&3>&/%I_AH0$/#0R9SJ.#!L#+FT<$/"+@$0&/"'A$P,21;=UT MZL&G^X'O&9R.>W$/J+@=8H525CRNED\'':\@[GR/MDF4X347MZ'S5FL+R7YKTT[Z5Y+\U[ M:29>6GT;J0=W[,<@15F B\3Y@ N1!2M$ R98J.60P<>SZ9*94N6=LCZ<,OA; M@KAEIN_.?/.F7?.O'/FG3,3YZR!F=2#=Z:Y/[V6AV8VIDTOK0YEWE/KPU,S>U,0 M;ZW.N[=DMUXCQA":6_->VO>6_/>FO?6]-Y:8S.I!T_M). +/R+[+?4)AD"^GEBO)&C9\OKE>HNG'K4ZD1=R\58H\F MLX[-S5M&LSW3EG_:O4%Q)_3A65>$OH1+5*EA\ Z=T[V'7%6>UI616:&F;0UG MM_!\R!;BEF+^CZ!M'2;"WIYDYR&E3WQS*-+A)1X*J&]/Q;1W(A<'T^.S,!%G M^PM(4N9LJ[KXDN!N 04TC+F"?A4'.8K#'3(?_'4[5]UPP]VD=V_;.Y?=JT5; MVQDQW_#'+CN]5]JNL3!V+[Y570,8[&.7ETW@9^!E>(8,_ P6$ZYEN7B3%_3PMF:ZU]M <3]D,01MPK8U@\@@5D5FG, M-;)B&SW"IB'; J'>ENW0ECU/\BQ:_$82X0@R:01=U:PY#82[Z33#? 4\HSB> MHVL2'H2<9>WPFU;9GHG8^Q:YN/^'OFJBWR!O-\C MC/$#_8\><$#Y;0^-L#_C88=Q89/'^/P9F<'@:A[/.B(\RY\E\HU'B$?7.' S@?K%&H(3QL,.X<(,H)K&$ MVU:?T1<,H^.!R9C8S?PTON%&@10ZM/&HGF2V)7+'PP4W ,@30LII8C[ 8/C[ M0E+4E$7I&!Z ] "D!R ] %G;I:VV1HG-/<@546D<@Q<$9*-(,6'L8K !RFD08I. MD9@>HAJJ>P$;Q35J#&PSLE&;/!_;.*[81B6=K\Q//IMGA"Y%N+*8]\67WU*< M,7$!W&;=VWTI325M<]C.DR,_AX]XF2^KF9']WCU5.%535?5[YU3=BMU!DA5Z M\)L=:J02JOC5;BR0+RNQN#01K]&N.LG%8Y3D?-F]Y'NVV'GS@C))H MVP\@%EB:R),\6Q"*_T3Q-VYGT3V"!1C*U0_1"#-TPS=*5*Q5U^0!T?(OO,2R MJ=_E(P<54:W)TK?5RK847SW2'P_PT3D?G?/1N88IVX?V--$8MF/GVJ:]1NK: M1:X(&1"?LV4VNQ+8L:RW0%/8%>FJC_M(T(>Q,Z_<"!08T-C#6VJ^Y8CK-, (,!;68 &)/E(__'%?EOC-1^R86--YU-^10/L^*^L$+A9 "S MM+U'QCTR[I%QCXR/Q#<;*";D?;,&1B]X;^K!8OTH2E-PX[FD1]SU&)%4T(CX M\M?TVLN:@]NT9!N1Z*W:#JW:;:AADL9?T9K/G#1"DSE%Q.*B*JO%49NK7%:O.#GFJ3S.T275_RYJ8!GA#>[R6ZONK13V;YENK+7SSDC M:=:_\HV].*0WO4_PO""3;\S)8TX><_*8 MD\_&-,)5%)M;9=%3V!;BBG3T()S..' %CH3I"6R3=D4F/F?Q-<\^9]$YOGVZ MG _)- G)U$4!CB@CKC;6>T1I;<9X?7>+SN!DTQJN");9]Z.766OQJAXBR2?O M U18V,UBQMIA;$:'@<3X./!Q93=6TEDD,=^B54ZC12C2E,F3I]?_*#M(91W2$LT/XYY,\]/6E >N4(]FL^'-(HC['H.PR ?GTU?TT7'Z.P M'Z/H@$X2_4,Q_\H#/B=2!D"]>XJ)WM'B2N>G@LI)Q#=D;N!-A&DT1^>$9=M# M3!+FH-V'P-WF),R&2 A#+WL,@8?"<=X2) 1<7O$'84;2%<;5N,!\'_?S<3^5 MGZ@W/5X?JP-M\\[(1X]Z HVWL8<^S#2FN9OA3.B@17DI?!MGU,M"I&7H&N,C M+35.?-=S+8XHT%+#K#^B$$L3/^$(HRUUG=T> @:G 7E(N1P7>!7@E$L4LBZ@'"]CF"OF S"H;;U!YLPA#^\^U&9+HBGH?P^@PAC'Y1Q:FX54:2?%S M28O&3SY/\BQ:_$:26)3[D3Y>U:PQ#5?IC)SQ&8 CE004K9J?=KRL M2>-G?R:/Z#<4)MGBG- 5H?*C$<#6C2D2-EA*6/D8E4S4#9M'G9["%4,J B0M M&C_Y3M00^HQB'(6)ZOG*=HVI6*+_RG&"[RF6'L\>0Q:=V M?C*P3"DNC<\R%QDAZ9T(\ Z=T_UU(\?I[) @\4)D9$J.9+8QG-T;("K)G&XU M:I/8QDUF2=#"N+^/L?IS8/IXD,VET0>3W \FM;8V$_/=:^RR@QVG:6_G&WN< MH%5=TSG$8X\HM"TLO?L^]M,N;4M,BS9TEW4^3H&I\1&PM'XX#FGIO':PO/YR M'/("PUY@P?UX'(*#0'1@F?UT'#)3HHI@87T\#F$!(-"QFZX^Q644*2X]2>*0 M3](8"+0;;8](&J.42TO\Q4B"8_Y+O,.8F,",HI M@EE"'EB0IV$>XVR7?ZZ- MJS=^@J4(>DMT^EAY.['RQLCQ.7]5XC\Q#==A(M[@[FHI\<,DC5]^L==2 C0W M&C/XWLNAD,,/XY,#7ZRQ6,4CD4*%/J'RW_(*)9S.^1\+46GE5AR[GLU0)"ND M:9>(X$,ODOZ",D$Y=S_6F*^$9T_?F$B$WIQE2>>3*,/KX@XJB93@ PR>P\D] M?YFA5!_J#S0$?DNKIL$;K1A@6&^T@L!Z;Q0PT!#X?;Z&H.X;50PP4/[JO4_ M0'9KTVZ*REP2.BG#OG=D,IOA!//=0,*:LD^0_M0W([N3 =/9.5DN25ID+NNY MD73LFZ5;E B7XH[ 2O5V_%9/^YG_=B$LT>+Z'LXNTH:30UA5Z350 ZUI.GX[*NC+X@!G+T02K M@C2^D]#LZ%[+ZPR+[C+/2RE?I*-KB9+S2*EZ\P;U$M2JS.NO=2T M^M3YA+2!)*1=A#051["V998T$15=\UYIY_8;CH"$OVC;*]6?<))GTM+)FM96 M*?\5I7Q>)WPAGL1+G&+QZL7],1>/PF*6WE\,ZV65$VXDD26Z)JR G/G&Z^,_-=C3X5;K"X (;WY,LB)VV^1:@D4NCP MB3TE)[WDJ#JO7'X7M$'?'KAZQCPTRZ&F=0^4<\W93*PS/N]F6$VYM+5ERK?O MO*1*.Y74S:W2_AP;V:FTA.R*ECW-W&FV0)2O)>0E1>IE'-;)=@X/5UF%R'<- M>I+T:'-L!GYYR.\(SQ?9=;8RCLA3M-,^X5Y(*Z$/"2,U1AL#I M 7&:C:KN,(/D567GUQK#O=PJG6'BTZI\6I5/J_)I5;+;ADU\]NZ4I(&5C0K,HE1$E\26ACAKY#IMH9K M?GM--1'%U72O:)@\\/=3GR_C(5WDK:_*!I,HRI=YD>A>H#(BH9VB!7=T\'KC M*U;>W5.[OUWN8C[1^0H3)CHHC,TV*40C^E@K#S6+LEU':G891:(&W7PT4^ M0K0DY>^A,ED5U':HF1:]T'VG MO.*SK_IJ*K&*C&RC/CZ+"%:IIUANQ3$[1%DI3WC)'GU?GQM52>=KL7&CK3P" M=D-HX?AGW'B]SS-!XATQ2F-N9_"^5J\12*:?=?+%)=S*S5/1LC^*7]X]#Z&\ MND=_'$CNAX>P(KM:'N9^CA-7-=LECB39K4:RD][$<4XH2I:)F9?@"KYN+)R: M&)%S.5%0>6FP!^+A;\ TJG&4'H6:3KM:H%:*YQ&N]:N@ZVJ"3Y.8RW7:T*M$[WKN> M2(N>=FE](/4H?2 MTKG;'KO:*/>8Z_YA5C,NRG?U7+OA6I!VC<-[G/"=<%LC M_I,T>QK:O:=:8U#R)F+=E"QGC<8*3@;-]Q=N^]T]H&2-/G-=7[ _U1QER+Q"#-_F PY1 M_2F--'\I2;%Q>/$6\Z M68I/=9B7C=77D35!+*$OB=V^H#MRA@IS:HUBL7R.6* M7E5!5-VE95D/*]VL)>X-+:RR. M81-U.L@7@(OG&(UW91@2+CH737=XZ@Q<3L;F^V K7M<-Z<-E-?YR]#5S]. B M@EOMPSW TF[8#2X[)XYA@$)<=O.S7Y2?O0^3,(U0P!8(92R(:[-RW M:SAX'^5W:Y'H,ZT'$O*)O.[L)'.4]U1AE"1=Z]DB)8/ MU\R"_39#H%-3[U'9UFX=X9 M)FDL_A''[=9A(HS_278>4OK$C1-5866COM:K M(V_2.P2!^\D=,E[T/?JJ[ZQ\!9)F=JL[<[.,/"%N?!9K-GCO O>SRLW>96Q7 MZ60VXR1QZAAW QF.<4@Y>7SZDJCXENO*WPA.L[_SYCF5:ERWZROW?46P7X_WB(9:K^H>"W*^(;_XJGU':KN<["*3DOFYX+/<+Z!=2?_+)GWSR)Y\&6 ._&,9,(. \8U?V M=)O7OKAM7'ONQ8P(,>A M.__ -6TU309TQ;FPL XT.1/:G7O22]V*KF7=34UY0]R_!])323KS6;O+[ M,4A1%N!B\@5M6OTX>;?.&OPX9\#4H M.KSM3UI3OI,7NF'(_H/MGA_>6$LWB!87EIZ%#$>O1 !JVS_5FE1O4)]>N?B$ MDWROJHV&_E>MAT"YX1N0]+)\XCRBQ81^]FN+:WM?6A!;?4'QID+;A-(PG1?] MY,?.VQIX>/+XG>*,[W,W>39=%>M;$QE(![-\%I#,<";<& DOAPW\F3('SE_] MCD0V&E^$UHB&<_0E7]Z+.PTV2]/!'=X21FJ.,@1.#XA360"UQG#GL$X/MJ _ MZN./^OBC/OZHCR1V:^#4N"(8&,M$;[FY,F>,!=)@%W&HL,P#VX8H^U5MY ME,Z\JVN/C.DC7GT (O'K3QVIM0THN9*;W94H-;B4*XD9[8LFG 7E($64+O KP)CQ>7LT/S[PW&'@>>^,[B2-)YM7=T=VQW6WV>=I+"W;6'^@>@6X MS$+H-C05$E&W-V.:P.Z,9GN0._^TTU3^X8^;D&8;*K;I1I^1V"1?2P+2UO+5 M"@1WS*G*LUL4QCAY^H2X M,BQQ*HS1RQ#3(CVXO+U)R5N#\7HJ]7[''UNQH.L;]DCO.5?W.:'XS\):J)S< MYATM![SQFM-2*LUEGL9,R86NN0^&.Q ,[[24Y+@0O_Z-%!_Y/9[(KV*/JRP5 M!-M)7)&./BBLLQ%< =O5>F+@3KB"H\,F#LQX<45);*21#%PM?!J)83 7XA8[ M-S^4(FFK\.=89@I /QI#"ZZ$'(%EF'4(67Z=X.^-U#?.S[8,:U>N.] M+8LC^V5 ??][[M6%9=5%X0[5W-CWB@*0!%5.("E_P/F2X9I3,'CTV8V6V MN?(1LPXC9B]+B1\67G_>)BIB0^"^P6EK]![L]L\/^8296#JY:E60"NG6(I52 M0,K>W('$\&S/9&O7-9__P-(\KMI\73-5JC1!%S,^O<%U^? M=TN+2!5E,(94O0; R25%_\Q1&E7MV#5Z]L/15;K*,U8HRHER&@%Z],[!J3$' MIP/CX(,Q!Q^&P$&5;E>:UC5Z]LX1.UQ8C7G3CM$_E[=; PZF@H"N=K,DM@6E M:AL*-4;PN13VX/Q?WR.0K'DZ-@Z!.05K8N!X6GM=@UDE,:-&[+Z]!? M(RULM*[(3!_T-O8;70GYMCC]U&:I*P*KJTL21,45L=18EAKAO'NMOO!R:I1&DQWV]8@Y50G!Z>'),(? B;ND;@7M7D"WGJ% M4E8\[L51,5D;]"C^KGEA0R>/MID:V"$#/@NPCPL;.GFAD-2T#C7)5H6&I'C0 MILY24>KK?(_&BY)$25P,UCDXZ86S7U'*#>VDR U?XA2+0DH97J,-5:'L,@0-EM@*HCX]S^SAW@SAW-VNY#VD?3T@;LM*2 M6HN:*Q*"'+T'[E:NH/6&2E/#,G%%4OX@^J 1PC6B]V18>$XS/Z4'5,>P$A#_ M.>=67U$":(7HYD(8&Z5204\><&E4 _H]I-,'I-/%^^R@8*B!'O5:P+*\M)B1 M!,=B'2Q_0*HZB;7'&2ZW2HBAP4C#Y7A*?Z4D7TUGVR_451E;'=LNV$<)8^7= M&#)([["%50J_H&QWM[V$QLHV5JF\16N4YM)*C:]_]I";A]P:0&Z=;+8><3L> MQ*V^D:*M5F:P\[LB33VZT- H= 6)LJ]V,&/+%?EZI&_02-\0J^-56Z;.30BE M#*0NCG.30BD&A1<%@70WOXC_B3@O_^;_ U!+ P04 " "7;@Q5[YE)%:GW M ?+@T $P '-F93(P,C(P-C,P7S$P<2YH=&WLO6MWH\BU/_P^GZ(>Y^1, M]UJ2+72UW3U>2RW+/-UD82A89! H7MYU/_]]57 02($ ("JEF M)6U=$%7L^NW[KEV?%]9216]+53-_/5M8UNKZXN+GSY_G/SOGNO%R(5Q=75V\ MD6O.G(NN#3P/7?CV;*CTTG:KU;^ ;[T+R1>RXE\;OL[YTKM4$Q7)#%]I8NG\ M17^]H%_!;]KMX'V5V"ET+A3-M$1-PO[UIASU9'"MBM[%RIO5 MA*%#/_"FHFBJHN'_^_+T[<(R1,V$W$N6@^T[MXWY ?#9HM(3!)T[#B?N5_%?$S MVS+P2^P"7%W ]^MGB[M.Z 2>+_ 4AJ[&/ 7])NHIK)41C1WR30@Z6XL21@[Y M^EDT?>0HIMYM"X,DK#E7A"!O14*^YT#>6J-2V8W*YB:6K86MR=B0]24._?KI M]NN= M-_,<\E?1E8J'3+]!;)^SOF(F,EFNSP18CJYCP\65.??KF87?K M'X5SJ"&-JNH;) M=\K;-9D?-IR7BBQC[>9/Y#5<<6\O85C)>;(WZXGH3?E?A#ID%5J"^[+?)-C7 M1,+1P#G78PVH_CX"6ABB.@$:O_V.W\^0 DHLP/W-Z,MN6N2_R[X@]#Y?A*91 MS+2>\(MB$F5DW<,W<;/:N.IF.KP;?_TQ?+I%T]%D?#^;W$U&4S2Y'Q4\Q^$2 M:S+\W[I3Q9;^B?@@3AW)')YW%AW MAB@1:X6"1+KL=R_[G4[G+#2V$AK0UA3GXQ_36V]X5S!>C_3E4K'(),RA)A/9 M 8P+0E[!YADBLX)KX>:@5J\U1054&C:0WIN;-Y?DR74C)BE"-/#F)!_!-L> 47EJZ=(?CZ+Q8$PM(L[_+JHV7O_*G6\KS$":O91U M2\:2LA1!-+LO0.=,[N] [)P+K6R/$P6$2%K7XW&BH+.].BD>A%YB#FUKH1N@ MJ>0@?E(]0+-_=B,T0 MD>X!>JO5@^ 'Z^_('86)=8P)-@WV9@Z%GN%AJ]0<:I"P52ON2II]/5 MZ:;^8%O$[R9^2FGS3Z><69V_T(G2!:D-.7?V5%CFFW%#Z VR$7P/\V%F8-&T MC?< R7/-NM=H]X5LL][#9BANUJW^9999]X0HN>+2^E]WHF+0A?_R_IU.$!.C M_HMH*N;P33&;(]$PW@')3WBE&Z!1ATL2Y/%_=0O^D:J3GWW'RV=LQ-SOSL#_ ML4F BM[3OR9PA?F$21 +1G)NM .UHKD@?@?\&9/8"E 1;A$QJ^PD[H(M-FCT MLBG]GI @ (,T\5_^IF!#-*3%^S?\BM4P62;:"D0(_4)().MZF<:F!0]@X8>Y M?R5?H\TU2G#%]UFC]@FOT7^QH8L]:"[K4P>=*^=$.@Z07W! MTLJD]+=/1%OLLS*%RJ+V@7STFBH*9M:EDQ#WKIF.*"'V0412MS'H7&6C<13V M(VA\ MJ"W35*2$*F 9A;VT2 MRF=.3'.P%P+I1,6G3E-K,+@X"=5.-=08!XN"=!N];C9KMAL5GSI=?<'2RJ3T MMT]$6S 3!^D>R$>OJ:)@95T&[0VO(G;[B/\DC_9V_=>]31[W8?ZP(EO*Z(.] M4(+D*TO.5KBVJ>9V/\+&8GS3M9<9-I8338(Y*Z_X416U1_$]WQ.0I4P(XQ F6W!R/(H)MN18^+(/2#X*9#N@\#Y TVX3W9S'QMTJV[,$E$MYQ? M+^CN?8!PT]OL>?YFPGR<;\DV4?A66:Y4NCTI? MGO- 8]+VI \GH6[HS_]I= M![H\<9QUXUZ+Z7Y![YTBD_=SD..(CHHCM^&/)K^']SEN_OC&^RA\]Q7=(N>] M,RW1L,C^O)OU#+W?K;_SIRD'+B5/L!["^<9[[PUR$:*%3QL"&4H8!S+>_9>. M1KAQAZ=@\6[A?>>])[>(I+67P+F$_S% 8&>[N'6SGI1_(_>;K#2[U[7A:J4J MDOBL;M,NL WU6K'P,A7]_'L3 ;]Y1W=S_S5\EWLQ&$%[>#&" ,ZX&%O/Z-5[ M,_6,@K?C=C_ !3=8>:/(RBO,ZR9P*=WW*EJZD1,_6[\G']YB35\J6M1MTPJ) MT"TNPK/?!5]/;G>9E]O=4N3V%FV$-6T$-FDCI*>-4#AM!.9IDU;?%T<;*BY; M+(K+UE[B,D(EL++H(95P"+7W+[JQEKA])&9KO8_TY4K7B!=(?8HG;(F*AN6Q M:&BD.8_K.1R8,"ZH'8?:>2O#8&_$=%(L9PY(5N!;$]R(M<>2^"QG-]YET0_U M^2)R')^B_G3*U.0YEVTH2?;25LF6Z0=K@0WRM8$7A%ZO&'Q^,#&/8B53/^X3B.@':[.NV;-.&6W>'L.[JNMS<*CR@55A74'!K\@06 MF5NA)[SXW'JMW4(K;-FWX>1;IT#_B]NIY40A*UDV;F^6$X6L9'&YW5BCQ>+V MWQ$L(K?C6%BPF,(2;L&4$6FKJ%8F\W)SRZ?$2%M=0,$MIA-89&YIG?#BG&Y356CQ>*VT1$L(K=QF%FP%B_A+\5L*7AW M2;IEXV9+.69+)8O+S98:+18W6XY@$;G9PL*"1>RN9:3$R:6 M3XF1MKJ @EM,)[#(W-(ZX<7G%EKM%EKA-ERI4:ABNQ!S6XRI*%3YB\MMJAHM M%K>-CF 1N8W#S(+Y>RZ NK*MXH>Y\Z#?L;70 8.OV+36CQ_\%.-[<8GI>GXQ ME)>%]1L656O!YG*:AG6]SR.>W9!#Z[:?\T"+?*"-->MGG;VOG*5[! -9PX:Y M4%83^)4!W[.Y@AZG;3\#K VL;NR#U&.)O#[@?(E8[/R]DXL,Y17TA"-![FQ- M9MRQBUHA[[NX9ZD_'_%%JH:3_-/@Z#&VWNW#A[&MX*7W^UQ'!.YGP0S_@ <2 MP<-E$Q+%F"\;#UD/ABYD>4>J;4F+WW159C?H5LP:1SWI"2WT1)OK7X"TS-_L)385\\C7>/,I3VB!E_AOMJ(JSX9B+X]YB;>?\X06^;O^AIU@ MRD@W5KHADN#G,:]VP@.?T+(_&OJ+IIL.(8YYU#7YLZJHBDQH CQ!TJ3/]XL'X M:NCVZF'N?<"HT^W%TS*38QV**X0N1>+(K+RG:5SE&P?=:8"NNG++\-ED''0G M!+ILYZ05+.D$+NE.$G39=O8?6-)QKYP9KYP1R50T2'@>[7@ $@H"W(F*\7=1 MM?$7H K-OI,G^2*:BELC+1K&.U#B":]T P3N<*G;FN7_ZE8Q)54G/W-($G._ M.P/_Q\::]$[OZ5\3N,)\PI)M&# 2F^#RM-(.>@6*L;,1+A9B>\XL1/GU[-(L M ?,ACC@@^R]_@Z46#6GQ_@V_8C6,O8FVLBV3?B$D8G?-"V/34I; = ]S_TK. M",GTCD#<-N$/A?T(KLRRA)PEJV/)-F?):EBRS5F2LV0D2W8X2U;#DAW.DL?( MDE[!.O? N =6+I +WAX3 63N@=5$MW /C+,D]\"88DGN@7&6Y!X84RS)/;!C M8\FXZDBGU9'?^^.;+M%2?VE1/>!H5BQP(U0&!J2I"#H1*)0([E7T<")5*!':J[88_14/VFXL\82"% M(EE8#K0 ^]=7 PP33(EJ.T;Y="$:&"P]+#^*[X0*0P.N><%N42->KE3]'3,. ME="C!_N 1M!@?[-TBXCK$3-1\S3D$X/2I%)% M?M3>RU\;B<.\#*@4!%L6$\Q:5E2;&(Q3$BE2+ 6;XS=)M64LWQGZDK17M2UJ M=S[,O7;BC]APB/D>?0,GV.G2DXKXAQ6[G21\974X8@3BAW%4.1%;B /NZ '' MED]8!>#^]43TBM-1!USR):L=DQ@'XL[YDXU%/JF=CK8A>A^A3&41XN(;AWB9 M$ _2^P@ASHK9P*7XD4OQZ@P5%B'.I?@12O&3L<4W0LKPF[EN+$5-&$?SPA%%/MM8703QNB' (LS4@9>-4/CWAE6U("Y TI)&1(2[7";7MKVQKH1O*?TF/K+_:ZCNY%YNK M&DJ<13ZBVVPWXW,6B89U$;*W(OZ3[UF$'*']^5I7NM;LZE0.#': 46GKKL[> M*N&[^$X@>^Q@"#WF812"MQY%*82B^9ZO=)VX_O.%\G9M8%.')\4FH(2\7V!1 MIK.7E=<;]">$/I,7\!?][Y_?Q-8G\DGXN\\K9%KO*JSC'&[JT)]+P66BOKTU(T7A3MFKPD/_&_TV MO/\Z1J.'[]\GT^GDX7[73 K!47!*_Q#-A:*]6+K60+_=S%$JW%./! M\]/'U'GT&4:;IV;R_A)A+21*)G9*Q0Q*>$^0ZXH?"+\'J,1SVZ$5O-O5#:N;WA3"FQ=\??ANVC\@1XT_+&L$4M" MNSO:SK7ZFPVJ#QOJN]->YPS10*@%-BK<"BR&ZV==5Y]%5=6M9_TMY:K",[;! MM/BTN;+.LR, TM]^#)]FXZ=O_T1/X\>'IQEZ_/$T_3&\GZ'9 P+)-@/QY5PM M=-##$Q)Z'^2/Z.$.S7X;HX#D\Z7><#0C7PM7G2XJ$T"$*70#60N,?%*B1VH4 MH+$F8]E=[UWKX/QD[%@7H56X)AW2ES"EA2R^OV,PH+24R_!76\.HTVH@\F$E M7!:4';I1YKHPQF8S0P13F:0KBN>S5@*?S9Z&]],)X:8#,%I%?+:FI<=H)".$ M@DH863H*Z>0RL5ZV/0.D&>G+I6(27PS=*6 # Q"(AQ8+RS%UE,BESI5IM76S MUV^WHB0)M_"JL? *-N,,,D5*T-_)?=);2D^8DTSW]5745/$6$/1H2=#5 R9>EL\6I/E_T#7%(%M MHX-Q8Z!_VX9BRHI$[1M]SB[U,V!X)KY-W.BRTY0BD]71[C2%?NMJT.OL@";S M:ZT$>9DNN?$"+/=?^OYC/9;ZP^3\Z7QZCMRZ5P--;M&]?KXY>R;7(HW "*H= M(5;M,#EU)FF>04P,9=G ING^^:9H6$CKF/1:Z/X/E@S/2?:-3!,%?_?V7E6.WIA-I5ZW)0=Y/G@TL XI"O#,"# MLA)5A-^P1(NSX6.P";%9%^,'5A"1)8PV=RY<]_6">M7EA?\^Q(*0L/[0P&(& MV/6%K0C?QWC.)VWFU,>%KF6+)+:O.O"R%1E++#5R^N0'B4@PO254<8\ZEFW@I168C34'7Z]6\2-'V(#RVAE&Z9- M HF6CN *ZKX)[0_/'XE8(SF)H61=)\YY%XGB9MJT])4[6_<#1P!Z)34AB7M[='_M,ZW+9H#,R8;F(JEL,N,#B^F)._T;KQ-Q,.S,..4]+ Z=CF6 ML/%V4H;P0T$,?9/=FKN47,!B]92+6()'EM!A-MLEY&O32E8$E M3+6@T$:THLM$'^"N !=DVB#ES04YX#[\D4W%O1H__H#.A,Q5-"UVUD"R^F^07;=N9DJ7^BO;5Y?IW#',8(A M#-"U5"P+0 G.LV09ND:4@/J.,"B$=S0ACR%*-.1S*UJB4Z:TP7GK>P3]K2<; MKNRV>H2C8%!;=;)GT^8,?2!4&7QJ=]KG[@6@)VAEQXI4=AR:]YSY^MR$S8^' MYY5RY6U:S@PL+UE=EU$Y9U;-F< ,(E+A?AB)$CC_L$B$O0A8#:(G(C]%L!#- MR"_,); TC&)X$A@6>+D2M7>B&^%NH$7(U%_0BZ'_M!;>M^>@)#&=FHSGBD9+ M-VE V FY29]B9NA\+7]J^!>FN"1VCMZESGH1'7D6,]\S4B)&Q0ZX(,VV%^,) MJO=S]&%$J:]K^&-BY*>$9-6^@9^KSOF@_,B/&\AWIM#NG7=+ROA](V!S0;"& MD_.!AZEH<;+#U0D_4/M<*.F!AD?Q%%&%&"EFV&F==TJ:X=21+,Y$??'BO%W+ MF#5K)JM,>K M=EC?!9AHMUT26SL46[(:HF^W>][F#!8WP[QH#=;_YE^3C;MDH-4X;%?D%1'> M;;[2NXP\X^20.X>JRF97$T::)QBM).D;:6HKCC5HA/U?ZO6"5:KIU&FU3!Y83\70C=T:@*?+H5"Z47TVMI4Q7S8?TXH.5 M06'JZ-G@;E/LT*O. -62 I:G^>O9Y/XNO,]8LY>R;KD7A('G-2RZA/^=W0C] M1N=RT!#:?0]OWC2#]3L+PZ/: CM)')J<=W/\?Z8-:%J?T+,H_0&2U];DYN97 M;CJ(UB6XSNTU"4[@=1E'9V4A>,J+2@;T81$J*BFJ5&6#2V3EU2DL^/7L\>N7 MWS=<>'?.;HF(D[4-%HVX:;06:9."_H3"=[N;/?FWBTC5!LERYO>F\7Z^F#=! M;SJ?;WY!H@[H\>O]C^]GM,W-NL]-L-&-]VK]8KV2C\.OX^:7I_'P]^;P;C9^ MND:B^E-\-S>7)T0%;_G;F9;?6=0-TOQV&TT:JFCV),SL8?1-T?[P[R\KYDH5 M 32*IH+F:3ZKP-R114KI:>G_+;8J*:9^*@C9#%V.DKYSJ%=2W?KP;OSUQ_#I M%DU'D_'];'(W&4T;:'(_"FR"+6\Z6STR'NX1;<#B-$TI?T*?1=K>C/9NLDAE MAOO:[>D$UUR(-[/AEV]CTB%@]' _ R).RYKICA@I&9RM^CC*Q6ZHE+Y&Q-5U M7J%XC]/=\>J&;GL;GFJVGT?_VO'_,DPIY 1?';SL;MT2XA$X!$U"I;CMEM#Q M%O[YYFYR/[P?38;?@(L)[PQGP;Y8Z2@6>KJR'BYI7TJM5FGW@^R>:<"UQ=J_QVT)Y5LBU(UVC(HEFI;^(*CE& DT7 M&%OF!H>%&G*A#[8FVK("O_JXSDG?8LGIKMH1Z&6"W\.292 N5SG!@Q"Q^$+ MT.^F$_40M8 &9TM&V?)A96;BR[5*(Y&^AQ5VFC"802Y$8?-Q!D-A6DPY5=[0 M=Z=FC/;T"S/RFGF/@5\)86^ZG&$YPQ;+L*.[%/P*/R5)KP3.'8GF MVI^L]H MSCTI5@62WO1JSZG,KD#B+&M!XD2&'/_'5JSW/93HB&9 39(@=>[%=>D&@[HD MONES)N5,FHM)[W4+[S1TZ46D\"/$K%'AG""'UIVY'-+<7-:>M[BI6DGVP.>Q M[[?#71RV#IJV-Q3;=U$37RAS_:_?/^16,27;Z<9,--E0$]5W4Z$Z<\V4Q-IU MZL'(-4_8M-5-W[3N'$H(>R/47_EQ!JV60?]&"AO3LVAG@T7ISQ5R6/"K8X+" M!ZKWGO"JJILVJ0@;/NNVAV[KR82O&LXX,H^%LT%55, MPWMNJBS0-HPX1#],VOW1U5*U9[,0V3B[<79+R6ZW>"Z2.'@J5EO'^9#W._1C M17908DW1C0"+U9V=?+)P5N*LE#:KI6@X%1NM W6(_ :1HR!!004"XW5G'TH* MSCJ<=5*RS@/I$I&*=WIKWJ$_0A/-V5&OZ%K=N<:A F<;SC8IV6;L\$:&'%%_ MS3[>C^O.-3X1;CJMVC,.CW=7RU%3^'07-Y%K1.L8S#3ZM#>=R*K?P-)Y?Y.1-R4W+B)#%MJ59>N&F1NS;-PAU()D^[M >Y:D4=84A%Y7V?-EB_ 9V[[D(/N>S5]0L/]+2AH'7Y;>#B;4G2:Y M[4NIS4S(]EZWEPEY&6IEDK(?3%GMP1[NIP_?)K?#V?@6?1E^&]Z/QFCZVW@< M;K$2L[2;;!I!+\)N&511H:.DW5D"Q:XL>R:;,! MLC7(,[=[<7ETKF@S\M-H:9XL#C,T_ H6_@/9WSX%&V=[0V^++G+^3;O7:R#O MGX^?4/0AF6?!OJ5Y9[GUN"XQ!H06+C%A^@$ Q75.]:CXE^)ZI-5T NW#S("H MOC4;O\6P\8#4AQ8=0-6 M1!>?.H KI&A.I>5"]PX7Z< !":>NASK'@VGTZ W5@7'EC_4005"P!PJ M]5$_/_NC/6\=%LO7L<[K6#.KLBHA=W;CGN*'AJ:)0YT@3XH5G)!O[1GAE(8Z M\N7C5EI: 49ZA9'J:HF\( >WOHHJ:8,2*L>BRS-\5@)'MMYU%+HB[.; MAY\:-LR%LD(*"=;!$I?FU]0B>\Q,3CV)I3MY5B*H\@DP".%N7JU4#(2[C5ZW&K_G^"I8JO-]'@V\$A49X;<5.0+ :8J@TRUU MDIN&$&D:X@B]HI19^ZI%0][:C&3ITBBNN.I7X_@5PQ.U\@\KK&L*D;$]H'2)OZ MO&F;V%$O#:1ABZN8JMDZ=U6&>X")]O(-BR:FZ_LP_P'6*%G^XZC(GV"LM) M3[Z;:,/Y7%$5T<+FU'XV%5D1#06;P/FZ1#\=:O)?=8# W^%RTDXGGW/4:0A7 M;1;E <=N)=C-7;-1 7:%QM6 2>QR9RJM+J,9LZ,-TIUR3D#(72H22 'M2''3D*V7K-:YZU60S4M+L9%0LYP2?$W+7HNS!";UNH]6N M-2=PEW6_5CK?)L,ODV^3V60\1H)0M?Q^-81^Y; M9&RM\TT1GQ65;G[@_75JS0VG--21+Q\WW5)*L:$D 54L$ZW$=](O_21"(BPY M>,F.6_X:87=='YUEW:= LU?-5IJ3#5/4!YWYJX:+0V>75V[57/\8-NF6HR_) M=B>18HR4;CUC#<^5HXS1,Y?52^;RW$7$X^5*U=\Q?L*J:&$YX"CMM;FSH@3V MB>BC>H&SG;N,^##@'%QU600G=XP*3 M&]@X*"L!9>YZX8)!V:ZS+N*N$=W?Y*N;=]3T5- 1JIW-E+VU4+1:%D3&3SQ) M8N2O"PYMAO,$Q_M> 956-1$57B#,"X1==LA?(%P\.W0&)] UY]0=OQ1=<[C; MQY"%G;NRMZ@89$/H,KG+CN.Q$CSFKJ\M#(^##G?VZJM_HIP]6,GF\3I\-6/P MW'48,1;IGMO7A$9WP&3>F\.S$GCF+L0X%#S[O*-;K=61TX1 U;67IH6-Y9%[ M/R<=;,G?(XY@)&# [B,TNFDXYS /;["(H[?CEK7 M,BK7>^N?]H=H1=7& MGU":FW33C=4C.:56:W,P(;%*%D+].-=75V<]EI=#J=75HVU:B#5JI1!T*ZR](9 M)0/G"(S>8.,9HI](,4VRUY=N\;4MTX(7BO:"1 O]U=8PZK0 ]Z"]Z 6W6,++ M9VR@CD _%;BI4;5LSUT$[K#K;L&^(S\C]'@CBA-#XTX))'3Z/C0BHWKLZGKN M+@]E62%<+*J(', .6AY)XDJQ1)4+^ZJ%??Y&>/ZB/L*:3K21LZ(!'9!+_%^V M>HTNF[W'.$(K06C^9GB'0FB_T>_4N0S[U+W/LYN9@473-MX]UQ)<$TDWK70. M&*DD;+3)R;:.UT/H@>#:%0:HO6+UG>O-,J32AR2Q ME+N\V\/>GGY2][+1K>BPK0A2?60 (:<+QF[N"NOBP-CK7S$&1NZ?I6_.9R]M MVJX1UG6N2 K?&5L]3^>ND'["EJAH6!Z+AJ9H+V9@>6^=UNG#P[3UA7X:=4T&=I;*7$7+:B4W$:Q^G)EX 763/"! MD*J;Q[B-Y^@W"B8*D]Q5+@&TT$V#HR!6)AI !W\#P-QCZV$^$]_VDRQM1H1* M:IH?F8H\;1[)77IS"CR2?Z\M=QKS%_"$MMDZ5?U<-==/["1)G=Q%(32RM-!5 MF('I0 -$C6J3BJ!'W2#C#"W+4)YMBYQ8--/)'G\8R-!5%2Z9D -!L9FSXVZG MT;ZJFQQBQM'DG%,,Y^3N85@AY_1:C5Z_FN/I>+<,-M1X8'L[S4@>KUK?R?9Q MY]RS=*!@^CDGR:K5MRY=/?O<95KYI"BY34/!D%SGG$YY'<]4@' MX9%>M]%JUYI''%5]83WK\CMY1XR9&_0G!&I&5EZ=5Y':\9>-:?^R,>/UA.E\ MG6E2\A*G1/97$E95]/CU_L?WQ#&VD!UBD0W" GV< ML5#''=.':>AU\.7"MT,?AU_'S2]/X^'OS>'=;/QTC43UI_AN>MQT3=I3X]!C M?T(+[-"PO7K[A%SS]<\M^A_\;LNR=;\Z0Q=1!/_M-IK@SG[V_QA]4[0_ M_#%DQ5RI(M!1T< MP1>6/"[L'/)ZJ O)6UWR0BTBR_BU(8+XLUI1C$' MG;@_ZW*EUN?GF\\B54\/*_,,68I%QJ.O%P;10W^&:R[$F^GP;OSUQ_#I%DU' MD_'];'(W&4T;:'(_ KD"]RA1[,&41P_WTX=OD]OA; P3FL&?[S"G*7JX0P^/ MXZ?A; (7[)[7%FL&%_,R<2V#L_GP0Q/!JR:"MXDF&K(6NFV"RP//A]\DO+*< M2DWJ!:VPX;X#22U^+&>.$9!SV(#J2E=R_'I&BL" U>B3$($_GMS)4K^>X=7 MYXHV(S^-%N79Q&%XXV8+1!3QEQUE?N@P>A)M$TWD;'=!+DF#08GM6\-SD;K> M7\_ZNY5-^J'SQZ1B +DYY ;STK>OHJ&(L)P:L4+5""X.L+@C@_ R.!81]@L0 M#?3;^*]F(*(P^@Z?+DPT!@3)?B7TYPN\O''_<5ELSS7<+P3) <,"8*;*&\MP M*2=WR*;0:W,,!X!*PF:5PY&O?#4K+_"5/]&5YSQ_JBM?/<^7D_'RU MD_*:NV\36B3DKE+*TN&O6,.&J%*'7927BJ:8%CF-Z16#0[_"FHDSI3$+8IZ] M1\G/)W$IF*L4&9A#SBLAS=+?* 66W51DM]D24FI^M*P6JI;5W4:WE_]0ZK)0S4PPM!H?Q#\ -OM&Q=P!WD/=\$!, MFKS/J3\HP 'P5V&]O6F_;4VE6_\9-N]QW%#<7!9@8A\ -R7;UQPW67%S58 1 M6PANNL%ME&5;L!PW&7$S:!5@)A8N;TJW$4MN<,&NW4=;52AT&=$'8OM];" - M9VNH=#JUW3PPRV3U"A4[(\+G>ECP,Z[2)LP(*A YY[OS'H MY#][F*.G+)4>DWO*9@H6#I^0-]'/W_J36X6'%T Q>9YL1F'Q FC0Z';RM^G< M6P"=>$S0VY+OFH?<),S,5C&)IDPFX41[A34@>^HR^8A54NV1' M@<&:U*KL/:>MP\&#@245?Q12VL)PO<<@)@&4T;CTXO=WAKYT / =6PM=7G-U MKM ^^/QUJ/K@<"X5SDE1K,N8Q%1&L_= >%X'LWH-H<-F075Q,2^.Z8(P'9,3 MRFB5'QS3[8:P1P-DCNECPW02I&-R51E=AH.9'=V&<%5JSHI7FV;W-.ZQ%78S MT#.&)<;>AY;XAGD1:F9W_K*(36AAWAS![13-!KGIUOSHFOF%KI5SW8RLU/C- M,D3@ D43C?>)A9=FD5VQ+WD*F@G@)1HZ16P48PIYP:K&3IO7-#*-OB(V=#&% MOJ!QWF^TV[R&OVK\)<&OB)U7C,'O1A@T.JT*D\4G'HN?^(8PF,8:GBL6^N V M@_A85%/[ _G(V48LS%_>8P[;/EV$""G"=RYBCY@O -S"JB\./.*8_+_8T&71 M7&SR-]"SW1*ZGP[1BKO"<#V'.T-P+V)K&X<[AWM-X%[$CCP.=P[W>L#]JHB- MA*<,=YX#".< #EQEU*FFQ4SV@X9*2O[E.DWHJHA-CH^&#CR>=]-PV0F!]'0[ M=&$11W#:B24%BZ^*V&RY#X0KS"RDI^ !ZRXXC N!<1&;/O>3Q!6F*#B0:P7D M)!P7L?5T3XNB_%Q'/J.B\)S(!GA/ZRWWOS9JL/S#PJX+: I?3)]_?A=^%WZ7 M8[[+2>?YPX:!<$DG\D4T%8GQXM>HZHV2K<]DJS)/YX5';$R)^MNT+L>BH8'= M;WK?TP7R#!@ZEZ+DJ=VV*JIM89E;E?MQ6YZ6"VFY MS5TB;E<>$982#(%V*T^_@S+ Q"W+F@(J3[.!L@'%;4NV )6$ISP[_4O2=C6P M+H\S8GEV\P],L(=E),(CB2_821F9R#;A,T4#R"Q7-CU)BF>7^%WX7?A=V,\N MG5 DH [9)?;V>+=;F5NK1)I!GO(<.KKSWEX^8^-A3J\U'VS+M$2-U)B%0V^9 M:IGZC4Z/=]YE'D^9&Z94A*=VJW')\<0^GC*W0*E./G7[)0=?F=O!.?57R#_H3 S)*55^=5I!'XR\;0 MOS2]V" M&UHZ&ND:[;(ADG34G:*)FJ2(*II:\ %M(7Y>YM0VB $K@B15- $[CU^__'ZV MB8Y6ZR]1&P/=3RCGT8_.Z.TV[G_)O&&18=S(H,(C[^] -%O.FH?_TOMG\ M2L*JBAZ_WO_XGCA&M!\1!_:S&VAU\N?"=JL?AUW'SR]-X^'MS M>#<;/UTC4?TIOIO>/DKBM6@X]-B?T ([-&ROWCXAUQ?[#?^^F/X=(NFH\GX?C:YFXRF#32Y'X%<@3N4*%M@PJ.' M^]OQ_71\B^#5].';Y'8X@S?3&?SY#K.;HH<[-!I.?T-WWQ[^,=T]PT1]=)FX MIL%Y??BAB;:L$!'LM&'JN&IAHB%KH=LF*%S2W*<4@NW646MNH.K3%2"T (4P MHKO'WW]OKD3)?^^P[%S19N2GT1(]62HF])G:Y##Z5(HF8XWJ =)JX+.K^0^= MS\PPRUQ)W"+O#X\-:Z3]>M;?K:P*&'^/WE^E23:\#(Y#5,@"[D3-\/BOILH; M^@Z?+4PT!M#)Z*^VAE&GU?A\@92)8/&^(YZWH6WT>XR06I@;F6552*#)[ M3MHR240R>?7TNB^61%\L%74"2%[$'&"H/S3T5P6\N2_O/P!.$\W7<6L5M^_)L:VK_!F1:HB?>D\8YYR:<4Z> M;@A5<4ZW,>ATZ\DYS'L9C'D6SJ'&W+-@_XFX9\'H$W'/(IL4 O4E82R[ L@$ M-64B?8[TGQHVS(6R L_".1SR&'V)74.5;MTD%T 5<6Z4M][D\-!;A:H;RS;P MP_R+;2H:-DUL#C79.Q'4G&C#^5Q1%='*9\;<="_S]\LNF+3,P.ID$=PNXBBH MLA$L=!I"3V 1Q-R\3E!L0_E5U"2XO:C)2-5%C58"GH9>V_33K(6BY3E6KW+O M/G[B2>Y].T^#HRTQ([[3TM [W7"A---]29)=D/3.;CJ-;BO_*3X5T?G88F G MSAEY6C4=F#/ZH&(;K=IR!O=Q2KFW-O* MQ5"N\'N[B"/)8L+O?@BUN,35E5"-"YN.U'LU,^3,P@2S)/%*$<>>'997;H1V M91YR?A[ACG3^/)6[A8[GJ9A_(IZG8O2)ZIBG\@XV! MV8:T$$TGUS32ERM1>R<-89>@_$Q+E_XHR^2/>Z3R;)M<$SBT*1,SJ42C/G-C ML>30PAHD#_,11<:4 ".?@=(8M/,W@CX (B:^H9^*M5CH*B&AB0RLTMX4EH[P?VS%>F\^BR0Z)OX4#9G'OVKH MTB?*DR(*MSUY\N1 9Z8#J/ZQQA2(&>]L+BP3"PMKID@FDJ^*XRK_^2[5T)^' MP(Z(7XHHURZ/7WJ@E5E-9Q54L<348-&K\/$1HTX4I^,4N<,Y#-0/](H9H^!NF 4"XU.IYJT=4$,5.VQ1W'G M^_##COAA1QZ3;)#VDW\J3X\?=L3284>9CQTZ^$%(I1YV-*8UJ/Z!1]Y;M@\] MBCWJZ+?A_=?Q%&:&QG_[,9G]DZT3CQK.1_A-PBL+F:0'L%MD]":GHXX^N MML1D!EMBZ_2C--KC$^M')%&2N/3JM/]RR/UHP:$$%D8ZT)DBP=&[9/2$PSN\ MB='C.PY/AT-OTMQ%^/(.=KF*=K6"JZ%%49+"2N83B$JHP"34CQ6"V\5XW&<5R51=#?E_ETC7' M,C/(0#/=$M5:\ 5'5_W0=8OGBJ18'%\<7P?!%]D(;> %UDSE%:-ONFERJ'&H M'01J=/<]AQ>'UX&-407C72CBSOY-@. MWQULK5-T[?XBJN1P%M1$MUC"RV=LH(X !&FUA=A%+K:Z]ZJTPO-H[HRO)^\> MK)P\;B8)5>*]Z"KQ%#O!:.B==###ANE4Z4TT=W/VHVZ0<8:692C/-JW#3TN6*1"L+]N+G?&+088^:3 M@"1;.8;^[L,F.X=)-W 0(DG <=;)D9AP7E"W8#>W_8D.717.QZ6HX MW4VZGQC!,RM0.V)[(;EYA@N&B/89' #' H $H19U7%]FH98Q8,Z%5UVQRU:4 M>_?1;FD4=2LZ1VYD1GB.P M+2 4PTT1>SV[><(KVY 6H@FST>< )=J.R'1:?902C8U[DM(R/'G&/[ ,B)E2 M4JAL$'6*6-;H;4@._%U4;3R40%X8Y*ALT_J.K84NYTI2#@:5!,%BZ%A"(*R6 MJ#ZPB1XSI210=ZJ*_^[#"3&J;QT4KE('UA&7E8]_X&!R#L9(EZLK)Z#,>86/ M7[%EE,0JA>00,U>HAYC"J?3RN*).+E,=(5CU^.RQ0"'IQXR1>JX5^/@,>Q:# MBA, G#WX^ QKC$)RNSEJXG.83+,R973BL+6 MJ48^\"CK(ZB<-WE2+_Z9RS3?@L2?HB'#/& ]YUBQ;)!]]'!F>EB8B0P_52.3 M2Y EOL'#<5(6NTT:N&!&O_(.C!JGRG&S/Q#>]9ZMQI5;*5OMY( M9&(2I7EGV=BAD-*&+,F?0_)037RV.L*7C4F4EB/*QD3IR@(.FRCB?%5/2+,P M"49-M4(*$U(GE1(8R(F1;'#0GLS#>:;>DV"49PJI64B9A>(JIY;(96(2%;I# M2='(RT(*&7*DK*H*+=P(C990<<1R>XG*+1ZM(_]4J'X2^:>0*H@,.:U#66WI MPG%"N\U9A[-.(99;(<42J?-@U8>RA4:'/>ZIZU:E"AM+47PTGVG*3 (T8LT4 M*;CQ&WF-CZ[AU.:I*]9"T:*.76%LBV/Z:2=)J70U*\FY]Z'\;]NTB PS9WJ, MK4R5-P75*("I)PQ"SU0L/,7&JR)A1V ]84E_T>A=J.S*9P5 MW06A&,XJI XFSS:LJMB1Q< H9\?BV;'T-F&%\.-5ND*1 FJH9!ZCXQ;O;@*X)S(G:9-3BRD1&2/'68\E,&Y\D3U(S?,./!8 M4P>%5&]DWDO&3;/">;%.&]98.9G^NVA("^]8^O:)'$N_":_.Z@W)NOVLXDUX ML7*B5/H9)TFZJ&/N4R7?*CP%L-MI]+J5U)JE)/EIM-X]!!-5[3W&SSBI6NUJ M$,]%!TBTL7""VT#H-SK=+I.F0?PB'M6I.H?@O\IS;#D9\#(W Q:466.!)]L] MSH[L.,SQC\VTPYS/C+S*S7^9FS46.T*>8]=O2^(Y(;_5F#_55R'_7;9ZC<$EY\#*.?!T3<5.JYV; MZ7*TJ"S&6.PU6E>5A#HXUYRLK9@0[NBT.@?B(:;4U3JPT;ULM-K]>@8WZK3[ MKZB#RNZQA10:.N/GDC&P?SAE(^E.*Z;I2W==]M!O=EK[GC:8G-N[K+@Q97WP M4_7XK)T3T&G%E.ULX/< &3D.^I,9G[7CQ3JMF%8IV5!?4!JLGF?-UA*(IVF] ML%,M7,=%JWK\2D"#)%4T0D<1Y8BXB>4<5C[ZS)@J254<"PT=[SJ-CYSF9UVNCS^83,[ MG'5J %UN4FUP3B'% JD3/8OQJ?)2D M@%^[D%J!'%FAZH]![UY6TA&=5VC60*DDLDPAM049,D6'LKO2L4FODCY>G$MJ MP"5)3%)(M4'J1%)E\>$>4^QQZGM[Z.(VZ6%/9&./?]H3PF_D]0DVUUJ]!69 MWFQT8Q-6;^R=45; ])-$4[I*#S9/'DL^?K);<5>DPZ"-F#,+J3[) ML_F)'R3(V9E)6I66K3L$/W?2E7R4LV>+LSAG<19I50-;FL4N+ARX5=.J!L!- M4$V%%)UDW"#&51#G9!9I56NGL5-($

^]IX*(AS-8NTJH%^YH8E!VXM@9N@ MC@HIJ,F\@XZ;E@?#9QVWZWEYTK?U)Y2+-C[S3FG:(%/VQ.OGYYLOHBIJ$D9- M]%=;PZ@#I"1P_WSQ?%-^VA76E?R_L_UD94O)_5:"^?/:2G[*),';CS[B;7P-^A-"GR]DY=5Y MY==Q!!_UEXV'_&7C^=:/)Y"2#W>2Y&6 <21,%BT@0%:EC3C%&-WK%MS0TM%( MUV@-#XF\HSM%$S5)$57DX]L\+W-J&\2 =4"2*IH U<>O7WX_V\1@J_47OZ+& M@\6ZQL8'CW5&;[=QO[O9DW_#H$1S)X,"@[B_#]U@,6\:^D_OF\VO)*RJZ/'K M_8_OB6,$.(&2)\Q2&Z0%^CACH;X[I@_4T.O@RX5?>/4X_#IN?GD:#W]O#N]F MXZ=K)*H_Q7?38YQK!%R/0X_]"2VP0\,V83"W7NO/+?H?_&ZKE,O]Z@Q=1!'\ MM]MH@I.5*X+PLS0^&\_)K-_[I[> M%H,%E^0R<46"D_KP0Q-!51,!ZA1N=CXY2S71D+70;1-L>O-CV=3:%J4N@JFB M0X1C7(WZZQF)LL)[346>UR"@\U5=CSX]<7G)!%)2H*5 MS"44EU"%22@O4ETW&56G_JPL,%!5TC7',C/(0#/=$M5:\ 5'5_W0=8OGBJ18 M'%\<7P?!5V@O#?JFFR:'&H?:0:#F%#)Q>'%X'<897H*%SQ4EA]>!%*53[\WQ MQ?'%M2.'5]W@52/M6*>N8 =FB^5A;077ZC7ZGDE-M(Q:GA 8K;/+!H?LE966$J(V Z1B!]S3B M;+'/2&R9-U&[X=+QPJWJ#19R:0Q A(RAN)+3_D*A4<#Y!IX!BN,88KR TD@'C0 M*@+$!64)=N.:QI?BJ4ZEYPN';V4^5?L*F M92@2Z6QE$@0@\:=HR# /6- Y5BS;@+F*&GQ+,U7(P"O;D!;DA'-R";+$-YB; MM2"Q?Q)=:2 -6U4<1EUUR_7LDRBG27KDO)*D2G^/&+ YQTXJ:&*:-I9O;8,D M@# Y[9X><;]&&[UJ2+#V#X(>K,IWNC$3WW".B%LWD 3J#"K) -4;B4Q,HIRS MAS*SPZ#L&/0A>2A&,Z_9ITH576_XLC&)VL7MF^!HJ.YC/-EDF 1:R9 M(H4V?B.OCV^WPV;++VNA:%$]OQC+LZ>?=I*,ZA:P>V(H_]LV+7JFZDR/,9.I MYJ:@&@4P]81!Y)F*A:?8>%4D[(BK)RSI+QJ]"Y5<^>K9VVSLC2T(7:?,6667 MXA7#6854NN39"%(5.[(8$^7L6#P[EKY7I1A^3%%LZBG$5/U!9EN#B8 M ^^8@9>@&@HI]Q__L03%2U]Q@_XZ12M:NH5OZ' M2[2Q<'[%0+AJ@&W I&D0OXA'==C%(?BO\AQ;3@:,.H&@U,P:"SS)2!O%4V7' MU(_-M,.>B M#GTX>*JOXK-[!$'@'%@U!YZRJ7B9F^FJ.3.H>W;3[U32*(OSS,E:BHG!CJL# M<1!3RBJPO:_1[K!Q\F+FR$:=MOX%]C,&=C-F[Y))SB=2==,LO[%E:-H5[!Y. M/WYI&X=#4TH0*MU63*^7[KKDH=_LM YW%$RH,66[XL:4(;*5NP^^/B NK>M* M>A#'U.UL@)BQ0Y X\NN&_/):1X;FE(3\F&8IV9!_TB(]I$9'16#BU4YWJB+VJQ^<& M0@T7K>KQV3,08@ZVR"8P3^3TJ!0K7J==.46%Q9_\PZ!,I,])ASNP%A$]1XI' MREF3!8E!QIBN#9DBY2%90#?G#260&0;9UF=:W[&UT.5\>[8;OQ?'UQ6/CYSH74A76:TG- ZYQ4^/KM^DE!(_C7SCI 0 M4S@5?QY7')GCQ,=GG@4*2<1FS"5PK<#'9]>S$&+.HR@MW<#9@X_/L,8H)/N< M8V]$#K,I>7=?^XHS03W&9R^J*A22D\Z<8CFU..PI;DA8'T#EI%N02(Z@@BG M8LZQ8MD@^)"HP;=4!B+#S]3(Y!)DB6\P+6M!ML&0F&8#:=CB.1O6I$N2<(DY M@R%5RJ:RPS2%:G8]U1%Q58_/GL]52,5"EFQ.!>('6NYU"',W/^.([QF>./=B%E RD305R#L(_0JL=G;[MV MNY!R@1R)H>J/++_LL!0KYT6:+"F51)8II+P@0[+H4'97RB[CE71HY5Q2 RY) M8I)""@Y2YY(J"Q!?#?H,L<>I;_"AB]ND1S.1W3W^V4P(OY'7^/0R1JNWP S( MFXWV:<+JC;T3Q0J8?I)H2E?LP>8Y8 M_4_\V#_.SDS2JK1LW4'X.5W-1SG;MCB+ER=]6W]"N6CC,^]8I0TR94^\?GZ^^2*JHB9AU$1_ MM36,.D!* O?/%\\WY:==85W)_SO;3U:VE-QO)9@_7ZWDITP2O.WH(]EVYW(K M/ UT<-7H7%5905+6PE5BG' 94*9_7]93)M5F=CKQ0N :6,6CF8<""!#.MT3 MD"'E%G]R\5%R$IH)^='-+3\*2E.S(%+:5<8.N30Y#OHR$.)AP2OIY18HF7NP M%G#0.FDA)C1ZE>[Y8 *@7 KPL$0Q J!_$ ' E.5PTVX(O2H;)7&1<41$/HTH M1I+(&.1W0O*7,50H/BY;_4:WRP4(%R#<\RA.BESFEB(Y&AD7XWL,+GDNA L! M[GBD?4HDJ:()O//U[J__[#9O)_=-25\V#1G&7]@:W$+6E[@IJ0JP=A/X4[<- M"8-C89*6$?1-W>5[F MU#:( >O@_-X=WL_'3-1+5G^*[Z3'.-0*NQZ''_H06V*%A MFS"86PCVYQ;]#WZW52/F?G6&+J((_MMM-,')RA5![MG#Z)NB_>&/(2OF2A7? M2<4M"$G3N\EHVD"3^]&Y M7QY7WK3O'V;C*2 "C1[NIP_?)K?#V?@6W4WNA_>CR? ;FL[@@^\PS6D%D_M@ M:R*H=I"X'T.C$T#]*8C# ,8TLAY]Q1HV1#5(ZQ+F%F;7@P]( MWRM@#P,-VMWS06]%)C%;8"1*I$V0J+V#]81\Z &= )#*!2-G'M[7']%/,%O1 MRL K<*S)C.A<#9G6V)*C,.A[&X:#F:\,!6:V4H%<+\Z"JN_D>[QRGH:.]$.C MST8G3R<^I PCTG,WR 7>4\_]!S6]!T6&K;HG=!CP'"IE!WH3\L/I>'0.STM? MZRM%(\X"? 5K)K[0GS?(5R9>W\^$P8@-#RL VDE<%Z^C#\"_IF+2Q](U> RX MD4;L=15&EFR#-/8*_N CTC#X-*9HO!.['HEH+BH&(9S/MMXT=]MS:!8@@[X" M0M)YP+UL%>8&*X$2>$K3+8>IO!D!BN%K&6AL*:_8FX9W-W>V-A#@'8L& 03] M2'OWI["BM?CG:(0-4IP&GSNN"WDHLA8P(D:R+X!,EU)T6$I>NO@1ZVF6@ZR% M"(_]C+%&I+),.G#)Y#'UI6*1'ZQLP[1%0!<8VZ8M+6)09F#560>X+ &C[O+M MYMD@;:R%8J([H%K2P@HMNJ[-OR%SH=NJ#(\$DQ+I#>#!_FUKCH-,B??=1[W# MRU>?3$1TA&V:WK(--5%]!Y 34JUG"!-W@O?TFB<7)7#)@P-$0@I_ZE@U\<\% M$1'9'X+@6\/$B#U<_U^7HD^$=JKBC6:.X//"E7Y5)$K5)G3B>0VCDA+Q6_*?VP% M0/G^"(B0W'\WS9S+?G?0;EU=;=HYE=' GW60&!6#(L81RA<92N$2N9^X\T%K MJV=(14H"/X6V[[0I;SG/$6!L$.PR^I_X^& _L@Z[G68SQD@T%V!VDS\DV/Y .18B&U! "+^,TS$W^"86(N ME)5C'6#3T5'NTHIORE+Y+[ENJ6O8"=*H:4)R M6VX ^AS] SMF#;53X2-X0&I BW]@8DDY-]?@UV"ZV>1Q8 1J_WG:VR<$>0@3 MP$5@1\S$5T4FJB_B<:C][%\KN=8@,1;5R.L)$4U,;"ZR-K#@?V PL@Q1,YT) MN@I9-,'+(/8WD)>H\FVBN-3#01HXA#EW;H&&Y!XP&/Z#7+\R='@*L.K].@0P M<&D^D)+86S''Z2)C.#;,3Y>FHA;Q- WR=1(&E^*[@SQJECE'1SK#K3"LC&X; M#C,#O6 %X)V,G\E=%PJ8G#^!]8F@(%D)3*]5/?7A/>*=H2^1!1Q%;DK^TAD1 M9P!K+V#K4;-']DT\DT #UHB"2)2)IC/JC_3(37D85SUO1$TQ-P[@BC4':,; MNPON9H0

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